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HEPATOCYTT-VEKSTFAKTOR, C-MET OG SYNDECAN-1 I MYELOMATOSE 
 
Myelomgruppen ved IKM forsker på sykdommen myelomatose, en form for benmargskreft. Gruppens arbeid har 
vært fokusert på hvordan miljøet i benmargen, med løselige og cellebundne vekstfaktorer, påvirker 
kreftcellene/myelomcellene. En av flere vekstfaktor i benmargen er hepatocyttvekstfaktor (HGF). 
Myelomgruppen var de første til å vise at myelomceller produserer HGF og samtidig uttrykker dens receptor c-
Met. Gruppen og andre har vist at høye nivåer av HGF i serum er et dårlig prognostisk tegn hos 
myelomatosepasienter, at HGF stimulerer vekst og overlevelse av myelomceller, og kan være viktig for den 
ødeleggelse av bein som sees ved myelomatose. Dette doktorgradsarbeidet fokuserer på HGF og c-Met og på 
syndecan-1, som er en viktig regulator av aktiviteten av vekstfaktorer i benmargen. I tillegg har vi undersøkt 
forekomsten av avvik i kromsomene i kreftcellene hos pasienter med myelomatose. 
 
I den første artikkelen ønsket vi å undersøke hvorvidt HGF og c-Met er tilstede, og om systemet er aktivt, også 
i vev fra pasienter, og ikke bare i cellelinjer på laboratoriet. Vi undersøkte forekomsten av HGF og c-Met i 
benmargsprøver fra pasienter med myelomatose og beslektede sykdommer ved hjelp av immunfarging. 58 av 68 
biopsier fra myelomatosepasienter, og 9 av 10 biopsier fra normal benmarg var positive for HGF. 25 av 63 
biopsier fra myelomatosepasienter og ingen av 10 biopsier fra normal benmarg var positive for c-Met. Med 
fosfo-spesifikke antistoffer fant vi at c-Met var fosforylert (dvs aktivert) i 15 av 21 c-Met-positive pasienter. 
Dette viser at c-Met ikke bare er tilstede, men at det også går et aktivt signal gjennom denne. Studien indikerer at 
c-Met er en faktor som skiller maligne fra normale plasmaceller, og at c-Met er aktivert i myelomatosepasienter. 
 
Omdanning av HGF fra inaktiv til aktiv form er avgjørende for biologisk funksjon. I den andre artikkelen 
undersøkte vi serumnivået av HGF aktivator (HGFA), som er en av de viktigste aktivatorer av HGF. Vi fant 
høyere serumnivåer av aktivert HGFA hos myelomatosepasienter enn hos friske kontrollpersoner. En mulig 
mekanisme for aktivering av HGF i myelomatose kan være økt nivå eller aktivitet av HGFA.  
 
En ekstracellulær porsjon av c-Met kan kappes av til en løselig reseptor i serum. Den løselige reseptoren kan 
nedregulere effekten av HGF på flere måter, men dette har ikke vært undersøkt i myelomatose. I den tredje 
artikkelen undersøkte vi serumnivåer av løselig c-Met. Vi fant ingen forskjell i serumkonsentrasjon av løselig c-
Met mellom myelomatosepasienter og friske kontrollpersoner. Likevel var det en negativ korrelasjon mellom 
serumkonsentrasjon av c-Met og sykdomsstadium, grad av plasmacelleinfiltrasjon i benmarg og nivå av M-
komponent hos myelomatosepasienter. Studien indikerer at det kan være relevant å undersøke en mulig biologisk 
betydning av løselig c-Met i myelomatose. 
 
Syndecan-1 er en viktig regulator av aktiviteten av flere vekstfaktorer. I den fjerde artikkelen undersøkte vi 
rollen til syndecan-1 som cofaktor i interaksjonen mellom HGF og c-Met. Det er kjent fra før at HGF kan binde 
til syndecan-1. Vi viser i denne studien at også c-Met kan binde til syndecan-1. Det er også tidligere vist at 
syndecan-1 lokaliseres til lipid rafts – kolesterolrike ”fett-flåter” – i cellemembranen. Slike lipid-flåter er viktige 
i cellesignalering, fordi viktige signalmolekylær konsentreres hit. Vi fant at HGF og c-Met lokaliseres sammen 
med syndecan-1 til lipid-flåter i myelomceller, og at intakte lipid-flåter er nødvendige for HGF-indusert 
signalering via PI3K-Akt, som er en viktig signalvei for overlevelse og tilvekst av myelomceller. 
 
Det at myelomcellene er avhengig av faktorer i benmargen er én side av sykdomsutviklingen ved myelomatose. 
En annen side er genetiske forandringer i myelomcellene. I den femte artikkelen har vi undersøkt forekomsten 
av genetiske avvik i myelomcellene hos 250 norske myelomatosepasienter. Vi fant at 45% av pasientene hadde 
en translokasjon (overbytning av genmateriale) der immunglobulingenet, som er sentralt ved myelomatose, blir 
flyttet nært andre gen (onkogen) som ofte fremmer celleveksten. 35% hadde tap av deler (delesjon) av 
kromosom 13 og 19% hadde delesjon av kromosom 17. 10% hadde delesjon av korte armen av kromosom 1 og 
34% hadde amplifikasjon av den lange armen av kromosom 1. Forekomsten av de genetiske avvikene hos norske 
myelomatosepasienter er lik den som er beskrevet i internasjonale materialer. Genetiske avvik kan komme til å 
få betydning for hvilken behandling som skal gis. 
 
Metoder som er brukt i doktorgradsarbeidet er immunhistokjemi, ELISA, konfokalmikroskopi, flowcytometri, 
immunprecipitering, Western blot og interphase FISH.  
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ABBREVIATIONS 
 
ASCT – autologous stem cell transplant 
ADAM – a disintegrin and metalloproteinase 
APRIL – a proliferation-inducing ligand 
BAD – Bcl-2 antagonist of cell death
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GRB2 – growth-factor-receptor-bound protein 2 
GSK3β – glycogen synthase kinase 3β
HAI-1 and HAI-2 – hepatocyte growth factor activator inhibitor 1 and 2 
HB-EGF – heparin-binding epidermal growth factor 
HDT – high dose therapy 
HMCL – human myeloma cell line 
HS – heparan sulphate             
HSPG – heparan sulphate proteoglycan 
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ICAM-1 – intercellular adhesion molecule 1 
Ig – immunoglobulin  
IGF-1 – insulin-like growth factor 1 
IGFBP – insulin-like growth factor-binding protein 
IGF-1R – insulin-like growth factor 1 receptor 
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IKK – IκB kinase 
IL-6 – interleukin-6 
IMWG – International Myeloma Working Group 
ISS – international staging system 
JAK – janus kinase 
JNK – jun amino-terminal kinase 
mAbs – monoclonal antibodies  
MAPK – mitogen activated protein kinase  
MAPKK – MAPK kinase 
MEK – MAP-Erk kinase 
MEKK – MEK kinase 
MGUS – monoclonal gammopathy of undetermined significance 
MIP-1α – macrophage inflammatory protein 1α 
MM – multiple myeloma 
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MMP – matrix metalloproteinase 
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mTOR – mammalian target of rapamycin 
NF-κB – nuclear factor-κB  
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PI3K – phosphatidylinositol 3-kinase 
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PLCγ – phospholipase Cγ 
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STAT – signal transducer and activator of transcription  
VEGF – vascular endothelial growth factor  
VCAM-1 – vascular cell adhesion molecule 1 
VLA-4 – very late antigen 4 
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INTRODUCTION 
1.1. General aspects of multiple myeloma 
1.1.1. Epidemiological and clinical aspects 
Multiple myeloma (MM) is a malignant plasma cell disorder that accounts for approximately 
1 % of cancer worldwide and 10-15% of all haematological malignancies (1, 2). Incidence 
rates vary from 0.4 to 6 per 100.000 (1, 3). In Norway, about 300 patients are diagnosed with 
MM per year (Cancer Registry of Norway). The median age at diagnosis is 65-70 years, but 
may be higher in unselected, population-based materials (3, 4). MM is more common in men 
than in women, and twice as common in African-Americans compared to Caucasians (2, 5). 
The incidence is higher in first-degree relatives of patients with MM (2). It is a disseminated 
disease which affects the bone marrow and frequently invades adjacent bone followed by 
bone destruction. Extramedullary expansions (plasmacytomas) of bone lesions, and true 
extramedullary plasmacytomas occur. The major clinical manifestations are symptoms from 
bone destruction with pain and/or fractures, anaemia, hypercalcaemia, renal failure and an 
increased risk of infections (6, 7). It has recently become clear that all, or almost all, cases of 
MM evolve from an asymptomatic premalignant state termed monoclonal gammopathy of 
undetermined significance (MGUS) (8, 9). MGUS is present in approximately 3% of the 
population above age 50, and about 1% per year progresses to MM or another B cell 
malignancy (10, 11). Other disorders of monoclonal plasma cells include MGUS, solitary 
plasmacytomas, systemic AL amyloidosis and POEMS (polyneuropathy, organomegaly, 
endocrinopathy, M protein, skin changes) syndrome (12). Immunoglobulin M (IgM) MGUS 
and Waldenström’s macroglobulinemia are related B-cell disorders that are not included in 
this work. 
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The current diagnostic classification distinguishes between smouldering/asymptomatic and 
symptomatic MM. The diagnostic criteria for symptomatic MM are [1] 10% or more clonal 
plasma cells on bone marrow examination, or a biopsy-proven plasmacytoma, [2] presence of 
serum and/or urine monoclonal protein and [3] signs of myeloma-related organ damage: 
Hypercalcaemia (C), renal insufficiency (R), anaemia (A), or bone destruction (B), with the 
acronym CRAB (6, 13). Exceptions from [2] are given in true non-secretory myeloma, which 
comprise approximately 2% of MM with no evidence of M protein on protein electrophoresis, 
serum immunofixation or serum-free light chain assay (12). The definition of smouldering 
myeloma requires 10% or more clonal bone marrow plasma cells and serum monoclonal 
protein (IgG or IgA) more than 30 g/L (12, 13).  
 
MGUS 
 
Asymptomatic MM  
(Smouldering MM) 
Symptomatic MM 
Clonal bone marrow plasma 
cells <10% 
 
Serum M protein  
< 30 g/L 
 
Absence of myeloma-related 
organ damage 
Clonal bone marrow plasma 
cells ≥ 10% 
and/or
Serum M protein ≥ 30 g/L  
 
 
Absence of myeloma-related 
organ damage  
Clonal bone marrow plasma 
cells ≥ 10% 
 
Serum and/or urine M protein 
present at any concentration 
 
Myeloma-related organ damage 
(CRAB) 
 
Table 1. Diagnostic criteria for MGUS, asymptomatic and symptomatic MM (6, 12, 13) 
 
Routine primary diagnostic work-up includes bone marrow aspirate or biopsy, plain 
radiographs of the axial skeleton (skull, vertebral spine, pelvis and long bones) and analyses 
of M protein in serum and urine. The serum free light chain assay may be able to replace the 
need for urine electrophoresis in the situation of screening for MM, and can be used for 
monitoring of disease course and response to therapy in those without measurable M protein 
by serum electrophoresis or immunofixation. In addition, clinical and biochemical analyses 
are performed to detect signs of myeloma-related organ damage. Today, cytogenetic analyses 
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with conventional karyotyping and/or fluorescence in situ hybridization (FISH) are 
increasingly being considered as part of routine primary diagnostic work-up (6). Cytogenetic 
abnormalities in multiple myeloma will be further discussed in a later section. In some 
instances MRI of the skeleton and PET-CT may be of value. 
 
1.1.2. Prognosis, staging, risk stratification and treatment 
MM is still an incurable disease. After the introduction of new drugs during the last decade, 
median overall survival has improved and is now estimated to four to five years, compared to 
approximately three years earlier (14, 15). However, MM is a heterogeneous disease, and the 
individual variation is large with some patients experiencing an aggressive disease course 
with survival only of weeks or months, while other patients may live for 10 years and more 
with the disease. The staging systems by Durie Salmon (16, 17) and the International Staging 
System ISS (17, 18) both yield prognostic information. ISS also seem valid in the era of new 
drugs like thalidomide, lenalidomide and bortezomib (15), and is the current standard for 
staging of myeloma. Yet these systems are not useful for guiding therapeutic choices.  
 
Stage I:    Serum β2-microglobulin <3.5 mg/L and    
                serum albumin ≥ 35 g/L  
Stage II:  Not fitting stage I or III 
 
Stage III: Serum β2-microglobulin ≥ 5.5 mg/L 
 
 
Table 2. International Staging System
There is increasing evidence that a risk stratification based on cytogenetics may be able to 
guide therapeutic decisions (19). Studies that have assessed various treatment options in 
patients with high risk cytogenetics include relatively small numbers of patients and limited 
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follow up, making it difficult to draw conclusions. While several studies suggest that use of 
bortezomib can improve the outcome of patients with t(4;14) or chromosome 13 
abnormalities (20, 21), there is no conclusive evidence that currently available drugs can 
overcome the negative prognostic impact of 17p deletion (del17p)(21), and new therapeutic 
strategies will have to be further evaluated in these patients. High risk cytogenetic 
abnormalities will be detailed and further discussed in a later section. Plasma cell labelling 
index > 3% was also shown to be associated with adverse prognosis (22), and the Mayo 
Clinic has implemented cytogenetics together with plasma cell labelling index in a risk 
adapted treatment algorithm (23). Gene expression profiling (GEP) can be of prognostic value 
and is used by some centres (24). However, general use of GEP is so far limited by the lack of 
availability and a uniform platform (6). The International Myeloma Working Group (IMWG) 
recently proposed a minimal testing panel for newly diagnosed MM patients which includes 
the established high risk cytogenetic factors t(4;14), t(14;16) and del17p (19, 23). 
Conventional metaphase cytogenetics is recommended in addition to FISH (25). However, 
tailored therapy based on risk factors and/or cytogenetic factors remains controversial. 
 
Melphalan – Prednisone has been the cornerstone for MM treatment since its introduction in 
the early 1960s (26). High dose therapy (HDT) with autologous stem cell transplant (ASCT) 
was introduced in the late 1980s and prolongs overall survival for those eligible (27). 
Eligibility for HDT with ASCT has therefore been the first dividing point in all treatment 
algorithms. The introduction of new drugs which can produce very good partial remissions 
and complete remissions (CR) with less toxicity than HDT with ASCT may come to 
challenge this concept. Also, the improved outcome of MM patients during the last decade, in 
parallel to the introduction of new drugs, has lead to discussion of whether time has come for 
a paradigm shift, towards more aggressive therapy aiming at CR, rather than sequential use of 
 15
drugs aiming at disease control (28). This “cure versus control” debate is still ongoing. There 
are some data to support that high risk patients need aggressive therapy to achieve a CR for 
accomplishing long term survival, while achieving a CR may not affect survival in standard-
risk patients (6, 29). Allogeneic stem cell transplantation has been associated with high 
mortality rates, and although new reduced conditioning regiments produce lower toxicity, the 
relapse rate increases, and allogeneic stem cell transplantation is still considered as 
investigational treatment (30, 31). A role for maintenance therapy with thalidomide, 
lenalidomide or bortezomib, after achieving optimal remission, is being evaluated in clinical 
trials (30). Further, the introduction of less toxic therapy and better risk stratification has 
brought up the topic of prophylactic treatment of smouldering myeloma (and even MGUS). 
However, until evidence for improved survival (or quality of life) by a prophylactic approach 
exist, observation until symptomatic disease remain the standard of care (6, 30). Several new 
drugs are currently being evaluated in trials (32). The IMWG uniform response and relapse 
criteria are detailed in (33). 
           
1.2. Pathogenesis  
1.2.1. Myeloma biology 
Normal B-cell development. Early B-cell development starts in the bone marrow, where B-
cell precursors go through rearrangement of the Ig heavy- and light-chain genes, resulting in a 
functional B-cell receptor. These cells then differentiate into mature, naïve B-cells which 
leave the bone marrow. After antigen activation, T helper cells stimulate the mature, antigen-
activated B-cells to undergo proliferation, somatic hypermutation of Ig heavy (IGH) and light 
chain (IGL) sequences, and class-switch recombination of Ig. This takes place in the germinal 
centre of the lymph node, and results in memory B-cells and terminally differentiated, non-
proliferating, long-lived plasma cells, capable of secreting antigen-specific antibodies (Figure 
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1). These cells home to the bone marrow where they receive survival signals as interleukin-6 
(IL-6) from stromal cells, and live for months to years (34, 35).  
 
 
Figure 1. Normal B cell differentiation. Reprinted by permission from Macmillan Publishers 
Ltd: Nat Rev Cancer (35), copyright 2005. 
 
General aspects on myeloma biology. MM is caused by the expansion of a single clone of 
plasma cells derived from B cells in the bone marrow. They are long-lived, with a low 
labelling index, usually 1-2% (34, 36). GEP has shown that the mRNA profiles of MGUS and 
MM are similar, but different from that of normal plasma cells (37). MM pathogenesis is 
regarded as a multi-step process of genetic alterations of the myeloma cells (Figure 2) and 
changes in the bone marrow microenvironment, but it is still not clear at what state of B cell 
differentiation the primary oncogenic event occurs. As in other human cancers, involvement 
of cancer stem cells have been discussed also in MM, and there are indications of the 
existence of a small subpopulation of cells with clonogenic capacity, more resembling 
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memory B-cells, that would be responsible for initiation, relapse and progression of the 
disease (34, 36).  
 
MM is a heterogeneous disease, both clinically and biologically. The basis for this 
heterogeneity is thought to involve both intrinsic disease biology and host factors. The IMWG 
molecular classification of multiple myeloma (19) is based on this intrinsic heterogeneity. It is 
a working classification based on today’s knowledge and expected to be modified with 
growing knowledge in coming years. 
 
 
Figure 2. Schematic presentation of clonal evolution of malignant plasma cells. Reprinted by 
permission from Macmillan Publishers Ltd: Leukemia (19), copyright 2009. 
1.2.2. Genetics in multiple myeloma 
MM can be divided into two categories based on chromosome numbers: hyperdiploid and 
non-hyperdiploid (19, 38, 39). This dichotomy has also been demonstrated in MGUS (40, 41), 
and the ploidy categories are valid over time (42). Patients in the hyperdiploid category have a 
better outcome (43, 44). The non-hyperdiploid group is characterized by a high frequency of 
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recurrent translocations involving the IGH locus on chromosome 14q32.3, of which the most 
common are t(11;14), t(4;14), t(14;16) and t(14;20) (19, 45, 46). These primary translocations 
cause various genes to be juxtaposed to a strong Ig enhancer that dysregulates their 
expression, and are looked upon as disease-defining events that remain during the course of 
the disease in a given patient (46). Translocations involving the IGL loci (2p12 or 22q11 for κ 
and λ, respectively) are less frequent (46). 
 
MM pathogenesis is considered to be a multistep process with sequential accumulation of 
genetic aberrations, including chromosome 13q deletion (del13q) and monosomy, del17p and 
chromosome 1 abnormalities. Chromosome 13 abnormalities are detected in around 50% of 
myeloma patients, and are associated with shorter survival. However, this prognostic 
association is considered to be a surrogate of its association with non-hyperdiploid MM, 
especially t(4;14) (19).  
 
Deletion of 17p13 (locus for the tumour suppressor gene TP53) is found in around 10% of 
MM patients (43), but is uncommon in MGUS. It is the cytogenetic factor with highest impact 
on prognosis. Patients with del17p have shorter overall survival, more aggressive disease and 
higher prevalence of extramedullary disease. In line with this, most myeloma cell lines have 
p53 abnormalities (19, 43). Chromosome 1 abnormalities, mainly 1p deletion (del1p) and 1q 
amplification, which are closely correlated, are also emerging as important prognostic factors 
(19, 47, 48), although contradictory data exist. Several authors have found a negative 
prognostic impact by chromosome 1 abnormalities (47-51), although the data is not yet 
considered sufficient to motivate routine use of chromosome 1 abnormalities to predict 
prognosis (25). Chromosome 1 abnormalities have also been implicated in transformation 
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from MGUS to smouldering myeloma and from smouldering myeloma to MM (50, 52). 
Several other candidates have been proposed as important progression factors (19). 
 
GEP has also been used for prognostic classification of MM patients. The myeloma research 
group at University of Arkansas for Medial Sciences (UAMS) identified by GEP a set of 70 
genes which predicted high-risk myeloma. They also identified 17 genes that were able to 
provide the same prognostic information (47). There was minimal overlap between the 
expressed signatures. Seven clusters of gene expression were identified, and this was the basis 
for the UAMS molecular classification of MM (24). The results have been validated by other 
groups, with identification of additional sub-groups (53). Some of the primary IGH 
translocations are associated with distinct gene expression profiles, like t(14;16) and t(14;20). 
However, some genetic events are not associated with any specific GEP pattern, and 
conversely, some GEP patterns are not associated with any known genetic events (19). 
 
The role of epigenetic factors in MM pathogenesis is subject to rising interest. DNA 
methylation is altered in many cancers, and tumour suppressor genes, like p53, are found to 
be silenced by methylation in MM. Also, aberrant expression of histone deacetylases 
(HDACs) have been shown in MM, and HDAC inhibitors are promising therapeutic agents 
(54). Further, an important role of post-transcriptional gene regulation by microRNAs is 
increasingly acknowledged (55). 
 
1.2.3. Cytokines and the bone marrow microenvironment 
The clinical heterogeneity of MM is thought to mirror both differences in intrinsic disease 
biology and host factors. The term “host factors” generally refers to factors like age and 
comorbidity, affecting prognosis and treatment toxicity. However, also the micro milieu of the 
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bone marrow is crucial for survival and thriving of myeloma cells. It is well established that 
interaction between myeloma cells and the bone marrow microenvironment is essential in 
MM pathogenesis (34). In this interaction, two components are crucial: adhesion molecules 
and cytokines.  
 
The bone marrow microenvironment consists of several cell types that secrete factors 
important for homing and adhesion of myeloma cells. These cell types include hematopoietic 
stem cells and progenitor cells, immune cells, stromal cells, endothelial cells, adipocytes, 
osteoclasts and osteoblasts (34).The chemokine stromal derived factor (SDF)-1α and its 
receptor CXCR4, which is expressed by myeloma cells, have crucial roles for homing of 
myeloma cells to the bone marrow (56). Binding of SDF-1α to CXCR4 induces motility and 
cytoskeletal rearrangements, i.e. migration, of myeloma cells. Several adhesion molecules 
then come to play, including CD44, very late antigen (VLA-4), intercellular adhesion 
molecule 1 (ICAM-1), vascular cell adhesion molecule 1 (VCAM-1) and syndecan-1  
(34, 36). Adhesion of myeloma cells to the bone marrow affects gene expression both in the 
myeloma cells and in the bone marrow stromal cells, leading to up-regulation of several 
cytokines (36). Further, adhesion of myeloma cells to bone marrow endothelial cells 
(mediated by SDF-1α), up-regulates expression of many angiogenic cytokines, and leads to 
secretion of several myeloma growth factors, like insulin-like growth factor 1 (IGF-1), IL-6, 
vascular endothelial growth factor (VEGF) and hepatocyte growth factor (HGF), from the 
endothelial cells. At the same time, the myeloma cells may secrete factors that stimulate 
angiogenesis, like VEGF and basic fibroblast growth factor (bFGF) (34).  
 
Osteoclasts produce myeloma growth factors, like IL-6. Conversely, myeloma cells activate 
osteoclasts, leading to bone destruction. Bone marrow stromal cells produce receptor activator 
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of nuclear factor-κB ligand (RANKL) and osteoblasts produce osteoprotegerin (OPG). 
RANKL, by interacting with its receptor RANK on osteoblasts, stimulates osteoclasts. OPG is 
a decoy receptor that binds to RANKL and prevents it from interacting with RANK, i.e. 
inhibits it from promoting osteoclastogenesis. By disturbing the OPG/RANKL ratio, myeloma 
cells promote bone destruction (57). Myeloma cells also inhibit osteoblast differentiation via 
dickkopf-related protein 1 (DKK1) (58) and HGF (59). Interactions between the myeloma 
cells and bone marrow cells thus trigger several signals which mediate growth, survival and 
migration of myeloma cells and, in addition, bone destruction and angiogenesis (34). 
 
Several cytokines interact and synergize to promote myeloma cell survival and/or induce cell 
growth and proliferation, including IL-6, IGF-1, FGF, HGF, epidermal growth factor (EGF), 
vascular endothelial growth factor (VEGF), macrophage inflammatory protein 1α (MIP-1α), 
tumour necrosis factor (TNF), B cell activating factor (BAFF), a proliferation-inducing ligand 
(APRIL), IL-15, IL-21 and more (60-70). Some of them are produced by the myeloma cells, 
and some by bone marrow stromal cells, thus acting in an autocrine or paracrine manner. 
Among these cytokines, IL-6 is since long time regarded as the major growth and survival 
factor of myeloma cells (60, 71). IL-6 and one of the most important other cytokines, IGF-1, 
will be described in more detail, but the focus of this work is on HGF, its receptor c-Met and 
related factors. 
                                  
1.2.4. Signalling common pathways and redundancy  
Several cytokines converge to activate common intracellular pathways, like the Ras/mitogen 
activated protein kinase (MAPK), phosphatidylinositol 3-kinase (PI3K)/Akt, nuclear factor-
κB (NF-κB) and janus kinase (JAK)/signal transducer and activator of transcription 3 
(STAT3) pathways (72). As an example consistent with this notion, it was shown that in the 
 22
presence of bone marrow stromal cells, myeloma cells survive independently of IL-6/STAT3 
signalling (73), indicating that additional factors from the bone marrow microenvironment 
might substitute for its actions. This is thought to explain the often disappointing results of 
inhibiting single cytokines, like IL-6, as these signalling cascades will be redundantly 
activated by other cytokines (72). The intracellular pathways most relevant for this work are 
further described in the c-Met signalling section. 
 
1.2.5. IL-6  
IL-6 was early recognized as the main cytokine inducing terminal differentiation of B cells 
into plasma cells (74). IL-6 has proved to be a major myeloma growth factor, and many 
myeloma cell lines are dependent of IL-6 for thriving (60, 71, 75). IL-6 knock out mice do not 
develop plasma cell malignancies (76). IL-6 promotes growth, protects myeloma cells from 
apoptosis and, in addition, may induce resistance to dexamethason (77). Serum levels of IL-6 
correspond with disease severity (78). When myeloma cells adhere to bone marrow stromal 
cells or osteoblasts, these are triggered to produce IL-6 (79-82). IL-6 may also be produced by 
myeloma cells (60, 83). IL-6-production by bone marrow stromal cells and by myeloma cells 
is stimulated by several cytokines, like TNF-α and IL-1 (84, 85). IL-6 thus acts in an 
autocrine or paracrine upon the IL-6 receptor complex which is expressed by the malignant 
cells of most MM patients, and by almost all myeloma cell lines (86, 87). The IL-6 receptor 
complex is composed of a ligand binding domain, IL-6 receptor-α (IL-6Rα), and a signal 
transducing domain (GP130/CD130). When bound to ligand, IL-6Rα dimerizes GP130 
followed by activation of intracellular signalling pathways. The intracellular portion of the IL-
6R complex lacks tyrosine kinase activity, but recruits other intra-cytoplasmic tyrosine 
kinases for downstream signalling mainly through the JAK/STAT3, Ras/MAPK and 
PI3K/Akt pathways (88-90). 
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1.2.6. IGF-1  
IGF-1 has a physiologic role in normal regulation of metabolism, development and growth, 
but is also thought to play crucial roles in many types of cancer (91). It is mainly produced by 
the liver under the influence of growth hormone and insulin, and circulates in a complex 
bound to IGF binding protein 3 (IGFBP-3). When IGFBP-3 binds to matrix proteins or cell 
surfaces, or is cleaved by proteases, it releases IGF-1. In addition, IGF-1 can be secreted 
locally in tissues, like the bone marrow, where it is produced by bone marrow stromal cells 
and osteoblasts, and by cancer cells. Thus IGF-1 may act in an endocrine, paracrine or 
autocrine manner (91). Numerous studies in cell lines and mouse models have established an 
important role of IGF-1 in myeloma pathogenesis (61, 92, 93). Klein and co-workers found 
that IL-6 and IGF-1 were equally important for myeloma cell growth and survival (92). 
Expression of the IGF-1 receptor (IGF-1R) on myeloma cells was found to be a negative 
prognostic factor (93-95), and serum concentration of IGF-1 was associated with shorter 
survival in MM patients (96). Upon binding of IGF-1 the IGF-1R goes through a 
conformational change, inducing kinase activity, leading to activation of the PI3K/Akt and 
MEK/ERK pathways (91). IGF-1 mediates proliferation, survival, homing and adhesion of 
myeloma cells (92, 97, 98). In addition, the growth factor activity of IL-6, heparin-binding 
EGF (HB-EGF) and HGF was found to be partly dependent on IGF-1/IGF-1R signalling (93).  
 
1.2.7. The HGF/c-Met system.  
HGF was first discovered in 1984 as a mitogen for rat hepatocytes (99). In 1989, cDNA for 
human HGF was cloned, and the structure was clarified (100, 101). In 1991, it was discovered 
that scatter factor (102), a motogen for epithelial cells, was identical to HGF (103, 104). HGF 
is now known as a mitogenic, motogenic and morphogenic factor, and has essential roles in 
human embryogenesis/development (105, 106). It is mainly secreted by mesenchymal cells, 
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and acts in a paracrine manner on epithelial cells. Knocking out HGF, or its receptor c-Met, is 
embryonically lethal due to impaired development of placenta and liver (105, 106). 
 
HGF is synthesized as a single chain pre-pro-form of 728 amino acids. The first 31 amino 
acids are cleaved to form pro-HGF. Pro-HGF is then further cleaved between Arg494 and 
Val495 to form the biologically active form. Active HGF is a heterodimer, composed of a 69 
kDa alpha-chain containing a hairpin domain and four kringle domains, and a 34 kDa serine 
protease (SP)-like beta-chain, linked by a disulphide bond (100, 101, 106) (Figure 3). 
Although the SP domain has lost its protease activity due to replacement of two amino acids 
in the active site, HGF is structurally similar to plasminogen, and its activation follows a 
similar pattern as the activation steps of the serine proteases of the coagulation cascade. HGF 
activator (HGFA), urokinase-type plasminogen activator (uPA), tissue plasminogen activator 
(tPA), coagulation factor XI and XII, plasma kallikrein and the membrane bound proteases 
matriptase and hepsin have all been shown to activate single chain HGF (107-113). HGFA, 
matriptase and hepsin are the most potent processors, the HGF-converting potency of HGFA 
being more than 1000 times that of uPA (108). HGFA is further described below. 
  
Į-chain 
Figure 3. Schematic illustration of HGF. Modified by permission from Blackwell Publishing: 
J Gastroenterol Hepatol  (106), copyright 2011. 
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The naturally occurring splice variants of HGF named NK1 and NK2 consist of the N-
terminal hairpin loop and one or two of the kringle domains, respectively (Figure 3). Both 
NK1 and NK2 can act either as agonists or as competitive antagonists (114). The synthetic 
splice variant NK4 is composed of the hairpin loop and four kringle domains and has 
antagonistic activity (115). 
 
HGF is a heparan sulphate (HS)-binding protein, and numerous studies have confirmed that 
HGF binds to sulphated glycosaminoglycans (GAG), or GAG covalently bound to proteins, 
termed heparan sulphate proteoglycans (HSPG) (116, 117). In studies of the interactions 
between HS and growth factors, heparin has commonly been used as a substitute for HSPG, 
mainly due to structural and chemical similarity (the main difference is that heparin has a 
higher amount of sulphation) and greater availability. The main heparin binding site is located 
in the N-terminal hairpin loop of HGF (116, 118). By binding to HSPG, HGF is sequestered 
in the extracellular matrix of most tissues, mainly in its inactive form (119). HSPG can 
potentiate HGF activity (116, 120, 121), but may also have opposite effects on HGF activity 
depending on their concentration (122). The interaction between HGF and the most abundant 
HSPG on plasma cells, syndecan-1, is further described below. 
 
HGFA. Activation of HGF in the bone marrow microenvironment is critical for HGF/c-Met 
signalling. One of the most potent activators is the factor XII-related serine protease HGFA 
(123). HGFA is a member of the kringle-containing serine protease super-family, and is 
mainly secreted by the liver, although extrahepatic expression has been reported in a number 
of normal and tumour tissues (124). It circulates in plasma as a single-chain 96-kDa pro-form, 
which is activated by thrombin, in the presence of negatively charged molecules, such as 
heparin, HS and chondroitin sulphate, in injured tissues and in tumours. The activated form of 
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HGFA consists of a heterodimer with a 66 kDa heavy chain and a 32 kDa light chain (125). 
Plasma kallikrein may further splice the HGFA heavy chain, resulting in a 34 kDa two-chain 
short form, which retains its enzymatic activity (125). An alternative mechanism for 
activation of pro-HGFA is by the kallikrein related peptidases 4 and 5 (126). Activation of 
HGFA leads to an increased heparin-binding capacity, possibly concentrating activated 
HGFA to cell surface HSPG (127). Since the major activator of HGFA is thrombin, it follows 
that the conversion of prothrombin to thrombin, i.e. activation of the coagulation cascade in 
injured tissues, is an important step in activation of the HGF/c-Met system.  
 
The system is regulated by the HGF activator inhibitors (HAI) -1 and -2 and plasma protein C 
inhibitor (124, 128). HAI-1 and HAI-2 are both membrane bound serine protease inhibitors. 
The activity of HGFA is suppressed by reversible binding to cell surface HAI-1, but the 
HGFA-HAI-1 complex can also be released by metalloproteinase-mediated shedding of the 
HAI-1 ectodomain. So, while HAI-2 is a strong inhibitor, it is possible that HAI-1 not only 
works as an inhibitor, but also as a reservoir of HGFA at the cell surface (113, 124, 129, 130).  
 
The role of HGFA in physiological and pathological conditions is not fully elucidated. Serum 
from HGFA knockout mice was unable to process pro-HGF, suggesting that HGFA is indeed 
the major activator of HGF in serum (131). Still, while knocking out HGF is embryonically 
lethal, no obvious developmental abnormalities were shown in HGFA-/- mice, clearly 
indicating that HGFA is redundant during tissue development, and can be compensated for by 
other proteases like matriptase and hepsin, acting in the local tissue environment (113, 131). 
On the other hand, HGFA has important roles in regeneration of injured tissue (113, 127). 
Several studies also indicate a role in tumour progression, and expression of HGFA has been 
observed in several tumour types, reviewed in (113). It has also been shown that myeloma 
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cells can express HGFA (132). HGFA may also activate pro-macrophage stimulating protein 
(MSP), a protein with structural homology to HGF (113). 
 
c-Met.  
The HGF receptor, c-Met, was cloned in 1984 (133). It is member of the scatter factor 
receptor family, together with the tyrosine kinase Ron, which is the receptor for MSP (134). 
c-Met is produced as a single chain precursor, which is cleaved by furin to form a 50 kDa 
extracellular alpha-chain and a 145 kDa transmembrane beta-chain, linked by a disulfide bond 
(133, 135). The extracellular portion of c-Met contains a Sema domain, to which semaphorin-
type proteins can bind (134), a cysteine-rich Met-related-sequence (MRS) domain, and four 
Ig-like structures (136, 137) (Figure 4). High affinity binding between HGF and c-Met occurs 
via the α-chain of HGF and the Ig-like region of c-Met (138), independently of HGF 
activation. Low affinity binding occurs only after activation of HGF, by binding of the HGF 
β-chain to the Sema domain of c-Met (139, 140). While the alpha-chain of HGF is necessary 
for high affinity binding to the receptor (but does not activate the receptor), the low-affinity 
binding of the β-chain to the c-Met Sema domain is necessary for receptor dimerization and 
activation (135, 139). It is believed that HGF-induced c-Met activation is mediated by 
formation of a 2:2 complex where c-Met dimerization is primarily mediated by dimer 
formation of HGF (141). 
 28
 
Figure 4. Schematic illustration of c-Met. Reprinted by permission from Blackwell 
Publishing: J Gastroenterol Hepatol  (106), copyright 2011. 
 
The intracellular portion of c-Met is composed of a juxtamembranous domain, a tyrosine 
kinase domain, and a carboxy-terminal (C-terminal) regulatory tail. The juxtamembranous 
domain with tyrosine 1003 is essential in downregulation of the receptor (142, 143). In the 
tyrosine kinase domain, two tyrosine residues (Tyr 1234 and Tyr 1235) regulate the kinase 
activity, while two other tyrosine residues (Tyr 1349 and Tyr 1356), located in the C-terminal 
regulatory tail, are essential for recruitment of downstream adapter molecules as described in 
the following section (105, 144).  
 
HGF - c-Met signalling. Upon HGF binding c-Met is dimerized, and autophosphorylation 
occurs on tyrosine residues Y1234 and Y1235 in the activation loop of the tyrosine kinase 
domain, which induces kinase activity, while phosphorylation on Y1349 and Y1356 form a C-
terminal multifunctional docking site. This phosphorylation of C-terminal tyrosine residues in 
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the docking site recruit scaffolding adaptor proteins, including growth-factor-receptor-bound 
protein 2 (GRB2)-associated binder 1 (GAB1) and α6β4-integrin. These adaptors act as 
supplementary docking platforms for further binding of intracellular signalling molecules, 
including GRB2, PI3K, p120 Ras-GTPase-activating protein (p120), phospholipase Cγ 1 
(PLCγ1), SH2-domain-containing protein tyrosine phosphatase 2 (SHP2), Src, Src-homology-
2 domain-containing transforming protein (SHC) and STAT3, summarized in (135). The 
scaffolding adaptor protein GAB1 is the most crucial substrate for HGF/c-Met signalling, and 
is responsible for most of the cellular responses to c-Met activation. Knocking out GAB1 is, 
like knocking out HGF or c-Met, embryonically lethal (145).  
 
While the c-Met receptor with its docking site and scaffolding adaptor proteins is unique, its 
downstream signalling pathways are the same as those evoked by several other tyrosine 
kinase receptors. Downstream effectors of c-Met include the MAPK cascades, the 
PI3K/Akt/mammalian target of rapamycin (mTOR) pathway, the Src/focal adhesion kinase 
(FAK) pathway, the  NF-κB inhibitor-α (IκBα) – NF-κB complex (105, 135) and the STAT3 
pathway. These are distinct but interacting cascades. As earlier described, several cytokines 
converge to activate common intracellular pathways.  
 
The PI3K-Akt pathway. c-Met can activate PI3K either indirectly via activation of Ras, or 
directly. Direct activation occurs when the regulatory subunit p85 of PI3K binds to the 
docking site of c-Met, leading to recruitment of the catalytic subunit p110, whereby PI3K is 
activated. The main function of active PI3K is to generate phosphatidylinositol (3,4,5)-
triphosphate (PI(3,4,5)P3), which in turn recruits pleckstrin homology (PH)-domain 
containing molecules to the plasma membrane. One of these is the serine/threonine kinase Akt 
(Figure 5). Activated Akt may inactivate the pro-apoptotic protein BCL-2 antagonist of cell 
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death (BAD), and promote degradation of the pro-apoptotic protein p53. By these two 
mechanisms, Akt acts anti-apoptotic. Akt also inhibits apoptosis indirectly via the NF-κB 
pathway. Further, Akt inactivates glycogen synthase kinase 3β (GSK3β), which normally 
suppresses expression of the positive cell cycle regulators Myc and cyclin D1, and activates 
mTOR. By these mechanisms, Akt stimulates proliferation and cell growth. The PI3K – Akt 
pathway is one of the major oncogenic pathways, and aberrations involving components of 
this pathway are commonly seen in cancer. One example is loss of phosphatase and tensin 
homologue (PTEN), the PI(3,4,5)P3 -phosphatase which converts PI(3,4,5)P3 back to 
PI(4,5)P2. PTEN is a tumour suppressor, and is absent in many tumours (146).   
 
 
Figure 5. Schematic illustration of the PI3K/Akt pathway. See text for details. Reprinted by 
permission from Macmillan Publishers Ltd: Nat Rev Cancer (146), copyright 2002. 
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The MAPK pathways. The MAPK subfamilies are characteristically composed of a series of 
phosphokinases, where the MAPK kinase kinase (MAPKKK) activates the MAPK kinase 
(MAPKK), which in turn activates the MAPK (Figure 6).  
 
 
Figure 6. Schematic illustration of the MAPK pathway. See text for details. Copyright © 2008 
From MolecularBiology of The Cell by Bruce Alberts, et al. Reproduced by permission of 
Garland Science/Taylor & Francis Books, Inc.  
 
The MAPK family includes the extracellular signal-regulated kinase 1 (ERK1) and ERK2, jun 
amino-terminal kinases (JNKs) and p38 pathways. Activation of the ERK pathway is 
triggered by Ras. Ras is activated by transition from the guanosine diphosphate (GDP) to 
guanosine triphosphate (GTP) state, and c-Met activates Ras through the GRB2 – son of 
sevenless (SOS) complex. This activation may occur directly or via an SHC adaptor. It may 
also occur via SHP2, which dephosphorylates the p120-binding site on GAB1, which 
normally deactivates Ras. Activated Ras recruits the serine/threonine kinase Raf, leading to a 
conformational change of Raf, which is thereby phosphorylated, and in turn activates MAPK-
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ERK kinase (MEK)1 and MEK2, which in turn phosphorylates ERK1 and ERK2. The JNK 
pathway starts with Rac mediating phosphorylation of MEK kinase (MEKK)1, which leads to 
phosphorylation of MEK4, which leads to activation of JNK 1,2 and 3. The p38 pathway also 
starts with Rac mediating phosphorylation of MEKK, leading to phosphorylation of MEK3 
and 6, leading to phosphorylation of p38α, p38β, p38γ and p38δ. The MAPK pathways are 
involved in cell proliferation, differentiation, transformation and apoptosis.  
 
Other important pathways include the p120/STAT3 pathway, implicated in cell 
proliferation and differentiation. The Ras-Rac1-p21 activated kinase (PAK)-pathway is 
important for cytoskeletal rearrangement and cell adhesion, and the Src/focal adhesion kinase 
(FAK) pathway regulates cell adhesion and migration. The NF-κB system is a family of 
transcription factors that are kept inactive in the cytoplasm by the inhibitory IκBs. In response 
to tyrosine kinase activation, the PI3K- and the Src pathways mediate activation of the IκB 
kinase (IKK). IKK mediates degradation of the IκBs, leading to release of NF-κB, which 
translocates to the nucleus and stimulates transcription of mitogenic and anti-apoptotic 
regulators (105, 135).  
 
Regulation of c-Met activity. HGF – c-Met activity may be enhanced by co-receptors, 
including HSPGs as described in the HGF and syndecan-1 sections (pages 22 and 36). CD44 
is another transmembrane glycoprotein, which works as a linker between the extracellular 
matrix and the intracellular actin cytoskeleton (147). CD44 can collaborate with c-Met, and is 
under some conditions necessary for c-Met signalling (148). c-Met may also interact with 
semaphorin receptors (plexins), and when oligomerized with plexins, c-Met can be activated 
by semaphorins independently of HGF (134, 135).  
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Several protein-tyrosine phosphatases can hamper c-Met signalling by dephosphorylation of 
tyrosines in the catalytic or docking domain (135). c-Met signalling is also negatively 
regulated by the ubiquitin ligase Cbl, which binds to phosphorylated Y1003 in the 
juxtamembranous region of c-Met, resulting in c-Met ubiquitination, endocytosis and 
degradation, providing a mechanism for terminating c-Met signalling (143). Another 
mechanism for downregulation of c-Met is by activation of protein kinase C, leading to 
phosphorylation of Ser985 in the juxtamembranous domain of c-Met, which in turn leads to 
suppression of HGF-induced activation of c-Met (142). Finally, c-Met can be downregulated 
by ectodomain shedding. 
 
c-Met shedding. Extracellular fragments of c-Met can be shed from the cell surface under 
physiologic conditions and in cancer (149-153). The membrane-bound metalloproteinases of 
the A Disintegrin And Metalloproteinase (ADAM) family, ADAM-10 (154) and ADAM-17 
(155), have been proposed as mediators of cell surface shedding of c-Met, and several splice 
variants of c-Met have been described (149, 153, 156). There is compelling evidence from 
cancer cell lines and mouse models that a soluble extracellular fragment of c-Met can act as a 
decoy receptor and downregulate HGF/c-Met activity (138, 152, 156-158). Ectodomain 
shedding may downregulate c-Met by three different mechanisms. First, the soluble 
ectodomain can compete for HGF, and prevent HGF from interacting with c-Met at the cell 
surface. Second, the soluble ectodomain can interact with full size c-Met, preventing it from 
dimerization and activation. By these mechanisms, c-Met decoys may inhibit both HGF-
dependent and HGF-independent c-Met activation (157). Third, shedding of the ectodomain 
may leave a surface-associated cytoplasmic remnant, which is subsequently detached from the 
membrane and degraded (152, 155). Contradictory data exist, though, since others have found 
that deletion of the c-Met ectodomain can lead to activation of the remaining tyrosine kinase 
 34
domain (159). Also, c-Met ectodomain fragments found in culture supernatant of mammary 
carcinoma cells could not compete efficiently with intact cellular c-Met for HGF binding 
(153). In conclusion, the biological effects of c-Met shedding may be different in different 
tumours and under different circumstances, but existing data suggest an important effect of c-
Met shedding in down-regulation of its activity. 
 
Effects of HGF/c-Met activity. The characteristic cellular responses to HGF - c-Met 
signalling in epithelial cells include “scattering” and invasion, induced by dissociation of cells 
and increased motility. By promoting cell survival, proliferation, morphogenesis, migration 
and angiogenesis, HGF/c-met signalling has essential roles in human embryogenesis, wound 
healing and tissue repair (105, 106). Efforts are made to utilize the positive effects of HGF in 
tissue regeneration, and HGF-treatment have also shown effectiveness in prohibiting 
development of fibrosis in various disease models including liver cirrhosis, lung fibrosis and 
dilated cardiomyopathy, reviewed in (106). Beyond the physiological roles, there is growing 
interest in the role of HGF/c-Met activity in tumour development. HGF/c-Met signalling is 
crucial in the event termed epithelial mesenchymal transition (EMT), a biological program  
characterized by loss of cell adhesion, repression of E-cadherin expression, and increased cell 
mobility (160). EMT is considered a central mechanism for metastasizing of epithelial 
tumours, in the biological program termed “invasive growth” (161, 162). In this way 
mechanisms that were meant for embryonic development and tissue repair are adopted by 
cancer cells for invasion and metastasis.  
 
HGF/c-Met activity is normally tightly regulated, by paracrine ligand delivery, ligand 
activation at the cell surface, and ligand-activated receptor internalisation and degradation 
(135). Deregulation of the HGF/c-Met pathway is common in cancer, and HGF and c-Met 
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expression and signalling have been demonstrated in several cancer types, including breast, 
colorectal, gastric, head & neck, liver, lung, pancreas, ovarian, renal, prostate, sarcoma and 
lymphoma (www.vai.org/met/) and (105). c-Met activation in cancer can be ligand-dependent 
or ligand-independent. Ligand-dependent deregulation may occur by paracrine activation – 
interactions between HGF, secreted by stromal cells, and c-Met, expressed by tumour cells, 
are central in the tumour-stromal interactions of several malignancies. It may also occur by or 
autocrine activation, as some tumours concomitantly secrete HGF and express c-Met (105, 
106). An additional mechanism is by acceleration of the conversion step of HGF to its 
activated form. It was recently shown that upregulation of matriptase had oncogenic effects 
via the Akt - mTOR pathway, mediated by conversion of pro-HGF to active HGF and 
signalling through c-Met (163). Ligand-independent activation may occur by mutation in the 
kinase or juxtamembranous domains of the MET gene (105), which is the causative genetic 
disorder in hereditary renal papillary carcinoma (164). MET mutations have been shown also 
in other cancer types including lung cancer, hepatocellular carcinoma and gastric carcinoma 
(105, 165). Although MET mutations occur at a relatively low frequency, they provide 
evidence of the oncogenic potential of the HGF/c-Met pathway (164). Also, HGF-
independent activation may occur through trans-activation of c-Met by other membrane 
receptors, including CD44, integrins, plexins, Ron and Fas. c-Met may also cooperate with 
other tyrosine kinase receptors in oncogenesis.  It has been shown that the gene encoding c-
Met is amplified in a subset of patients with non-small cell lung cancer resistant to the EGFR 
tyrosine kinase inhibitor gefitinib, and that c-Met can take over the activation of PI3K and 
ErbB3 from EGFR. In these instances, it would be necessary to inhibit both EGFR and c-Met 
to induce cell death (165, 166). 
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The HGF/c-Met signalling pathway as a target in cancer therapy. As one of the most 
frequently activated oncogenic proteins in human cancer (www.vai.org/met/) and (105), the 
HGF/c-Met pathway has become an increasingly attractive target in cancer treatment. 
Silencing the overexpressed MET gene in tumour cells was shown to suppress tumour growth 
and metastasis, and induced regression of established metastases in mouse models (167). 
Several inhibitors of the HGF/c-Met pathway are under preclinical and clinical development. 
Small synthetic molecules that inhibit c-Met tyrosine kinase activity comprise the largest 
group of agents currently under evaluation. Other approaches to inhibit HGF-c-Met activity 
include siRNA, ribozymes, neutralizing monoclonal antibodies (mAbs) directed against HGF 
or c-Met, soluble c-Met receptors, HGF-forms that resist proteolytic activation or its 
conformational consequences, and antagonists composed of selected domains of HGF (168, 
169). Among the latter group, NK4 was the first described inhibitor. NK4 consists of the HGF 
N-terminal and the four kringle domains and is a competitive inhibitor of HGF-induced c-Met 
activation. In addition, anti-angiogenic properties of NK4 has been demonstrated, and NK4 
have been shown to inhibit invasion and metastasis in several cancer types (170). NK4 also 
inhibits growth of myeloma cells (115). Other advanced drug candidates are mAbs against 
either HGF or c-Met. Most of them work by blocking HGF/c-Met binding, while the mAb 
DN-30 works by a different mechanism, by inducing ectodomain shedding and receptor 
degradation (152). 
 
HGF and c-Met in multiple myeloma. HGF is secreted by bone marrow stromal cells as 
well as by hematopoietic cells of the myeloid lineage and mature neutrophils in the bone 
marrow microenvironment (171-173), but neither HGF nor c-Met are expressed by normal 
plasma cells (93, 174, 175). In 1996, Børset et al showed that malignant plasma cells can 
produce HGF, and also express c-Met (176). HGF may therefore interact with c-Met in a 
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paracrine or autocrine manner. Serum HGF levels are elevated in MM patients as compared to 
healthy individuals, and high levels are associated with poor prognosis (177-179). The levels 
of HGF are higher in the bone marrow than in the circulation of MM patients (180), 
suggesting that the bone marrow is the main source of the elevated serum HGF. Also, levels 
of HGF mRNA in crude bone marrow biopsies of MM patients are significantly higher than in 
healthy individuals (Tian et al, manuscript in preparation). HGF was the only growth factor 
among the 70 most upregulated genes in malignant compared to normal plasma cells, as 
assessed by gene array analysis (174). Others have confirmed upregulation of the genes 
encoding HGF (175) and c-Met (93, 175) in myeloma cells as compared to normal plasma 
cells, and in another study, HGF and c-Met were among the transcripted genes distinguishing 
MM from the related B-cell lymphoproliferative disorders chronic lymphocytic leukaemia 
and Waldenströms macroglobulinemia (181). 
 
In vitro, HGF stimulates survival, proliferation, adhesion and migration of malignant plasma 
cells (63, 182-184), stimulate angiogenesis (185) and inhibit osteoblastogenesis (59). Besides 
its own actions as a growth factor, HGF may also potentiate the actions of IL-6 in 
proliferation and migration of myeloma cells (186). HGF and c-Met may thereby in many 
ways contribute to MM pathogenesis, and are considered as potential therapeutic targets also 
in MM (115) . However, the functional data on the actions of HGF and c-Met in MM are 
mainly derived from in vitro studies, and further studies in mouse models are warranted.     
 
1.2.8. Syndecan-1 
The syndecan family of HSPGs comprises four members, named syndecan-1 to -4 (187). 
Almost all cells express at least one of the syndecans, and they are the major source of cell 
surface HS. Syndecan-1 (CD138) is a type-I membrane protein with HS (and sometimes 
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chondroitin or dermatan sulphate) attached to its extracellular domain. The HS chains mediate 
attachment of heparin binding growth factors, and their structure is modified by heparanase 
and sulphatases. The short cytoplasmic tail of the core protein consists of a variable region 
(unique for syndecan-1), flanked by two conserved regions (that are identical between all 
syndecans). The C-terminal conserved region has a binding site for PDZ-domain containing 
proteins. These proteins are thought to connect syndecan-1 to signalling and cytoskeletal 
components (188, 189).  
 
Syndecan-1 is expressed in epithelial cells, and in some lymphoid cells: It is the 
predominating HSPG on normal and malignant plasma cells, and is also present on pre-B cells 
(190). Its relative specificity for plasma cells has made it useful for immunomagnetic 
separation of plasma cells from bone marrow (191).  
 
The syndecans bind a wide variety of molecules via their HS chains, thereby promoting 
adhesion between cells, and between cells and extracellular matrix (192, 193). They synergize 
with integrins to regulate cell adhesion (194). An important characteristic is also the ability to 
bind growth factors, thereby concentrating them at the cell surface (195). Syndecan-1 may 
also be shed from the cell surface, and by binding to soluble syndecan-1, growth factors may 
be sequestered/concentrated in the extracellular matrix (195). Several cytokines are known to 
bind to HS chains, such as FGF (196, 197), HGF (120, 122, 198), APRIL (199), VEGF (200), 
HB-EGF (64) and members of the bone morphogenetic protein (BMP) family (201). IGF-1 
does not bind HS, but it has been shown that binding of IGFBP-3 to HS chains weakens its 
affinity for IGF-1, leading to local release of IGF-1, indicating that both cell surface-bound 
and soluble syndecan-1 also can contribute to local concentration of IGF-1 (202).  
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By presenting a growth factor for its receptor, HSPGs can facilitate receptor dimerization. 
This phenomenon is best characterized for the FGF receptor, which is dependent on HS for 
signalling (Figure 7) (196, 203). Further, upon binding to a ligand, syndecans on the cell 
surface may translocate to lipid rafts (204), which are detergent insoluble, cholesterol-rich 
microdomains of the plasma membrane that function as platforms for cellular signalling 
(205). Possible consequences/implications of this latter phenomenon for growth factor 
signalling in cells abundant of syndecan-1 are largely unknown. 
 
 
Figure 7. By presenting a growth factor for its receptor, HSPGs can facilitate receptor 
dimerization.  Copyright © 2002 From MolecularBiology of The Cell by Bruce Alberts, et al. 
Reproduced by permission of Garland Science/Taylor & Francis Books, Inc. 
 
Several mediators of syndecan-1 shedding have been described, including matrix 
metalloproteinase (MMP)1, MMP7 (matrilysin), MMP9, and uPA (206-209). Soluble 
syndecan-1 remains biologically active, and accumulate in the extracellular matrix of the bone 
marrow, where it can act as a reservoir for growth factors (195). These reservoirs are thought 
to play a role in promoting myeloma pathogenesis, and possibly contribute to regeneration of 
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tumour after chemotherapy. There is a gradient of syndecan-1 concentration between bone 
marrow and peripheral blood, levels being higher in bone marrow than in serum of MM (180). 
High serum levels of soluble syndecan-1 in MM patients are associated with a poor prognosis 
(210, 211). 
 
We have taken particular interest in the interaction of syndecan-1 with HGF and c-Met in 
MM. It has previously been shown that soluble syndecan-1 can be measured at high levels in 
the bone marrow of MM patients (122, 180), and that HGF and syndecan-1 can exist as a 
complex (122). Syndecan-1 is targeted to the uropod of polarized myeloma cells where it can 
sequester HS-binding proteins (198), and it has been shown that syndecan-1 promotes HGF/c-
Met signalling (120). This phenomenon has mainly been explained by a syndecan-1-mediated 
concentration of HGF at the cell surface, presentation of HGF to c-Met and facilitation of 
receptor dimerization, in a mechanism parallel to the way in which FGFR dimerization is 
facilitated by HSPG (Figure 7) (196, 203). FGF signalling requires not only FGF-HS binding, 
but also FGF receptor – HS interaction (212), and a similar mechanism has been suggested in 
the case of HGF signalling, where HS may interact with both HGF and c-Met (118, 137, 213). 
In contrast, others have demonstrated little or no heparin binding capacity of c-Met (117). 
Recently, it was shown that heparanase, an enzyme that cleaves HS chains but also enhances 
syndecan-1 synthesis and shedding (206, 214, 215), in addition may stimulate HGF 
expression, the activity of which is further enhanced by interaction with shed syndecan-1 
(216). Syndecan-1-dependent growth of myeloma cells stimulated by other heparin-binding 
growth factors, such as EGF and APRIL, has also been demonstrated (64, 199). 
 
Thus, syndecan-1 regulates and promotes the activity of several myeloma-relevant growth 
factors, acting both on the cell surface and within the extracellular matrix of the bone marrow 
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environment. Since, within the bone marrow, syndecan-1 is almost exclusively expressed by 
plasma cells, it would theoretically be an ideal therapeutic target in MM (217). Antibodies 
against syndecan-1 can be used for targeting cytotoxic agents to myeloma cells, exemplified 
by murine/human syndecan-1-specific mAbs conjugated with cytotoxic maytansinoid 
derivates which have shown efficacy in vitro and in vivo (218). Antibodies against syndecan-1 
could also be used to stimulate immune-mediated myeloma cell killing (219, 220), or the 
syndecan-1 molecule itself could be the target. Knocking down syndecan-1 expression by 
RNA interference, as well as altering the HS structure, inhibited growth of primary myeloma 
tumours in severe combined immunodeficiency (SCID) mice (217, 221). Syndecan-1 
knockdown cells formed fewer focal subcutaneous tumour lesions when injected 
intravenously into mice, and syndecan-1 knockdown tumours exhibited lower levels of VEGF 
and reduced angiogenesis compared with tumours expressing normal syndecan-1 levels (221). 
Inhibition of heparanase, which enhances syndecan-1 synthesis and shedding, also inhibited 
myeloma growth in vivo (217).  
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2. AIMS 
The first aim of this work. The results of several in vitro studies point to HGF and its 
tyrosine kinase receptor c-Met as important contributors in MM pathogenesis. Most studies 
have been carried out in myeloma cell lines, and it is important to gain more knowledge about 
the expression of these factors in patients with MM. Thus, the first aim of this work was to 
contribute to knowledge about expression of c-Met, HGF and HGFA in patients with 
malignant plasma cell disease. More specifically, we wanted to investigate: 
 1) whether HGF and c-Met are present in bone marrow and extramedullary tumour biopsies 
from patients with monoclonal plasma cell disease and whether c-Met is activated, using a 
phospho-specific anti-c-Met antibody. 
2) whether the soluble form of c-Met can be detected in serum and bone marrow plasma of 
MM patients, and whether the concentration is different than in healthy individuals. 
3) whether HGFA can be detected in serum and bone marrow plasma of MM patients, and 
whether the concentration is different than in healthy individuals. 
 
The second aim of this work was to expand the knowledge about HGF/c-Met/syndecan-1 
interaction. It has previously been shown that syndecan-1 promote c-Met signalling. This has 
mainly been assigned to syndecan-1-mediated concentration of HGF at the cell surface, and to 
presentation of HGF to c-Met with facilitation of receptor dimerization. The syndecans have 
previously also been shown to localize in lipid rafts, and to mediate raft dependent 
endocytosis. We wanted to investigate whether HGF and c-Met are localized in lipid rafts 
together with syndecan-1, and whether lipid raft localization, and possibly raft dependent 
endocytosis, affects c-Met signalling.   
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The third aim of this work. Dependence on the bone marrow microenvironment and 
cytokines is one side of MM pathogenesis. Cytogenetic aberrations in the myeloma cells are 
another side, and the third aim of this work was to examine the prevalence of cytogenetic 
aberrations in Norwegian MM patients. We wanted to investigate whether there was a 
correlation between the defined cytogenetic abnormalities and clinical parameters at 
diagnosis. The final aim is to examine a possible prognostic impact of the defined genetic 
aberrations in terms of progression free and overall survival. The survival analysis will start 
by the end of 2011, and in this work we therefore report only findings at diagnosis.                                         
                                                                                                                                                                              
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 44
3. MATERIAL AND METHODS 
3.1. Statement of approval 
All the studies were approved by the Regional Ethics Review Board, and were performed 
according to the declaration of Helsinki.   
 
3.2. Patient samples 
Paper I – III includes serum and biopsies from patients diagnosed with MM, MGUS or 
solitary plasmacytoma in Central Norway from January 1996 to December 2005.  
 
For paper I, biopsies from patients with MM, MGUS and solitary plasmacytoma were 
identified from registered diagnostic codes at the Department of Pathology, St Olav’s 
Hospital, Trondheim. The biopsy material includes bone marrow biopsies, bone marrow clots 
from aspirates, and biopsies from plasmacytomas. During this time period, bone marrow 
biopsies were not routinely performed in all MM patients in this region. Thus, the study does 
not include all MM patients diagnosed in Central Norway in 1996-2005, but a selection based 
on the availability of adequate amount and quality of paraffin-embedded biopsy material.  
 
Paper II and III include serum and bone marrow plasma samples from MM patients diagnosed 
at St Olav’s Hospital during the same time period. The samples represent a selection of 
patients based on availability of serum and bone marrow plasma that had been frozen at the 
time of diagnosis, before initiation of treatment.  
 
Paper IV presents in vitro studies, mainly in human myeloma cell lines. The study also 
includes primary myeloma cells from freshly separated CD138-positive cells from four 
patients with MM.  
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The study described in Paper V is performed in another cohort of patients, and includes bone 
marrow samples from Norwegian MM patients examined by FISH from January 2006 to 
December 2010. The study includes all Norwegian MM patients from whom a bone marrow 
sample was sent for FISH analysis during this time period, provided that adequate amount and 
quality of bone marrow was available and that the FISH analysis was technically successful. 
Patients from 23 Norwegian hospitals were included. Plasma cells were purified by 3 different 
methods: In 2006 – 2008 the analyses were performed on bone marrow smears or smears of 
mononuclear cells, and the plasma cells were identified by antibodies against Ig kappa and 
lambda. This is a time consuming method, and from 2008 the analyses were performed on 
plasma cells after automated CD138 separation, which has been the standard since. 
 
3.3. Experimental procedures 
Immunohistochemistry for CD138 (syndecan-1), HGF, c-Met and phospho-c-Met on sections 
of paraffin-embedded biopsies was performed as detailed in Paper I. As very few earlier 
publications present immunohistochemical studies of HGF in bone marrow, we first validated 
the method in a pilot study as described. Enzyme-linked immunosorbent assays (ELISAs) 
were used for the measurement of activated HGFA, HGF and soluble c-Met in serum and 
bone marrow plasma, as detailed in Papers II and III. As the c-Met ELISA had been validated 
only for use in cell culture supernatants by the manufacturer, we first performed a pilot study 
in order to validate the ELISA kit for analyses in serum, and to confirm that it was able to 
detect the extracellular portion of c-Met. Confocal microscopy was used for studies on 
cellular distribution and colocalization of HGF, syndecan-1 and c-Met, as detailed in Paper 
IV. Flow cytometry was used for cell surface detection of HGF, c-Met and syndecan-1 as 
described in Paper IV. Immunoblotting was used for detection of non-phosphorylated and 
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phosphorylated proteins after stimulation with cytokines with or without pharmacological 
inhibitors, as described in Paper IV. Complexes between c-Met and syndecan-1 were detected 
by immunoprecipitation followed by Western Blot, as described in Paper IV. Chromosomal 
abnormalities (Paper V) were detected by interphase FISH.
 
3.4. Statistics                                                                                                                           
Pearson’s χ2 or Fisher’s exact tests were used for between-group comparisons of discrete 
variables. Comparisons between groups for continuous variables were performed using 
Student’s T-test or Mann Whitney U test. Correlations between two parameters were 
estimated by Spearman’s rank correlation analysis. Survival between groups was compared 
by the log rank test. For analysis of immunohistochemical staining, the inter-observer 
agreement was estimated by Cohen’s kappa statistics. Kappa between 0.4 and 0.6 was 
considered as a moderate agreement, kappa between 0.6 and 0.8 as a substantial agreement, 
and kappa >0.8 as an excellent agreement (222). In 2 x 2 tables with small or zero values 
(Paper I), exact p-values and exact confidence intervals for OS were computed using StatXact 
8 (Cytel Inc.Cambride, MA, USA). All other statistical calculations were performed by SPSS 
14.0 - 16.0 (SPSS Inc., Chicago, IL, USA). The level of statistical significance was set at p = 
0.05. All p-values were 2-tailed.  
 
 
 
 
 
 
 
 47
4. MAIN RESULTS/SUMMARY OF THE WORK 
Paper I  
In this study we aimed to examine whether HGF and c-Met are present in bone marrow and 
extramedullary tumour biopsies from patients with monoclonal plasma cell disease and 
whether c-Met is activated, using a phospho-specific anti-c-Met antibody. Expression of 
HGF, c-Met and phospho-c-Met was studied by immunohistochemistry in biopsies from 80 
patients with MM, MGUS and solitary plasmacytomas. We found cytoplasmic staining for 
HGF in the plasma cells in 58 of 68 biopsies from MM patients (85%), but also in biopsies 
from nine of ten healthy individuals. We found membranous staining for c-Met in 25 of 63 
MM patients (40%), and in none of ten healthy individuals. Membranous staining for 
phospho-c-Met was found in biopsies from 15 of 21 c-Met-positive MM patients. Thus, this 
study indicates that c-Met is a factor that discriminates normal from malignant plasma cells, 
and that the HGF/c-Met system is activated in MM patients.  
 
Paper II.                                                                                                                                     
Conversion of pro-HGF to its active form is a critical limiting step for its biological effects. In 
this study we aimed to examine the levels of one of its most potent activators, HGFA, in 
serum and bone marrow plasma of patients with MM. The activated form of HGFA was 
measured by ELISA in serum (n = 49) and bone marrow plasma (n = 16) from MM patients, 
and in serum from healthy controls (n = 24). The median concentration of activated HGFA in 
MM and control sera was 39.7 ng/mL (range 6.2 - 450.0) and 17.6 ng/mL (range 4.8 - 280.6), 
respectively. The difference was statistically significant (p=0.037). The median concentration 
of activated HGFA in bone marrow plasma was 6.1 ng/mL (range 3.5 - 30.0). In conclusion, 
we found that the concentration of the activated form of HGFA was elevated in serum from 
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patients with MM compared to healthy individuals, providing a possible mechanism for 
increased activation of HGF in MM.  
 
Paper III  
A soluble extracellular fragment of c-Met may function as a decoy receptor and downregulate 
the biological effects of HGF and c-Met. In this paper, we aimed to examine serum levels of 
soluble c-Met in MM patients and healthy individuals, and to investigate a possible 
relationship with clinical disease parameters and survival. The concentration of c-Met and 
HGF were measured by ELISA in serum (n = 49) and bone marrow plasma (n = 16) from 
MM patients, and in serum from healthy controls (n = 26). The median serum concentration 
of soluble c-Met was 186 ng/mL (range 22-562) in MM patients and 189 ng/mL (range 124-
397) in healthy individuals. There was a significant negative correlation between serum c-Met 
and disease stage, bone marrow plasma cell percentage, and serum concentration of M-
protein. In conclusion, we found equal median concentration of soluble c-Met in MM patients 
and healthy individuals, but still there was a negative correlation between serum soluble c-
Met and parameters of disease burden in MM patients.  
 
Paper IV 
In this paper we aimed to study the interactions between HGF, c-Met and syndecan-1 in MM. 
It has previously been shown that syndecan-1 promote c-Met signalling. The syndecans have 
also been shown to localize in lipid rafts, and to mediate raft dependent endocytosis. We 
wanted to investigate whether HGF and c-Met are localized in lipid rafts together with 
syndecan-1, and whether lipid raft localization, and possibly raft dependent endocytosis, 
affects c-Met signalling. We studied cell lines and primary myeloma cells by confocal  
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microscopy, flow cytometry, immunoprecipitation and Western Blot. We found that c-Met 
can exist as a complex with syndecan-1 in myeloma cells, and that c-Met is concentrated to 
the uropod of myeloma cells together with syndecan-1. We also found that HGF, c-Met and 
syndecan-1 are located to lipid rafts in the plasma membrane of myeloma cells. Disruption of 
lipid rafts by methyl-β-cyclodextrin inhibited HGF-mediated phosphorylation of Akt, but not 
phosphorylation of c-Met and ERK 1/2. Inhibition of dynamin by Dynasore inhibited 
endocytosis and reduced HGF-induced phosphorylation of Akt, whereas phosphorylation of c-
Met and ERK1/2 was unaffected. This study indicates that binding of HGF and c-Met to 
syndecan-1 and localization in lipid rafts, followed by raft dependent endocytosis, is 
important for HGF-induced Akt signalling in myeloma cells. 
 
Paper V 
Detection of cytogenetic abnormalities by fluorescence in situ hybridization (FISH) yields 
prognostic information in MM. In this study we examined the prevalence of the most common 
primary translocations and deletions/amplifications in 250 Norwegian MM patients, of whom 
214 were previously untreated. The final aim of the study is to examine a possible prognostic 
impact of the defined genetic aberrations in terms of progression free and overall survival. The 
survival analysis will start by the end of 2011, and in this work we therefore report only 
findings at diagnosis. FISH was performed on CD138 separated cells or with cytoplasmic-
immunoglobulin-FISH on mononuclear cells to detect IGH split, del13q, del17p, del1p and 1q 
amplification. When an IGH split was found, FISH was performed for t(4;14), t(11;14), t(6;14) 
and t(14;16). The results are summarized in table 3. There was no correlation between any of 
the IGH translocations and del13q, del17p or chromosome 1 abnormalities, but there was a 
strong correlation between del13q and del17p (p = 0.001), and between del1p and amp1q (p < 
 50
0.001). Clinical information was available in 135 patients. In these patients there were no 
significant correlations between genetic and immunological or clinical features.  
 
IGH split t(4;14) t(11;14) t(6;14) t(14;16) t(?;14) ¹ Del13q Del17p Del1p Amp1q 
45% 14% 16% 1% 2% 12% 35% 19% 10% 34% 
 
Table 3. Frequency of cytogenetic aberrations in Norwegian MM patients.
 
¹ Patients in whom an IGH split was found, but the translocation partner was not identified. In a majority of 
these patients there were not enough material to perform analysis of t(6;14) and t(14;16). 
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5. DISCUSSION 
5.1. Methodological considerations     
Results and interpretation are critically dependent on the quality of the methods used, and this 
chapter will focus on some important methodological considerations of this work. 
        
Patient samples and myeloma cell lines. As described in the Methods section, the 
immunohistochemistry (Paper I) and the serum studies (Paper II and III) do not include all 
MM, MGUS and plasmacytoma patients diagnosed in Central Norway in 1996-2005, but a 
selection based on availability of biopsy material, serum and/or bone marrow plasma. During 
this time period, bone marrow biopsy was not routinely performed in all MM patients. There 
is therefore a possibility that the immunohistochemistry study comprises a selection of 
patients in whom there were particular differential diagnostic considerations, leading the 
physician to perform a bone marrow biopsy in addition to a bone marrow smear. Therefore, 
we cannot state that this population is representative of the general Norwegian MM 
population. Similar considerations apply to the MGUS patients of the immunohistochemistry 
study: the samples include only a small selection of patients in whom bone marrow biopsies 
were performed. This might have selected patients in whom the distinction between MGUS 
and MM was difficult. Finally, we cannot exclude sampling bias caused by selection of 
patients who where diagnosed and treated at a University Hospital. 
 
A strength and weakness of the studies presented in Paper I – III lies in the long follow up 
time for the patients. Including patients diagnosed as far as 15 years ago gives opportunity for 
long time follow up. However, as introduction of new drugs has improved the overall 
prognosis during the last decade, a patient diagnosed in 1996 is not necessarily comparable 
with one diagnosed in 2005. This may affect survival analysis, as further discussed below. β2-
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microglobulin was not routinely analysed in the MM patients during the first years, making 
retrospective ISS staging incomplete. Further, the retrospective nature of these studies leaves 
us without knowledge about cytogenetic changes in the patients.  
 
Paper V includes a different cohort of MM patients from 23 Norwegian Hospitals from whom 
bone marrow samples were sent for FISH analysis from January 2006 to December 2010. All 
Norwegian MM patients who were analysed by FISH during this time period were included, 
provided a successful FISH analysis was performed. Although this cohort includes patients 
from several local hospitals there is an over-representation of patients from University 
Hospitals, which might lead to a selection, particularly of younger patients. 
 
For paper IV we worked with the human myeloma cell lines (HMCL) INA-6 and CAG. 
HMCLs grown in monoculture in the laboratory are central research tools in most preclinical 
studies in MM, as isolated primary myeloma cells only rarely survive outside the bone 
marrow microenvironment. HMCLs differ significantly from primary myeloma cells. Most 
HMCLs are established from extramedullary manifestations in relapsed patients, often from 
pleural effusions, or from blood in plasma cell leukaemia, representing cells that are 
independent of the bone marrow microenvironment (223, 224). During cell line 
establishment, a clonal selection of rapidly proliferating cells may also occur (225). Thus, 
these cells are typically more proliferative, and exhibit genetic features of highly aggressive 
disease, with secondary genetic changes rarely encountered in newly diagnosed MM patients. 
The limitations with HMCLs as a tool for studies of factors thought to be important in the 
bone marrow microenvironment are obvious. Still, HMCLs have proven useful in providing 
simplified systems for studies on biological and molecular mechanisms for central functions 
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of myeloma cells (223, 226), and have provided essential knowledge that have during the 
years also contributed to development of new therapy (227). 
 
We also worked with variants of the EBV-transformed B-lymphoblastoid cell line ARH-77, 
which was established from a patient with plasma cell leukaemia, and which does not express 
syndecan-1 (192).  ARH-77syn-1 and ARH-77A5P3  stably express syndecan-1, while ARH-
77neo expresses only control vector (193, 228). Although these cell lines are useful tools that 
have earlier been used in several studies on the function of cell-bound syndecan-1, they are 
not true myeloma cell lines, making it even more obvious that observations made in these 
cells are not necessarily valid for the in vivo situation in MM, and have to be interpreted with 
caution. 
 
Because of these considerations, we also studied freshly isolated primary myeloma cells when 
this was possible. Primary myeloma cells were isolated from bone marrow aspirates by 
immunomagnetic CD138 separation (191). This was done “by hand” using immunomagnetic 
beads before our laboratory in 2008 had access to automated CD138 separation (RoboSep©). 
The high specificity of CD138 (syndecan-1) for plasma cells in the bone marrow has made it 
to the most common tool for separation of plasma cells (191). CD138 has also become the 
most common way of identifying plasma cells on histological examination (229). However, it 
should be noted that a CD138-negative subpopulation of myeloma cells with more immature 
features and higher proliferative potential have been described, which will be excluded in all 
research performed on CD138-selected cells (230). Kappa/lambda staining is an alternative 
way of identifying plasma cells in immunocytochemical/-histochemical studies, that would 
also include a possible CD138-negative population, and could be considered for future 
studies. 
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Immunohistochemistry is a semi-quantitative method. It is common in research publications 
to present a rather detailed analysis of immunohistochemical staining by grading the number 
of stained cells and/or the staining intensity, and sometimes to combine these parameters to a 
“staining index”. After testing of the antibodies and experience with their staining 
characteristics, we decided to modify this approach for the study presented in Paper I. The 
immunohistochemical staining was performed by the same, very experienced, technician in 
the same laboratory. The scoring was performed independently by two researchers. The 
specificity of the staining was tested by three types of controls: Omitting the primary 
antibody, replacing it with non-immune serum, and pre-adsorbing the antibody with 
corresponding antigen peptide. For c-Met and phospho-c-Met, we encountered problems with 
non-specific staining in some sections, and the non-specific staining was difficult to 
discriminate from a weak cytoplasmic staining of the cells. We therefore chose to define a cell 
as positive for c-Met or phospho-c-Met only if there was a clear membranous staining. We 
also decided to define a biopsy section as positive if 10% or more of the cells were positive, 
with no further grading/quantification than negative or positive. The strict but rather coarse 
definitions used may underestimate the percentage of positive cells and the number of positive 
biopsies. However, we found it to be the most robust way to categorize and interpret the 
results.  
 
Confocal microscopy. Some methodological issues, like non-specific antibody staining, are 
common to immunohistochemistry and confocal microscopy, making rigorous control 
measures necessary. Even with adequate controls for non-specific staining, there will remain a 
risk for cross-reactivity of the primary antibody with similar epitopes on other proteins, 
especially when using short peptide antibodies. The interpretation of results will always 
comprise some degree of subjectivity, and there is a possibility for bias when capturing 
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images. By examining the same phenomenon by more than one method, exemplified by the 
combination of confocal studies with immunoprecipitation and flow cytometry for the studies 
on c-Met – syndecan-1 interaction in Paper IV, we have efforted to make the results more 
robust.  
 
Serum analyses. Only serum from peripheral blood, and plasma from bone marrow, were 
available for analyses in the studies presented in Paper II and III. Optimally, we would have 
analyzed either serum or plasma from both localizations. Although the difference between 
measurements in serum and plasma in many cases are negligible, there can be significant 
differences. In control experiments, we found lower concentrations of activated HGFA in 
plasma than in serum from blood samples drawn at the same time from the same patient. 
Because this phenomenon was also confirmed by the ELISA manufacturer (IBL, Japan), we 
did not perform a full control series to quantify the serum/plasma difference, but settled with 
the fact that we could not compare bone marrow plasma samples with serum samples. Results 
by this ELISA were otherwise reproducible with variation coefficients <10%.  
 
This chapter has focused only on some important methodological considerations of this work. 
However, the methodological problems mentioned are universal and shared by all 
investigators in the field. There are possible uncertainties with all laboratory methods, 
underscoring the importance of adequate controls. By relevant control measures and, when 
possible, by studying the same phenomenon by more than one method, we have tried to partly 
overcome these uncertainties. 
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5.2. General discussion, conclusion and future directions 
MM pathogenesis is multifaceted and involves intrinsic properties of the myeloma cells, 
including the disease-defining primary translocations and later occurring genetic events, but 
also complex interactions with several cell types and cytokines in the bone marrow 
microenvironment. While Paper V focuses on cytogenetic aberrations, the main focus of this 
work lies on the cytokine HGF and its receptor tyrosine kinase c-Met.  
 
5.2.1. Expression of HGF and c-Met in the bone marrow of MM patients.  
HGF and its receptor c-Met are established as mediators of growth, survival, adhesion and 
migration of myeloma cells in vitro (63, 182-184). HGF/c-Met signalling can also contribute 
to angiogenesis (175, 180) and inhibit osteoblastogenesis (59), and may therefore by multiple 
means contribute to MM pathogenesis. Most studies have been carried out in myeloma cell 
lines, and this work aimed at gaining more knowledge about the expression of these and 
related factors in patients with MM. c-Met is upregulated in MM patients compared to healthy 
individuals at the mRNA level (93, 175). In this work, we have shown that c-Met also at the 
protein level is a factor that distinguishes malignant from normal plasma cells. We also show 
that c-Met exist in its phosphorylated state in a proportion of MM patients, supporting that the 
HGF/system is active in MM (Figure 8).  
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Figure 8. Bone marrow section showing membranous staining for phosphorylated c-Met in 
the plasma cells of a patient with MM. Enlarged section from photography with original 
magnification x 600. Photography by A Bofin, Department of Laboratory Medicine, 
Children’s and Women’s Health, Faculty of Medicine, NTNU, Trondheim. 
 
These findings are significant both from a biological and a clinical point of view: First, they 
add substance to earlier in vitro data on the effects of HGF/c-Met signalling in myeloma cell 
lines, and in this way add to knowledge about myeloma biology. Second, they support that the 
HGF/c-Met axis should be evaluated as a therapeutic target in MM, and that 
immunohistochemistry could be a method for identifying patients who are candidates for 
HGF/c-Met targeted therapy. However, before immunohistochemical analyses of c-Met and 
phospho-c-Met could be introduced as methods for the clinical setting, the methods will have 
to be further validated, and one should search for antibodies with a better signal-to-noise ratio 
than the ones used here, to make evaluation feasible. 
 
We found positive staining for c-Met and phospho-c-Met in the nucleus of the myeloma cells 
in some samples (Figure 9). Nuclear localization of c-Met, or a carboxy-terminal fragment of 
c-Met, has previously been described in other cancer cell types (231, 232). Because the pre-
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defined criterion for a c-Met- or phospho-c-Met-positive case in this study was the presence 
of a clear membranous staining, we did not include nuclear staining in the analysis, but a 
possible translocation of c-Met to the nucleus in MM is a new finding that  should be subject 
to future studies. 
 
Figure 9. Bone marrow section showing nuclear staining for c-Met in the plasma cells of a 
patient with MM. Original magnification x 400. Photography by KF Wader. 
 
Malignant plasma cells can produce HGF, but HGF is also secreted by many other cell types 
in the bone marrow, including stromal cells and cells of the myeloid lineage. Immunostaining 
for HGF could therefore be expected be found in several cell types and in the extracellular 
matrix. In contrast, we found HGF staining concentrated to the myeloma cells, with a 
comparatively very week staining of the background and other cell types (Figure 10).  
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Figure 10.  Bone marrow section showing HGF staining concentrated to myeloma cells, with 
a comparatively week staining of the background and other cell types. Original magnification 
x 600. Photography by KF Wader. 
 
We also found HGF immunoreactivity of normal plasma cells, seemingly in contrast to earlier 
gene expression data which showed that HGF is not expressed by normal plasma cells (174, 
175). A reasonable explanation of this contradictory finding is that HGF is concentrated to the 
plasma cells through binding to syndecan-1. A general impression from the microscopy part 
of this study was that the HGF-staining everywhere appeared as a mirror of the syndecan-1 
(CD138) staining. In this scenario, HGF would bind both to normal and malignant plasma 
cells, although it would have biological consequences only in malignant cells that express the 
c-Met receptor. In conclusion, this study supports that bone marrow plasma cells are richly 
supplied with HGF, but immunohistochemistry will probably not prove useful as a method for 
discriminating myeloma patients with HGF-producing plasma cells from those who are 
soaked in HGF from paracrine sources.                                                    
 
5.2.2. Syndecan-1, lipid rafts and Akt signalling   
Previous studies have shown that HGF can exist in a complex with syndecan-1, and bind to 
syndecan-1 at the surface of myeloma cells (120, 122, 198). In the present work (Paper IV) 
 60
we have shown that also c-Met can exist in a complex with syndecan-1, which would lead to a 
tightly bound ternary complex between HGF, c-Met and syndecan-1 in MM cells (Figure 11). 
Syndecan-1 has previously been shown to localize in lipid rafts, which are cholesterol-rich 
microdomains of the plasma membrane that function as platforms for cellular signalling (204, 
205, 233). We found that HGF and c-Met colocalize with syndecan-1 in lipid rafts, and 
further, this raft localization (followed by raft dependent endocytosis) was important for 
HGF/c-Met signalling through the PI3K/Akt pathway. Thus, a mechanism by which 
syndecan-1 promotes Akt signalling in MM cells may be recruitment of c-Met to these 
signalling microdomains (Figure 11). In this way c-Met signal transduction seem to be 
assisted not only by functional interaction with signalling amplifiers, but also by structural 
and topographical regulation at the plasma membrane.  
 
 
 
Figure 11. Schematic illustration of syndecan-1, HGF and c-Met in a lipid raft domain of the 
plasma membrane. See text for details. Illustrated by KF Wader. 
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So, while recent years’ research on syndecan-1 in MM mainly has focused on the shed, 
soluble form of syndecan-1 (195, 234), our data suggest an important role also for cell 
surface-bound syndecan-1. Akt-signalling is an important pro-survival factor in MM cells (90, 
235), and the relevance of our findings is mainly a contribution to insights into the 
mechanisms by which HGF, c-Met and syndecan-1 interact to promote HGF/c-Met signalling 
through Akt in myeloma cells. Hopefully improved knowledge about such basic mechanisms 
in the future can contribute to identification of ways to inhibit the HGF/c-Met axis. An 
equally attractive target for MM therapy could be syndecan-1, as a promoter of the activity of 
several myeloma-relevant growth factors.  
 
5.2.3. Activation of HGF 
For biological activity, HGF has to be activated from its pro-form by proteolytic cleavage. 
HGFA is one of the main activators of HGF (113), and we have shown in this work that 
serum levels of activated HGFA are higher in myeloma patients than in healthy individuals of 
the same age. This finding points to another mechanism by which HGF/c-Met activity may be 
enhanced in multiple myeloma - by increased level and/or activity of one of its main 
activators. The fact that HGFA is mainly activated by thrombin (113, 125) poses an 
interesting connection between activation of the coagulation system and activation of a 
tumour-promoting cytokine. Further, it is interesting that HGFA earlier has been shown to 
bind to HSPG (127) and that its activation requires the presence of negatively charged 
molecules, such as heparin, HS or chondroitin sulphate (125). In that way, not only HGF, but 
also activated HGFA, could possibly be sequestered in the bone marrow and concentrated to 
myeloma cells mainly via syndecan-1. It has also earlier been shown that myeloma cells may 
produce HGFA (132). We do not know whether the malignant plasma cells are the source of 
the elevated serum concentration of activated HGFA in myeloma patients, or if other factors, 
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like an activated coagulation system, may contribute. It is a draw back of our study, that only 
serum from peripheral blood, and bone marrow plasma, were available for analysis. The assay 
we used measures lower HGFA concentrations in plasma than in serum, and thus we could 
not reliably examine whether there was a difference between the levels of HGFA in the bone 
marrow and in the peripheral blood. Several other activators of HGF exist, and the role of  the 
most potent ones, matriptase and hepsin, would be relevant to study in MM. It would also be 
relevant to examine the expression and function of the HGFA inhibitors, especially HAI-1, in 
MM.  
 
5.2.4. Down-regulation of c-Met activity by decoy receptors 
HGF/c-Met activity may be regulated in several ways. One way of down-regulating its 
activity is by decoy c-Met receptors. Compelling evidence support that shedding of the c-Met 
ectodomain can hamper HGF/c-Met signalling, by different mechanisms as described in the 
introduction (page 33). Thus, the soluble ectodomain can compete for HGF, and prevent HGF 
from interacting with c-Met at the cell surface. The soluble ectodomain can also interact with 
full size c-Met, preventing it from dimerization and activation. Shedding of the ectodomain 
also leave a surface-associated cytoplasmic remnant, which is subsequently degraded. Serum 
levels of c-Met may therefore be of relevance in MM patients. In our study the median serum 
concentration was not different in MM patients than in healthy individuals, but serum levels 
of soluble c-Met still showed a consistent negative correlation with several parameters of 
disease burden: bone marrow plasma cell percentage, ISS stage and concentration of serum M 
protein. Although these correlations should be regarded only as observations that give no 
information about causality, they may indicate a biological relevance of c-Met shedding in 
multiple myeloma, which hopefully will be elucidated in the future. 
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5.2.5. General remarks 
Papers I, II and III are the first ones to comprehensively study the concentration in serum and 
the expression in biopsies, respectively, of the examined factors in MM patients. In none of 
these studies we found an impact on survival by the factors studied. The studies are however 
retrospectively performed in relatively small patient cohorts, and in a heterogeneous 
population with regards to therapy. For example, few of the earliest patients had access to new 
drugs like thalidomide, lenalidomide and bortezomib. To proper answer the question of a 
possible prognostic impact of serum levels of HGFA and c-Met, and of c-Met expression by 
immunohistochemistry, new studies should be performed based on the knowledge gained in 
these first studies, and in a more homogeneous population with regards to therapy. 
 
However, it should be noted that factors that may be biologically important in the 
pathogenesis of a disease, do not necessarily need to have prognostic associations. For 
example, if a given subtype of MM was dependent on a specific factor, the presence of this 
factor would not necessarily have any prognostic impact in MM patients (as a group), but 
could still be an important predictive factor, as it would sort out patients who could be 
considered for treatment directed against this specific factor. This way of thinking has lead to 
the concepts “prognostic classification” versus “predictive classification” (19). 
 
5.2.6. Conclusive remarks on HGF and c-Met in multiple myeloma 
This work has made contributions to a growing mass of knowledge about HGF, c-Met and 
related factors in MM. Do the accumulated data to date mean that the HGF/c-Met axis is 
important in MM? Still, there are no really good in vivo data to firmly establish HGF and c-
Met as major players in myeloma pathogenesis. Serum levels of HGF are elevated and 
associated with poor prognosis in MM patients, and there are correlations between serum 
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levels of HGF and bone marrow angiogenesis (180) and between serum levels of HGF and 
bone disease (59). These correlations, however, do not prove causality, and there is a 
possibility that HGF in these studies is merely a marker for tumour burden. Another 
possibility is that serum HGF is a marker for syndecan-1, which might be a more important 
actor, given its role as a multifunctional regulator of several cytokines in the bone marrow. 
Still, the accumulating mass of data on the effects of HGF on crucial functions in myeloma 
pathogenesis, as cell survival, proliferation, adhesion, migration, angiogenesis and impaired 
osteoblastogenesis, its prognostic impact in serum, and the fact that both HGF and c-Met are 
upregulated in malignant compared to normal plasma cells (93, 174, 175), supports that the 
HGF/c-Met axis should be further evaluated in vivo. The future will hopefully bring valid data 
from mouse models, followed by studies on targeting the HGF/c-Met axis in MM patients.   
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 Abstract  
Aims 
Interaction with the bone marrow microenvironment plays an important role for homing and 
survival of myeloma cells. One cytokine involved in this process is hepatocyte growth factor 
(HGF). HGF, by binding to the receptor tyrosine kinase c-Met, mediates a broad range of 
tumor progression activities. Our aims were to investigate whether HGF and c-Met are 
present in bone marrow and extramedullary tumors from patients with monoclonal plasma 
cell disease, and whether c-Met is activated. 
Methods and Results 
Expression of HGF, c-Met and phospho-c-Met was studied by immunohistochemistry in 
biopsies from 80 patients with monoclonal plasma cell disease. Cytoplasmic staining for HGF 
in the plasma cells was demonstrated in 58 out of 68 biopsies from multiple myeloma patients 
(85%), but also in biopsies from nine of ten healthy individuals. Membranous staining for c-
Met was found in 25 of 63 multiple myeloma patients (40%), and in none of ten healthy 
individuals. Membranous staining for phospho-c-Met was found in biopsies from 15 of 21 c-
Met-positive myeloma patients (71%).  
Conclusions 
Our data point to c-Met as one of the factors that distinguish normal from malignant plasma 
cells, and indicate that the HGF/c-Met system is activated in multiple myeloma patients. 
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Introduction 
Multiple myeloma is an incurable hematological malignancy, caused by clonal expansion of 
malignant plasma cells in the bone marrow. The bone marrow microenvironment plays an 
important role for homing and survival of myeloma cells. Several cytokines are involved in 
the interaction between malignant plasma cells and the bone marrow microenvironment. One 
of them is hepatocyte growth factor (HGF). HGF is produced by bone marrow stromal cells,1,2 
and may also be produced by myeloma cells.1,3,4 Serum HGF levels are elevated in myeloma 
patients as compared to healthy individuals, and high levels are associated with poor 
prognosis.5,6  
  
When binding to HGF, the receptor tyrosine kinase c-Met becomes phosphorylated at specific 
tyrosine residues in the cytoplasmic domain, creating docking sites for intracellular signal 
transducers. Important signaling pathways downstream of c-Met are the Ras – mitogen 
activated protein kinase (MAPK), the phosphatidylinositol 3-kinase (PI3K) – Akt, and the 
signal transducer and activator of transcription (STAT) signaling pathways.7 In vitro, HGF 
stimulates survival, proliferation, adhesion and migration of malignant plasma cells8-10 and 
inhibit osteoblastogenesis,11 suggesting that the HGF/c-Met system by several mechanisms 
may contribute to multiple myeloma pathogenesis. Besides its own actions as a growth factor, 
HGF may also potentiate the actions of interleukin-6 in proliferation and migration of 
myeloma cells.12 Growing evidence points to HGF as an important factor in the development 
of multiple myeloma, and the HGF/c-Met system is therefore a promising target for multiple 
myeloma therapy.13,14 
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We aimed to investigate whether HGF and c-Met are present in bone marrow and 
extramedullary tumors from patients with monoclonal plasma cell disease and whether c-Met 
is activated, using a phospho-specific anti-c-Met antibody. Secondly, we aimed to investigate 
a possible relationship between HGF/c-Met staining and patient outcome in terms of survival. 
 
Material and methods 
Patient samples  
We analyzed bone marrow samples from 80 patients diagnosed with monoclonal plasma cell 
disease in central Norway between 1996 and 2005. 68 patients had multiple myeloma, six 
patients had monoclonal gammopathy of undetermined significance (MGUS), and six patients 
had a solitary plasmacytoma (table 1A). The material consisted of bone marrow trephine 
biopsies, clots from bone marrow aspirates and biopsies from plasmacytomas localized 
extramedullary or in bone. For ten of the myeloma patients, bone marrow plasma and serum 
were also available. All samples were obtained at diagnosis, and before initiation of treatment. 
We included all biopsies that were taken from previously untreated patients with monoclonal 
plasma cell disease during this time period, provided that sufficient material was available. 
We also examined ten bone marrow biopsies that were taken during the same time period 
from individuals in whom a bone marrow disease had been suspected, but was not confirmed. 
These persons are in the following sections termed as healthy individuals, referring to their 
morphologically normal bone marrow, although their complete health status is not known. 
 
 5
Clinical information about the myeloma patients was obtained retrospectively from the patient 
records, without knowledge of the HGF/c-Met results. Registered information was stage 
according to Durie Salmon and International Scoring System (ISS), type and concentration of 
serum and urin M-protein, plasma cell percentage in bone marrow aspirate, serum β2-
microglobulin and overall survival. Bone disease was assessed by X-ray, and scored 
semiquantitatively. Five regions were defined: The cranium, vertebral spine, pelvis, long 
bones and other areas. Each region was scored according to the following system: 0 (no 
osteolytic lesions), 1 (less than five osteolytic lesions) or 2 (five or more lesions). The total 
score was calculated as the sum of all five regions. The serum M-protein was of IgG type in 
66%, IgA type in 7%, other Ig isotypes in 4% and more than one isotype in 3% of the 
patients. 16% of the patients had only light chain secretion and 3% had non-secretory 
myeloma. 23% of the patients were in International Scoring System (ISS) stage 1, 31% were 
in stage 2 and 23% in stage 3; for 22% no ISS information was available (Table 1B). The 
study protocol was approved by the Regional Ethics Committee. The study was carried out in 
accordance with the declaration of Helsinki.  
  
Antibodies and other reagents 
A polyclonal antibody against the HGF β chain (H495) from IBL (Hamburg, Germany) was 
used at dilution 1:50. A polyclonal antibody against the HGF alpha chain (H-145) from Santa 
Cruz Biotechnology (SCBT) (Santa Cruz, CA, USA) was used at dilution 1:100. The 
monoclonal HGF antibody 2D7 was made in our laboratory as previously described5 and used 
at dilution 1:100. The anti-c-Met C-28 antibody from SCBT was used at dilution 1:200. The 
anti-phospho-c-Met pYpYpY1230/1234/1235 antibody from Biosource/Invitrogen (Carlsbad, 
CA,USA) was used at dilution 1:100. The anti-CD138 antibody (clone MI15) from Dako 
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(Glostrup, Denmark) was used at dilution 1:100. Peptides for control experiments were 
purchased from IBL (HGF), SCBT (c-Met) and Biosource (phospho-c-Met).  
  
Immunohistochemistry 
The biopsies were fixed in formalin, decalcified in EDTA and embedded in paraffin. Sections 
cut at 4 μm were mounted on Cryostat glass, deparaffinised in xylene and rehydrated through 
a graded series of ethanol solutions to distilled water. Heat induced antigen retrieval was done 
in a steamer for 12 min. For the HGF staining, the sections were incubated with primary 
antibody in Tris-buffered saline, 0.25% BSA, 0.25% Tween 20, pH 7.6 for 1 hour at room 
temperature. For the c-Met and phospho-c-Met staining, blocking of non-specific staining in 
Tris-buffered saline, 2.5% BSA, pH 7.6 was done for 1 hour, before incubation with the 
primary antibodies in Tris-buffered saline, 0.25% BSA, 0.25% Tween 20, pH 7.6 for 24 hours 
at 4 ºC. Endogenous peroxidase activity was quenched with H2O2, and immunohistochemical 
reactions were visualized with DakoCytomation EnVisionDAB, K5007. Sections were 
counterstained with hematoxylin. All the slides were processed by the same technician in the 
same laboratory. 
  
We validated the HGF immunohistochemistry method in a pilot study, using the three 
antibodies described above on 12 bone marrow biopsies. These biopsies were not part of the 
main study population. The HGF beta antibody from IBL had a minimum of background/non-
specific staining and was chosen for the main study. The C-28 anti-c-Met antibody has been 
widely used for immunohistochemistry studies,15,16 and was therefore not included in the pilot 
study. Control for specificity was carried out by 1) omitting the primary antibody, 2) 
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replacing it with non-immune rabbit immunoglobulins, and 3) preincubating the primary 
antibody over night at 4 ºC with a molar excess of the antigen by which it was raised. To test 
the specificity of the immunoreaction of phosphorylated c-Met, a blocking experiment was 
performed, where the primary antibody was pre-incubated over night at 4 ºC with a molar 
excess of the phosphorylated or non-phosphorylated antigen peptide. An 
immunohistochemical staining that was blocked by the phosphorylated, but not by the non-
phosphorylated peptide, was considered a phospho-specific reaction. 
  
The plasma cells were identified by CD 138 staining of sections adjacent to the HGF and c-
Met sections. Only cases with positive immunoreaction for CD138 in the plasma cells were 
included. For each antigen, we evaluated the percentage of immunoreactive cells per case and 
the cellular location of the staining. The percentage of positively stained cells was determined 
by counting at least 200 plasma cells from two different areas. For patients with MGUS, and 
for healthy individuals, a lower number of plasma cells were counted. We scored the 
expression as positive when the proportion of immunoreactive plasma cells was 10% or 
higher. The scoring was performed independently by two researchers (KFW and UMF) 
without knowledge of diagnosis or clinical information. Discrepancies were resolved by joint 
review together with a senior pathologist (AB) on a multihead microscope. The inter-observer 
agreement by kappa statistics was estimated to 0.58, defined as moderate agreement.17 The 
main source of disagreement was coexistence of background staining and faint cell staining in 
the same slide. Images were captured using a Nikon Eclipse 80i microscope and Nikon dig 
SIGHT DS5-M camera, and processed by Nikon Imaging Software NIS-Elements (Nikon 
Instruments Europe B.V., Badhoevedorp, Netherlands). 
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ELISA 
HGF was measured with an ELISA from R&D systems (Minneapolis, MN, USA). The assay 
was performed according to the manufacturer’s instructions. All samples were run in 
duplicates. The standard curve was linear between 0.5 and 8 ng/mL. Due to limited quantities 
of sample material the measurements could not be repeated and therefore samples with HGF 
concentrations above 8 ng/mL were given the value 8 ng/mL. Variation coefficients for the 
measurements were <10%. 
  
Statistics 
Inter-observer agreement was estimated by Cohen’s kappa statistics. Kappa between 0.4 and 
0.6 was considered as a moderate agreement, kappa between 0.6 and 0.8 as a substantial 
agreement, and kappa >0.8 as an excellent agreement.17 Pearson’s χ2 or Fisher’s exact tests 
were used for between-group comparison of discrete variables. Comparisons between groups 
for continuous variables were performed using Mann Whitney U test. Survival between 
groups was compared by the log rank test. In 2 x 2 tables with small or zero values (Table 
2A,B), exact p-values and exact confidence intervals for OS was computed using StatXact 8 
(Cytel Inc.Cambride, MA, USA). All other statistical calculations were performed by SPSS 
16.0 (SPSS Inc., Chicago, IL, USA). The level of statistical significance was set at p = 0.05. 
All p-values were 2-tailed.  
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Results 
HGF accumulates in normal and malignant plasma cells 
First, we examined the expression of HGF as assessed by immunohistochemistry in biopsies 
from 80 previously untreated patients with plasma cell disease and ten healthy individuals. 
Cytoplasmic staining for HGF in the plasma cells was demonstrated in 58 of 68 biopsies from 
multiple myeloma patients (85%), six of six MGUS biopsies (100%) and six of six 
plasmacytoma biopsies (100%). We also found positive reaction for HGF in plasma cells in 
nine of ten of the normal bone marrow samples (90%), and in the plasma cells of a reactive 
gingival lesion (Table 2A) (Figure 1). The specificity of the staining was verified by control 
experiments as described in Methods (Figure 1). There was no significant difference in 
percentage of positive cases, or staining intensity, between biopsies from healthy individuals 
and biopsies from patients with multiple myeloma, MGUS or solitary plasmacytoma (Table 
2A). In the bone marrow of normal individuals, MGUS and multiple myeloma, other 
hematopoietic cells, mainly megakaryocytes, myeloid precursors at all stages and mature 
neutrophils were faintly positive for HGF, but by far the strongest staining was seen in the 
plasma cells (Figure 1).  
 
The HGF-negative patients had a lower bone marrow plasma cell percentage as assessed by 
bone marrow aspirate (median plasma cell infiltration 10%) than the HGF-positive patients 
(median plasma cell infiltration 34%). The difference was statistically significant (p = 0.016). 
Information of ISS stage was available for six of the ten patients with a HGF-negative biopsy. 
None of the six HGF-negative patients were in ISS stage 3, while 16 of 47 (34%) of the HGF-
positive patients were in ISS stage 3. The difference was not statistically significant (p = 
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0.10). There was no significant difference in the severity of bone disease, concentration of 
serum M-protein, serum β2-microglobulin or overall survival between patients with a HGF-
negative or positive biopsy (data not shown).  
  
We then examined the concentration of HGF in serum and bone marrow plasma of ten of the 
myeloma patients. The concentration of HGF was higher in the bone marrow than in serum in 
eight of ten patients. In one patient the levels were higher in serum, and one patient was not 
evaluable due to levels above the dynamic range (Figure 3). 
 
c-Met is expressed in malignant plasma cells.  
Sections from the same 68 biopsies were then stained for c-Met. Biopsies from five of the 68 
patients were not evaluable because of high background staining, and were therefore excluded 
from analysis. Positive staining for c-Met in the plasma cells was demonstrated in biopsies 
from 25 of 63 evaluable multiple myeloma patients (40%) (Table 2B). The staining pattern 
was membranous and/or cytoplasmic. In some cases there was also a faint nuclear staining. 
The staining of the plasma cells was specific, as shown by the control experiments described 
in Methods. However, there was some background staining in several cases, and due to 
difficulties in discriminating a weak cytoplasmic/nuclear staining from the background, we 
decided only to regard cells with a clear membranous staining as truly positive. None of the 
ten biopsies from healthy individuals had positive c-Met staining in plasma cells. The 
difference between myeloma patients and healthy individuals was statistically significant, p = 
0.021. Positive staining for c-Met was also seen in four of six MGUS patients (67%), but in 
only one of six patients with a solitary plasmacytoma (17%) (Table 2B).  
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There was concomitant positive staining for both HGF and c-Met in the plasma cells of 23 of 
63 myeloma patients (36%), four of six MGUS patients (67%) and one of six plasmacytoma 
patients (17%). There was no significant correlation between positive HGF and c-Met  
staining. There was no significant difference in disease stage according to ISS, severity of 
bone disease, concentration of serum M-protein, serum β2-microglobulin, or overall survival 
between patients with a c-Met-negative or positive biopsy (data not shown).  
  
c-Met is phosphorylated in malignant plasma cells. 
We then examined whether c-Met is phosphorylated in patients with malignant plasma cell 
disease and in healthy individuals. For this purpose, we performed immunohistochemical 
staining with a phospho-specific antibody, in a subset of 21 biopsies from myeloma patients, 
four biopsies from MGUS patients, and seven biopsies from healthy individuals. The 
selection criteria were: 1) Biopsy positive for total c-Met and 2) Biopsy of optimal technical 
quality. The phospho-c-Met staining pattern of the plasma cells was membranous and/or 
cytoplasmic. In some cases there was also a faint nuclear staining. Following the same 
evaluation criteria as for total c-Met, we decided only to regard cells with a clear membranous 
staining as truly positive (Figure 2). Specificity was shown by a peptide competition 
experiment as described in Methods (data not shown). Positive staining for phospho-c-Met in 
the plasma cells was demonstrated in biopsies from 15 of the 21 myeloma patients (71%), and 
one of the four MGUS patients. All of the biopsies from healthy individuals were negative.  
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Discussion 
In this study we examined expression of HGF and c-Met by immunohistochemistry in 
biopsies from bone marrow or extramedullary plasmacytomas in patients with plasma cell 
disease. We show that HGF and c-Met are concomitantly expressed in the plasma cells, and 
that c-Met exists in its phosphorylated state, in a substantial proportion of myeloma patients, 
suggesting that the HGF/c-Met system is active in myeloma patients in vivo. Expression of c-
Met and phospho-c-Met was strictly confined to malignant plasma cells, as opposed to plasma 
cells of healthy subjects. Thus, this study points to c-Met and its activation as one of the 
factors that discriminate malignant from normal plasma cells. 
  
Serum levels of HGF are elevated in multiple myeloma patients as compared to healthy 
individuals,5,6 and levels of HGF are higher in the bone marrow than in the circulation.5,18 
Levels of HGF mRNA in crude bone marrow biopsies of myeloma patients are significantly 
higher than in healthy individuals (Tian et al, manuscript in preparation). HGF can be 
produced by myeloma cells,3,4 and by stromal cells as well as by hematopoietic cells of the 
myeloid lineage and mature neutrophils in the bone marrow microenvironment.1,2,19 In this 
study, we found the strongest staining for HGF in the plasma cells, and a comparatively weak 
staining of other cells of the bone marrow. We found negative immunostaining for HGF in 
only a small subset of ten myeloma patients (15%). In accordance with other studies, our 
study demonstrates that the bone marrow is richly supplied with HGF, and that HGF 
accumulates in the plasma cells. 
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We found positive immunostaining for HGF also in normal plasma cells, seemingly in 
conflict with gene expression data from Zhan et al20 and Hose et al,21 who showed that HGF 
is not expressed by normal plasma cells. However, there are several possible explanations for 
the accumulation of HGF in plasma cells. HGF is a heparin binding growth factor, which is 
able to interact with heparan sulfate proteoglycans (HSPG). The main HSPG on myeloma 
cells is CD138 (syndecan-1). We have earlier shown that HGF can exist as a complex with 
syndecan-1,22 and bind to syndecan-1 on the surface of myeloma cells.23 It is therefore 
possible that the strong immunostaining for HGF in both normal, MGUS and myeloma 
plasma cells found in this study, reflects HGF that is secreted by other cells and thereafter 
bound to syndecan-1 on the plasma cell surface. Alternatively, the detected HGF originates 
from the plasma cells. It is also possible that both these mechanisms are operative. 
 
In contrast to HGF, c-Met staining was exclusively confined to MGUS and myeloma patients 
as there was negative staining of the bone marrow plasma cells of ten healthy individuals. 
Expression of c-Met has earlier been detected by various methods in multiple myeloma cell 
lines.3,13 Upregulation of the gene coding for c-Met has previously been shown by gene 
expression profiling in plasma cells of myeloma patients as compared to healthy donors.21,24 
Using immunohistochemistry, we found expression of c-Met also at the protein level in 40% 
of myeloma patients. Our results agree well with Derksen et al, who found expression of c-
Met by Western blot in cell lysates of frozen-stored bone marrow aspirates in seven of 13 
multiple myeloma patients, but in none of seven normal bone marrow samples.8 We and 
others have earlier by in vitro studies shown that the HGF/c-Met system may promote 
proliferation, survival, adhesion and migration of myeloma cells8-10 and contribute to the 
myeloma bone disease.11 Importantly, in this study we found positive staining for 
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phosphorylated c-Met in a subset of biopsies, supporting that the HGF/c-Met system is active 
not only in cell lines, but also in myeloma patients. 
  
HGF and c-Met expression and signaling have been demonstrated in several cancer types, 
including breast, colorectal, gastric, head & neck, liver, lung, pancreas, ovarian, renal, 
prostate, sarcoma and lymphoma.7,25 The HGF/c-Met system, mediating a broad range of 
tumor progression features like proliferation, invasion, survival, metastasis and 
angiogenesis,26 has been proposed as a promising target for therapy in different types of 
cancer,25 including multiple myeloma.13 Several studies on targeting c-Met in cancer have 
included competitors of HGF or c-Met, monoclonal antibodies directed against HGF or c-
Met, and small-molecule tyrosine kinase inhibitors directed against c-Met.13,25,27-29 Our data 
support that the HGF/c-Met system is a potential target also in multiple myeloma. In this 
context, immunohistochemistry might be a useful method to select patients who could be 
candidates for such therapy.  
In conclusion, our study points to c-Met as one of the factors that discriminate normal plasma 
cells from myeloma cells. It exists in its phosphorylated state in biopsies from myeloma 
patients, indicating that the HGF/c-Met system is activated, and thus may be a target for 
therapeutic intervention in multiple myeloma.  
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 Table 1A. Overview over cases and biopsy material. 
 
 
 
 
 
 
Diagnosis No of cases No of biopsies
stained for HGF
No of biopsies
stained for c-Met
No of biopsies
stained for p-Met
Healthy 10 10 10 7
MGUS 6 6 6 4
Myeloma 68 68 68 21 
Solitary
plasmacytoma of
bone
2 2 2 0
Solitary
extramedullary 
plasmacytoma
4 4 4 0
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Table 1B. Patient characteristics 
 
 
 
 
 
 
 
 
 
 
 
 
3    (4%)Information not available
15  (22%)Information not available
2    (3%) Information not available
Age Median (range) 69  (30 – 88)
Sex Male/female 47/21
ISS 1 16  (23%)
2 21  (31%)
3             16  (23%)
DS 1 9   (13%)
2 25  (37%)
3 32  (47%)  
DS A or B A 54  (79%)
B 11  (16%)
M-protein isotype IgG 45  (66%)
IgA 5    (7%)
IgG + IgA 2    (3%)
Other Ig subtype 3    (4%)
Light chain only 11  (16%)
Non-secretory 2    (3%)
Serum M-protein, g/L Median (range) 25  (0 – 76)
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Table 2A. Number and percentage of HGF-positive plasma cells in biopsies from patients 
with MGUS, multiple myeloma and solitary plasmacytoma, as compared with healthy 
individuals.  
 
 
 
 
 
 
HGF
No of cases No of  positive 
cases
% positive cases 95% CI of OR* p-value
Healthy 10 9 90 reference reference
MGUS 6 6 100 0.015, infinite* 1.000
Myeloma 68 58 85 0.013, 5.68 1.000
Solitary
plasmacytoma 
6 6 100 0.015, infinite* 1.000
*The odds ratio (OR) and the upper limit of the 95% confidence interval (CI) is infinite due to 
zero values in one or more cells.  
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Table 2B. Number and percentage of c-Met-positive plasma cells in biopsies from 
patients with MGUS, multiple myeloma and solitary plasmacytoma, as compared with  
healthy individuals.  
 
 
 
 
 
 
 
c-Met
No of cases No of positive cases % positive cases 95% CI for OR* p-value
Healthy 10 0 0 reference reference
MGUS 6 4 67 1.61, infinite* 0.016
Myeloma 63 25 40 1.32, infinite* 0.021
Solitary
plasmacytoma 
6 1 17 0.043, infinite* 0.750
*The odds ratio (OR) and the upper limit of the 95% confidence interval (CI) is infinite due to 
zero values in one or more cells.  
 
 
 
 
 
 
 
 
 
 22
Figure legends
Figure 1. Immunohistochemical staining of biopsies with malignant or non-malignant 
plasma cells. Panel (A-C) show 4 μm sections with cytoplasmic staining for HGF in (A) 
multiple myeloma plasma cells, (B) plasma cells of a reactive lesion and (C) plasma cells of 
normal bone marrow. Panel (E-G) show membranous and cytoplasmic staining for c-Met in 
(E) multiple myeloma plasma cells. Only cells with a clear membranous staining were defined 
as positive. No membranous staining was seen in (F) plasma cells of a reactive lesion and (G) 
plasma cells of normal bone marrow. (D+H) Negative control. Controls for specificity were 
carried out as described in the Methods section. (I-K) CD138 and (L) Hematoxylin-Eosin-
Saffron (HES) staining for identification of plasma cells. Images were captured using a Nikon 
Eclipse 80i microscope and Nikon dig SIGHT DS5-M camera, and processed by Nikon 
Imaging Software NIS-elements (Nikon Instruments Europe B.V., Badhoevedorp, 
Netherlands). Original magnification x 1000. 
 
Figure 2. Immunohistochemical staining for phospho-c-Met in bone marrow biopsies 
from patients with monoclonal plasma cell disease. Only cases that were positive for c-Met 
were included. Panel (A) shows membranous staining for phospho-c-Met. Only cells with a 
clear membranous staining were defined as positive. (B) Negative control section, showing 
non-specific staining of cytoplasm, but no membranous staining. Images were captured using 
a Nikon Eclipse 80i microscope and Nikon dig SIGHT DS5-M camera, and processed by 
Nikon Imaging Software NIS-elements (Nikon Instruments Europe B.V., Badhoevedorp, 
Netherlands). Original magnification x 1000. 
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Figure 3. Concentration of HGF as measured by ELISA in bone marrow plasma and serum of 
a subset of ten multiple myeloma patients. All samples were run in duplicates. The standard 
curve was linear between 0.5 and 8 ng/mL. Due to limited quantities of sample material the 
measurements could not be repeated and therefore samples with HGF concentrations above 8 
ng/mL were given the value 8 ng/mL. 
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Paper II

Elevated serum concentrations of activated hepatocyte
growth factor activator in patients with multiple myeloma
K. F. Wader1,2, U. M. Fagerli1,2, R. U. Holt1,3, B. Stordal1, M. Børset1,4, A. Sundan1, A. Waage1,5
1Department of Cancer Research and Molecular Medicine, Faculty of Medicine, Norwegian University of Science and Technology, Trondheim;
2Department of Oncology, St Olavs Hospital, Trondheim; 3Department of Food and Medical Technology, Sør-Trøndelag University College,
Trondheim; 4Department of Immunology and Transfusion Medicine, St Olavs Hospital, Trondheim; 5Department of Hematology, St Olavs Hospital,
Trondheim, Norway
Hepatocyte growth factor (HGF) stimulates survival,
proliferation (1), adhesion (2) and migration (3) of malig-
nant plasma cells and is a potential contributor to the
bone disease of multiple myeloma (4). HGF is produced
by myeloma cells and by stromal cells in the bone mar-
row microenvironment, and thereby acts in an autocrine
or paracrine manner through its receptor c-Met (5–7). We
and others have previously shown that serum HGF levels
are elevated in myeloma patients compared with normal
controls, and associated with poor prognosis (8, 9).
HGF is secreted as a single chain precursor which is
proteolytically converted to its biologically active hetero-
dimeric form. The most potent activator is the factor XII-
related serine protease hepatocyte growth factor activator
(HGFA) (10, 11). HGFA is mainly secreted by the liver,
although extrahepatic expression has been reported in a
number of normal and tumour tissues (12). It circulates in
plasma as a single-chain 96-kDa pro-form, which is acti-
vated by thrombin in the presence of negatively charged
molecules to its 34-kDa active two-chain heterodimeric
form (13). The HGFA activity is regulated by the HGF
activator inhibitors (HAI)-1 and -2, reviewed in (12).
Tjin et al. (14) showed that myeloma cells express
HGFA and thereby proteolytically convert single chain
HGF into its active form. We aimed to examine the lev-
els of the activated form of HGFA in serum and bone
marrow plasma from myeloma patients, and to correlate
the serum levels with clinical stage, parameters of disease
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activity and survival. Secondly, we aimed to investigate a
possible relationship between the concentrations of
HGFA and HGF.
Patients and methods
We examined serum samples drawn at diagnosis from 49
patients diagnosed with multiple myeloma in mid-Nor-
way between 1996 and 2005. We also examined bone
marrow plasma from the same patients when available
(n = 16). Serum and bone marrow plasma samples were
drawn before initiation of treatment and frozen at )80C
until they were analyzed. In six patients, we also exam-
ined serum drawn at time of ﬁrst response, deﬁned
according to the EBMT ⁄ IBMTR ⁄ABMTR criteria (15)
and at ﬁrst relapse, deﬁned as the time point where treat-
ment was re-introduced. Control samples were obtained
from 24 healthy volunteers. Because of limited quantities
of sample material, HGF was analyzed in only 20 of the
24 controls. Clinical information about the myeloma
patients was obtained retrospectively from the patient
records. Registered information was stage according to
Durie Salmon and International Scoring System (ISS),
type and concentrations of serum and urine M-compo-
nent, plasma cell percentage in bone marrow aspirate,
serum b2-microglobulin and overall survival. The study
protocol was approved by the Regional Medical Ethics
Committee and the study was performed according to
the declaration of Helsinki.
The median age of the myeloma patients (33 men and
16 women) was 65 yr (range 30–87 yr), and of the con-
trols (15 men and 9 women) was 68 yr (range 44–81 yr).
The patients were representative of the general myeloma
population with serum M-component of IgG type in 29
patients (59%), IgA in seven patients (14%), other Ig is-
otypes in three patients (6%), only light chain secretion
in nine patients (18%) and non-secretory myeloma in
one patient (2%). Twenty patients (41%) were in stage 1
according to ISS, 13 patients (26%) in stage 2 and 11
patients (22%) in stage 3; for ﬁve patients (10%), no
information was available.
We used a commercially available enzyme-linked
immunosorbent assay (ELISA) for the measurement of
activated HGFA (IBL, Gunma, Japan) in serum and
bone marrow plasma. The assay was performed accord-
ing to the manufacturer’s instructions. All samples were
run in duplicates. The standard curve was linear between
0.9 and 15 ng ⁄mL, and samples were diluted to concen-
trations within this range. The intra-assay and interassay
variation coefﬁcients for this assay are 5.5% and 5.5%
at 6.5 ng ⁄mL according to the manufacturer. Variation
coefﬁcients for our measurements were <10%.
HGF was measured with an ELISA from R&D systems
(Minneapolis, MN, USA). The assay was performed
according to the manufacturer’s instructions. All samples
were run in duplicates. The standard curve was linear
between 0.5 and 8 ng ⁄mL. Because of limited quantities of
sample material, the measurements could not be repeated
and therefore samples with HGF concentrations lower
than 0.5 ng ⁄mL and above 8 ng ⁄mL were given the values
0.5 and 8 ng ⁄mL. Variation coefﬁcients for our measure-
ments were <10%. Up to two freeze–thaw cycles of serum
did not affect the measured levels of HGF or HGFA.
SPSS Statistical Software version 14.0 was used for
statistic calculations (SPSS Inc, Chicago, IL, USA).
Comparisons between groups were performed by the
Mann–Whitney U-test. Correlations between two para-
meters were estimated by Spearman’s rank correlation
analysis. Survival analysis was conducted by the
Kaplan–Meier method, using median values as cut off.
The level of statistical signiﬁcance was set at P < 0.05.
P-values were two-tailed.
Results
Serum levels of activated HGFA in patients at the time
of diagnosis and in controls are shown in Fig. 1. The
median HGFA concentrations in myeloma and control
sera were 39.7 (range 6.2–450.0) and 17.6 ng ⁄mL (range
4.8–280.6), respectively. The difference was statistically
signiﬁcant (P = 0.037). The median level of activated
HGFA in bone marrow plasma of myeloma patients was
6.1 ng ⁄mL (range 3.5–30.0) (data not shown). Thus,
HGFA levels were lower in bone marrow plasma than in
serum. However, serum and plasma HGFA levels cannot
be directly compared, as measurement of levels in serum
will be 2–3 times higher than in plasma in this assay
according to the manufacturer and own validation exper-
iments (data not shown).
There was no correlation between the serum levels of
HGFA and disease stage according to ISS or Durie
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Figure 1 Serum concentrations of activated HGFA measured by
ELISA in 49 multiple myeloma patients and 24 age- and gender-
matched controls. Bars indicate median concentration.
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Salmon, concentration of serum M-component, serum
b2-microglobulin, percentage of plasma cells in the bone
marrow or overall survival (data not shown). The HGFA
levels did not covariate with disease activity in serial
measurements of serum drawn at diagnosis, remission
and relapse in six myeloma patients (data not shown).
The median HGF concentrations in myeloma and con-
trol sera were 2.5 (range 0.7–8.0) and 1.6 ng ⁄mL (range
0.5–4.0), respectively (Fig. 2). The difference was statisti-
cally signiﬁcant (P < 0.001). The median HGF concen-
tration in bone marrow plasma was 8.0 ng ⁄mL. There
was no correlation between the levels of HGFA and
HGF in serum (rs = 0.14, P = 0.26) or bone marrow
plasma (rs = 0.31, P = 0.38).
Discussion
HGF has a number of myeloma-relevant activities; how-
ever, it has to be converted to its heterodimeric form to be
biologically active. Urokinase-type plasminogen activator
(uPA), tissue plasminogen activator, factor XIIa and ma-
triptase have all been shown to activate single chain HGF
at low rates (11, 16–18). The most potent activator is, how-
ever, the factor XII-related serine protease HGFA, with
an HGF-converting potency of more than 1000 times that
of uPA (11). Tjin et al. (14) showed that myeloma cells
express HGFA, thereby activating HGF. We here demon-
strate for the ﬁrst time that HGFA exists in its activated
form in serum from myeloma patients, and that serum
concentrations are higher than in healthy controls. We
also found detectable activated HGFA in 16 of 16 samples
of bone marrow plasma from myeloma patients.
The role of HGFA in regulating HGF activity in
injured tissue is well established (12). Recent data sup-
port an important function of HGFA also in solid
tumours such as colorectal cancer (19) and glioblastoma
(20). Among lymphomas, the HGF receptor is predomi-
nantly expressed in diffuse large B-cell lymphoma
(DLBCL), and interestingly, DLBCL cells also express
HGFA, possibly activating HGF produced by macro-
phages in the tumour microenvironment (21).
The activity of HGFA is tightly regulated. Secreted as
an inactive single chain pro-form, cleavage by thrombin
is essential for its function. In a recent publication, the
kallikrein-related peptidases 4 and 5 were shown to have
HGFA-activating properties similar to thrombin (22).
The activity of HGFA is also controlled by the Kunitz
type serine protease inhibitors HAI-1 and HAI-2 (12).
It is possible that the myeloma cells directly contribute
to the elevated HGFA levels in serum of myeloma
patients. However, we found no correlation between the
serum HGFA concentration and disease stage or tradi-
tional markers of tumour burden. As we have measured
only the activated form of HGFA, the elevated levels in
myeloma patients might also mirror a higher degree of
activation of pro-HGFA in patients compared with con-
trols. The complex mechanisms regulating activation of
HGF in multiple myeloma, including a potential role for
the HGFA inhibitors HAI-1 and HAI-2, should be
addressed in further studies.
We found no correlation between serum levels of
HGFA and HGF. This is partly in disagreement with
Nagakawa et al. (23), who found a positive correlation
between serum levels of HGF and HGFA in patients
with untreated and advanced stage prostate cancer. How-
ever, the fact that we have measured total HGF, which
is both single chain HGF and the active heterodimer,
may obscure a positive correlation between HGFA and
active HGF.
In conclusion, activated HGFA is present at high
levels in serum and bone marrow of myeloma patients.
Although this study has obvious limitations because of
the relatively small number of study subjects, it clearly
demonstrates the presence of a necessary prerequisite for
activation of the HGF system in multiple myeloma. It
also points to the activation step of HGF as a possible
target for therapeutic intervention.
Acknowledgements
This work was supported by grants from the Norwegian
Cancer Society, The Cancer Fund of St Olavs Hospital,
The Research Council of Norway and The Liaison Com-
mittee between the Central Norway Regional Health
Authority (RHA) and the Norwegian University of
Science and Technology (NTNU).
References
1. Derksen PW, de Gorter DJ, Meijer HP, Bende RJ, van
Dijk M, Lokhorst HM, Bloem AC, Spaargaren M, Pals
0.0
2.5
5.0
7.5
H
G
F 
(ng
/m
L)
Myeloma Control
>8.0
Figure 2 Serum concentrations of HGF measured by ELISA in 49
myeloma patients and 20 age- and gender-matched controls. Bars
indicate median concentration.
HGF activator in multiple myeloma Wader et al.
382
ª 2008 The Authors
Journal compilation 81 (380–383) ª 2008 Blackwell Munksgaard
ST. The hepatocyte growth factor ⁄met pathway controls
proliferation and apoptosis in multiple myeloma. Leuke-
mia 2003;17:764–74.
2. Holt RU, Baykov V, Ro TB, Brabrand S, Waage A, Sun-
dan A, Borset M. Human myeloma cells adhere to ﬁbro-
nectin in response to hepatocyte growth factor.
Haematologica 2005;90:479–88.
3. Holt RU, Fagerli UM, Baykov V, Ro TB, Hov H, Waage
A, Sundan A, Borset M. Hepatocyte growth factor pro-
motes migration of human myeloma cells. Haematologica
2008;93:619–22.
4. Standal T, Abildgaard N, Fagerli UM, Stordal B, Hjert-
ner O, Borset M, Sundan A. Hgf inhibits bmp-induced
osteoblastogenesis: possible implications for the bone
disease of multiple myeloma. Blood 2007;109:3024–30.
5. Hov H, Holt RU, Ro TB, Fagerli UM, Hjorth-Hansen H,
Baykov V, Christensen JG, Waage A, Sundan A, Borset
M. A selective c-met inhibitor blocks an autocrine hepato-
cyte growth factor growth loop in anbl-6 cells and
prevents migration and adhesion of myeloma cells. Clin
Cancer Res 2004;10:6686–94.
6. Matsumoto K, Nakamura T. Emerging multipotent
aspects of hepatocyte growth factor. J Biochem
1996;119:591–600.
7. Birchmeier C, Birchmeier W, Gherardi E, Vande Woude
GF. Met, metastasis, motility and more. Nat Rev Mol Cell
Biol 2003;4:915–25.
8. Seidel C, Borset M, Turesson I, Abildgaard N, Sundan A,
Waage A. Elevated serum concentrations of hepatocyte
growth factor in patients with multiple myeloma. The
nordic myeloma study group. Blood 1998;91:806–12.
9. Iwasaki T, Hamano T, Ogata A, Hashimoto N, Kitano
M, Kakishita E. Clinical signiﬁcance of vascular endo-
thelial growth factor and hepatocyte growth factor in
multiple myeloma. Br J Haematol 2002;116:796–802.
10. Miyazawa K, Shimomura T, Kitamura A, Kondo J,
Morimoto Y, Kitamura N. Molecular cloning and
sequence analysis of the cDNA for a human serine prote-
ase reponsible for activation of hepatocyte growth factor.
Structural similarity of the protease precursor to blood
coagulation factor XII. J Biol Chem 1993;268:10024–8.
11. Shimomura T, Miyazawa K, Komiyama Y, Hiraoka H,
Naka D, Morimoto Y, Kitamura N. Activation of
hepatocyte growth factor by two homologous proteases,
blood-coagulation factor XIIA and hepatocyte growth
factor activator. Eur J Biochem 1995;229:257–61.
12. Kataoka H, Miyata S, Uchinokura S, Itoh H. Roles of
hepatocyte growth factor (HGF) activator and HGF
activator inhibitor in the pericellular activation of
HGF ⁄ scatter factor. Cancer Metastasis Rev 2003;22:
223–36.
13. Shimomura T, Kondo J, Ochiai M, Naka D, Miyazawa
K, Morimoto Y, Kitamura N. Activation of the zymogen
of hepatocyte growth factor activator by thrombin. J Biol
Chem 1993;268:22927–32.
14. Tjin EP, Derksen PW, Kataoka H, Spaargaren M, Pals
ST. Multiple myeloma cells catalyze hepatocyte growth
factor (HGF) activation by secreting the serine protease
HGF-activator. Blood 2004;104:2172–5.
15. Smith A, Wisloff F, Samson D. Guidelines on the diagno-
sis and management of multiple myeloma 2005. Br J
Haematol 2006;132:410–51.
16. Mars WM, Zarnegar R, Michalopoulos GK. Activation
of hepatocyte growth factor by the plasminogen activators
uPA and tPA. Am J Pathol 1993;143:949–58.
17. Lee SL, Dickson RB, Lin CY. Activation of hepatocyte
growth factor and urokinase ⁄plasminogen activator by
matriptase, an epithelial membrane serine protease. J Biol
Chem 2000;275:36720–5.
18. Naldini L, Tamagnone L, Vigna E, Sachs M, Hartmann
G, Birchmeier W, Daikuhara Y, Tsubouchi H, Blasi F,
Comoglio PM. Extracellular proteolytic cleavage by
urokinase is required for activation of hepatocyte growth
factor ⁄ scatter factor. EMBO J 1992;11:4825–33.
19. Kataoka H, Hamasuna R, Itoh H, Kitamura N, Koono
M. Activation of hepatocyte growth factor ⁄ scatter factor
in colorectal carcinoma. Cancer Res 2000;60:6148–59.
20. Uchinokura S, Miyata S, Fukushima T, Itoh H, Nakano
S, Wakisaka S, Kataoka H. Role of hepatocyte growth
factor activator (HGF activator) in invasive growth of
human glioblastoma cells in vivo. Int J Cancer
2006;118:583–92.
21. Tjin EP, Groen RW, Vogelzang I, Derksen PW, Klok
MD, Meijer HP, van Eeden S, Pals ST, Spaargaren M.
Functional analysis of HGF ⁄met signaling and aberrant
hgf-activator expression in diffuse large b-cell lymphoma.
Blood 2006;107:760–8.
22. Mukai S, Fukushima T, Naka D, Tanaka H, Osada Y,
Kataoka H. Activation of hepatocyte growth factor acti-
vator zymogen (pro-HGFA) by human kallikrein 1-related
peptidases. FEBS J 2008;275:1003–17.
23. Nagakawa O, Yamagishi T, Fujiuchi Y, Junicho A,
Akashi T, Nagaike K, Fuse H. Serum hepatocyte growth
factor activator (hgfa) in benign prostatic hyperplasia and
prostate cancer. Eur Urol 2005;48:686–90.
Wader et al. HGF activator in multiple myeloma
ª 2008 The Authors
Journal compilation 81 (380–383) ª 2008 Blackwell Munksgaard 383
Paper III
 Is not included due to copyright 

Paper IV
 Is not included due to copyright 

Paper V
 Is not included due to copyright 


 
Dissertations at the Faculty of Medicine, NTNU 
 
1977 
1. Knut Joachim Berg: EFFECT OF ACETYLSALICYLIC ACID ON RENAL FUNCTION 
2. Karl Erik Viken and Arne Ødegaard: STUDIES ON HUMAN MONOCYTES CULTURED IN  
VITRO 
1978 
3. Karel Bjørn Cyvin: CONGENITAL DISLOCATION OF THE HIP JOINT. 
4. Alf O. Brubakk: METHODS FOR STUDYING FLOW DYNAMICS IN THE LEFT 
VENTRICLE  AND THE AORTA IN MAN. 
1979 
5. Geirmund Unsgaard: CYTOSTATIC AND IMMUNOREGULATORY ABILITIES OF 
HUMAN    BLOOD MONOCYTES CULTURED IN VITRO 
1980 
6. Størker Jørstad: URAEMIC TOXINS 
7. Arne Olav Jenssen: SOME RHEOLOGICAL, CHEMICAL AND STRUCTURAL 
PROPERTIES    OF MUCOID SPUTUM FROM PATIENTS WITH CHRONIC 
OBSTRUCTIVE BRONCHITIS 
1981 
8. Jens Hammerstrøm: CYTOSTATIC AND CYTOLYTIC ACTIVITY OF HUMAN 
MONOCYTES AND EFFUSION MACROPHAGES AGAINST TUMOR CELLS IN VITRO 
1983 
9. Tore Syversen: EFFECTS OF METHYLMERCURY ON RAT BRAIN PROTEIN. 
10. Torbjørn Iversen: SQUAMOUS CELL CARCINOMA OF THE VULVA. 
1984 
11. Tor-Erik Widerøe: ASPECTS OF CONTINUOUS AMBULATORY PERITONEAL 
DIALYSIS. 
12. Anton Hole: ALTERATIONS OF MONOCYTE AND LYMPHOCYTE FUNCTIONS IN 
REALTION TO SURGERY UNDER EPIDURAL OR GENERAL ANAESTHESIA. 
13. Terje Terjesen: FRACTURE HEALING AND STRESS-PROTECTION AFTER METAL 
PLATE FIXATION AND EXTERNAL FIXATION. 
14. Carsten Saunte: CLUSTER HEADACHE SYNDROME. 
15. Inggard Lereim: TRAFFIC ACCIDENTS AND THEIR CONSEQUENCES. 
16. Bjørn Magne Eggen: STUDIES IN CYTOTOXICITY IN HUMAN ADHERENT 
MONONUCLEAR BLOOD CELLS. 
17. Trond Haug: FACTORS REGULATING BEHAVIORAL EFFECTS OG DRUGS. 
1985 
18. Sven Erik Gisvold: RESUSCITATION AFTER COMPLETE GLOBAL BRAIN ISCHEMIA. 
19. Terje Espevik: THE CYTOSKELETON OF HUMAN MONOCYTES. 
20. Lars Bevanger: STUDIES OF THE Ibc (c) PROTEIN ANTIGENS OF GROUP B 
STREPTOCOCCI. 
21. Ole-Jan Iversen: RETROVIRUS-LIKE PARTICLES IN THE PATHOGENESIS OF 
PSORIASIS. 
22. Lasse Eriksen: EVALUATION AND TREATMENT OF ALCOHOL DEPENDENT 
BEHAVIOUR. 
23. Per I. Lundmo: ANDROGEN METABOLISM IN THE PROSTATE. 
1986 
24. Dagfinn Berntzen: ANALYSIS AND MANAGEMENT OF EXPERIMENTAL AND 
CLINICAL PAIN. 
25. Odd Arnold Kildahl-Andersen: PRODUCTION AND CHARACTERIZATION OF 
MONOCYTE-DERIVED CYTOTOXIN AND ITS ROLE IN MONOCYTE-MEDIATED 
CYTOTOXICITY. 
26. Ola Dale: VOLATILE ANAESTHETICS. 
1987 
27. Per Martin Kleveland: STUDIES ON GASTRIN. 
28. Audun N. Øksendal: THE CALCIUM PARADOX AND THE HEART. 
29. Vilhjalmur R. Finsen: HIP FRACTURES 
1988 
30. Rigmor Austgulen: TUMOR NECROSIS FACTOR: A MONOCYTE-DERIVED 
REGULATOR OF CELLULAR GROWTH. 
31. Tom-Harald Edna: HEAD INJURIES ADMITTED TO HOSPITAL. 
32. Joseph D. Borsi: NEW ASPECTS OF THE CLINICAL PHARMACOKINETICS OF 
METHOTREXATE. 
33. Olav F. M. Sellevold: GLUCOCORTICOIDS IN MYOCARDIAL PROTECTION. 
34. Terje Skjærpe: NONINVASIVE QUANTITATION OF GLOBAL PARAMETERS ON LEFT 
VENTRICULAR FUNCTION: THE SYSTOLIC PULMONARY ARTERY PRESSURE AND 
CARDIAC OUTPUT. 
35. Eyvind Rødahl: STUDIES OF IMMUNE COMPLEXES AND RETROVIRUS-LIKE 
ANTIGENS IN PATIENTS WITH ANKYLOSING SPONDYLITIS. 
36. Ketil Thorstensen: STUDIES ON THE MECHANISMS OF CELLULAR UPTAKE OF IRON 
FROM TRANSFERRIN. 
37. Anna Midelfart: STUDIES OF THE MECHANISMS OF ION AND FLUID TRANSPORT IN 
THE BOVINE CORNEA. 
38. Eirik Helseth: GROWTH AND PLASMINOGEN ACTIVATOR ACTIVITY OF HUMAN 
GLIOMAS AND BRAIN METASTASES - WITH SPECIAL REFERENCE TO 
TRANSFORMING GROWTH FACTOR BETA AND THE EPIDERMAL GROWTH 
FACTOR RECEPTOR. 
39. Petter C. Borchgrevink: MAGNESIUM AND THE ISCHEMIC HEART. 
40. Kjell-Arne Rein: THE EFFECT OF EXTRACORPOREAL CIRCULATION ON 
SUBCUTANEOUS TRANSCAPILLARY FLUID BALANCE. 
41. Arne Kristian Sandvik: RAT GASTRIC HISTAMINE. 
42. Carl Bredo Dahl: ANIMAL MODELS IN PSYCHIATRY. 
1989 
43. Torbjørn A. Fredriksen: CERVICOGENIC HEADACHE. 
44. Rolf A. Walstad: CEFTAZIDIME. 
45. Rolf Salvesen: THE PUPIL IN CLUSTER HEADACHE. 
46. Nils Petter Jørgensen: DRUG EXPOSURE IN EARLY PREGNANCY. 
47. Johan C. Ræder: PREMEDICATION AND GENERAL ANAESTHESIA IN OUTPATIENT 
GYNECOLOGICAL SURGERY. 
48. M. R. Shalaby: IMMUNOREGULATORY PROPERTIES OF TNF-α AND THE RELATED 
CYTOKINES. 
49. Anders Waage: THE COMPLEX PATTERN OF CYTOKINES IN SEPTIC SHOCK. 
50. Bjarne Christian Eriksen: ELECTROSTIMULATION OF THE PELVIC FLOOR IN FEMALE 
URINARY INCONTINENCE. 
51. Tore B. Halvorsen: PROGNOSTIC FACTORS IN COLORECTAL CANCER. 
1990 
52. Asbjørn Nordby: CELLULAR TOXICITY OF ROENTGEN CONTRAST MEDIA. 
53. Kåre E. Tvedt: X-RAY MICROANALYSIS OF BIOLOGICAL MATERIAL. 
54. Tore C. Stiles: COGNITIVE VULNERABILITY FACTORS IN THE DEVELOPMENT AND 
MAINTENANCE OF DEPRESSION. 
55. Eva Hofsli: TUMOR NECROSIS FACTOR AND MULTIDRUG RESISTANCE. 
56. Helge S. Haarstad: TROPHIC EFFECTS OF CHOLECYSTOKININ AND SECRETIN ON 
THE RAT PANCREAS. 
57. Lars Engebretsen: TREATMENT OF ACUTE ANTERIOR CRUCIATE LIGAMENT 
INJURIES. 
58. Tarjei Rygnestad: DELIBERATE SELF-POISONING IN TRONDHEIM. 
59. Arne Z. Henriksen: STUDIES ON CONSERVED ANTIGENIC DOMAINS ON MAJOR 
OUTER MEMBRANE PROTEINS FROM ENTEROBACTERIA. 
60. Steinar Westin: UNEMPLOYMENT AND HEALTH: Medical and social consequences of a 
factory closure in a ten-year controlled follow-up study. 
61. Ylva Sahlin: INJURY REGISTRATION, a tool for accident preventive work. 
62. Helge Bjørnstad Pettersen: BIOSYNTHESIS OF COMPLEMENT BY HUMAN ALVEOLAR 
MACROPHAGES WITH SPECIAL REFERENCE TO SARCOIDOSIS. 
63. Berit Schei: TRAPPED IN PAINFUL LOVE. 
64. Lars J. Vatten: PROSPECTIVE STUDIES OF THE RISK OF BREAST CANCER IN A 
COHORT OF NORWEGIAN WOMAN. 
 
1991 
65. Kåre Bergh: APPLICATIONS OF ANTI-C5a SPECIFIC MONOCLONAL ANTIBODIES FOR 
THE ASSESSMENT OF COMPLEMENT ACTIVATION. 
66. Svein Svenningsen: THE CLINICAL SIGNIFICANCE OF INCREASED FEMORAL 
ANTEVERSION. 
67. Olbjørn Klepp: NONSEMINOMATOUS GERM CELL TESTIS CANCER: THERAPEUTIC 
OUTCOME AND PROGNOSTIC FACTORS. 
68. Trond Sand: THE EFFECTS OF CLICK POLARITY ON BRAINSTEM AUDITORY 
EVOKED POTENTIALS AMPLITUDE, DISPERSION, AND LATENCY VARIABLES. 
69. Kjetil B. Åsbakk: STUDIES OF A PROTEIN FROM PSORIATIC SCALE, PSO P27, WITH 
RESPECT TO ITS POTENTIAL ROLE IN IMMUNE REACTIONS IN PSORIASIS. 
70. Arnulf Hestnes: STUDIES ON DOWN´S SYNDROME. 
71. Randi Nygaard: LONG-TERM SURVIVAL IN CHILDHOOD LEUKEMIA. 
72. Bjørn Hagen: THIO-TEPA. 
73. Svein Anda: EVALUATION OF THE HIP JOINT BY COMPUTED TOMOGRAMPHY AND 
ULTRASONOGRAPHY. 
1992 
74. Martin Svartberg: AN INVESTIGATION OF PROCESS AND OUTCOME OF SHORT-TERM 
PSYCHODYNAMIC PSYCHOTHERAPY. 
75. Stig Arild Slørdahl: AORTIC REGURGITATION. 
76. Harold C Sexton: STUDIES RELATING TO THE TREATMENT OF SYMPTOMATIC NON-
PSYCHOTIC PATIENTS. 
77. Maurice B. Vincent: VASOACTIVE PEPTIDES IN THE OCULAR/FOREHEAD AREA. 
78. Terje Johannessen: CONTROLLED TRIALS IN SINGLE SUBJECTS. 
79. Turid Nilsen: PYROPHOSPHATE IN HEPATOCYTE IRON METABOLISM. 
80. Olav Haraldseth: NMR SPECTROSCOPY OF CEREBRAL ISCHEMIA AND REPERFUSION 
IN RAT. 
81. Eiliv Brenna: REGULATION OF FUNCTION AND GROWTH OF THE OXYNTIC 
MUCOSA. 
1993 
82. Gunnar Bovim: CERVICOGENIC HEADACHE. 
83. Jarl Arne Kahn: ASSISTED PROCREATION. 
84. Bjørn Naume: IMMUNOREGULATORY EFFECTS OF CYTOKINES ON NK CELLS. 
85. Rune Wiseth: AORTIC VALVE REPLACEMENT. 
86. Jie Ming Shen: BLOOD FLOW VELOCITY AND RESPIRATORY STUDIES. 
87. Piotr Kruszewski: SUNCT SYNDROME WITH SPECIAL REFERENCE TO THE 
AUTONOMIC NERVOUS SYSTEM. 
88. Mette Haase Moen: ENDOMETRIOSIS. 
89. Anne Vik: VASCULAR GAS EMBOLISM DURING AIR INFUSION AND AFTER 
DECOMPRESSION IN PIGS. 
90. Lars Jacob Stovner: THE CHIARI TYPE I MALFORMATION. 
91. Kjell Å. Salvesen: ROUTINE ULTRASONOGRAPHY IN UTERO AND DEVELOPMENT IN 
CHILDHOOD. 
1994 
92. Nina-Beate Liabakk: DEVELOPMENT OF IMMUNOASSAYS FOR TNF AND ITS 
SOLUBLE RECEPTORS. 
93. Sverre Helge Torp: erbB ONCOGENES IN HUMAN GLIOMAS AND MENINGIOMAS. 
94. Olav M. Linaker: MENTAL RETARDATION AND PSYCHIATRY. Past and present. 
95. Per Oscar Feet: INCREASED ANTIDEPRESSANT AND ANTIPANIC EFFECT IN 
COMBINED TREATMENT WITH DIXYRAZINE AND TRICYCLIC ANTIDEPRESSANTS. 
96. Stein Olav Samstad: CROSS SECTIONAL FLOW VELOCITY PROFILES FROM TWO-
DIMENSIONAL DOPPLER ULTRASOUND: Studies on early mitral blood flow. 
97. Bjørn Backe: STUDIES IN ANTENATAL CARE. 
98. Gerd Inger Ringdal: QUALITY OF LIFE IN CANCER PATIENTS. 
99. Torvid Kiserud: THE DUCTUS VENOSUS IN THE HUMAN FETUS. 
100. Hans E. Fjøsne: HORMONAL REGULATION OF PROSTATIC METABOLISM. 
101. Eylert Brodtkorb: CLINICAL ASPECTS OF EPILEPSY IN THE MENTALLY RETARDED. 
102. Roar Juul: PEPTIDERGIC MECHANISMS IN HUMAN SUBARACHNOID HEMORRHAGE. 
103. Unni Syversen: CHROMOGRANIN A. Phsysiological and Clinical Role. 
 
1995 
104. Odd Gunnar Brakstad: THERMOSTABLE NUCLEASE AND THE nuc GENE IN THE 
DIAGNOSIS OF Staphylococcus aureus INFECTIONS. 
105. Terje Engan: NUCLEAR MAGNETIC RESONANCE (NMR) SPECTROSCOPY OF PLASMA 
IN MALIGNANT DISEASE. 
106. Kirsten Rasmussen: VIOLENCE IN THE MENTALLY DISORDERED. 
107. Finn Egil Skjeldestad: INDUCED ABORTION: Timetrends and Determinants. 
108. Roar Stenseth: THORACIC EPIDURAL ANALGESIA IN AORTOCORONARY BYPASS 
SURGERY. 
109. Arild Faxvaag: STUDIES OF IMMUNE CELL FUNCTION in mice infected with MURINE 
RETROVIRUS. 
1996 
110. Svend Aakhus: NONINVASIVE COMPUTERIZED ASSESSMENT OF LEFT 
VENTRICULAR FUNCTION AND SYSTEMIC ARTERIAL PROPERTIES. Methodology and 
some clinical applications. 
111. Klaus-Dieter Bolz: INTRAVASCULAR ULTRASONOGRAPHY. 
112. Petter Aadahl: CARDIOVASCULAR EFFECTS OF THORACIC AORTIC CROSS-
CLAMPING. 
113. Sigurd Steinshamn: CYTOKINE MEDIATORS DURING GRANULOCYTOPENIC 
INFECTIONS. 
114. Hans Stifoss-Hanssen: SEEKING MEANING OR HAPPINESS? 
115. Anne Kvikstad: LIFE CHANGE EVENTS AND MARITAL STATUS IN RELATION TO 
RISK AND PROGNOSIS OF CANCER. 
116. Torbjørn Grøntvedt: TREATMENT OF ACUTE AND CHRONIC ANTERIOR CRUCIATE 
LIGAMENT INJURIES. A clinical and biomechanical study. 
117. Sigrid Hørven Wigers: CLINICAL STUDIES OF FIBROMYALGIA WITH FOCUS ON 
ETIOLOGY, TREATMENT AND OUTCOME. 
118. Jan Schjøtt: MYOCARDIAL PROTECTION: Functional and Metabolic Characteristics of Two 
Endogenous Protective Principles. 
119. Marit Martinussen: STUDIES OF INTESTINAL BLOOD FLOW AND ITS RELATION TO 
TRANSITIONAL CIRCULATORY ADAPATION IN NEWBORN INFANTS. 
120. Tomm B. Müller: MAGNETIC RESONANCE IMAGING IN FOCAL CEREBRAL 
ISCHEMIA. 
121. Rune Haaverstad: OEDEMA FORMATION OF THE LOWER EXTREMITIES. 
122. Magne Børset: THE ROLE OF CYTOKINES IN MULTIPLE MYELOMA, WITH SPECIAL 
REFERENCE TO HEPATOCYTE GROWTH FACTOR. 
123. Geir Smedslund: A THEORETICAL AND EMPIRICAL INVESTIGATION OF SMOKING, 
STRESS AND DISEASE: RESULTS FROM A POPULATION SURVEY. 
1997 
124. Torstein Vik: GROWTH, MORBIDITY, AND PSYCHOMOTOR DEVELOPMENT IN 
INFANTS WHO WERE GROWTH RETARDED IN UTERO. 
125. Siri Forsmo: ASPECTS AND CONSEQUENCES OF OPPORTUNISTIC SCREENING FOR 
CERVICAL CANCER. Results based on data from three Norwegian counties. 
126. Jon S. Skranes: CEREBRAL MRI AND NEURODEVELOPMENTAL OUTCOME IN VERY 
LOW BIRTH WEIGHT (VLBW) CHILDREN. A follow-up study of a geographically based 
year cohort of VLBW children at ages one and six years. 
127. Knut Bjørnstad: COMPUTERIZED ECHOCARDIOGRAPHY FOR EVALUTION OF 
CORONARY ARTERY DISEASE. 
128. Grethe Elisabeth Borchgrevink: DIAGNOSIS AND TREATMENT OF WHIPLASH/NECK 
SPRAIN INJURIES CAUSED BY CAR ACCIDENTS. 
129. Tor Elsås: NEUROPEPTIDES AND NITRIC OXIDE SYNTHASE IN OCULAR 
AUTONOMIC AND SENSORY NERVES. 
130. Rolf W. Gråwe: EPIDEMIOLOGICAL AND NEUROPSYCHOLOGICAL PERSPECTIVES 
ON SCHIZOPHRENIA. 
131. Tonje Strømholm: CEREBRAL HAEMODYNAMICS DURING THORACIC AORTIC 
CROSSCLAMPING. An experimental study in pigs. 
 
1998 
132. Martinus Bråten: STUDIES ON SOME PROBLEMS REALTED TO INTRAMEDULLARY 
NAILING OF FEMORAL FRACTURES. 
133. Ståle Nordgård: PROLIFERATIVE ACTIVITY AND DNA CONTENT AS PROGNOSTIC 
INDICATORS IN ADENOID CYSTIC CARCINOMA OF THE HEAD AND NECK. 
134. Egil Lien: SOLUBLE RECEPTORS FOR TNF AND LPS: RELEASE PATTERN AND 
POSSIBLE SIGNIFICANCE IN DISEASE. 
135. Marit Bjørgaas: HYPOGLYCAEMIA IN CHILDREN WITH DIABETES MELLITUS 
136. Frank Skorpen: GENETIC AND FUNCTIONAL ANALYSES OF DNA REPAIR IN HUMAN 
CELLS. 
137. Juan A. Pareja: SUNCT SYNDROME. ON THE CLINICAL PICTURE. ITS DISTINCTION 
FROM OTHER, SIMILAR HEADACHES. 
138. Anders Angelsen: NEUROENDOCRINE CELLS IN HUMAN PROSTATIC CARCINOMAS 
AND THE PROSTATIC COMPLEX OF RAT, GUINEA PIG, CAT AND DOG. 
139. Fabio Antonaci: CHRONIC  PAROXYSMAL HEMICRANIA AND HEMICRANIA 
CONTINUA: TWO DIFFERENT ENTITIES? 
140. Sven M. Carlsen: ENDOCRINE AND METABOLIC EFFECTS OF METFORMIN WITH 
SPECIAL EMPHASIS ON CARDIOVASCULAR RISK FACTORES. 
1999 
141. Terje A. Murberg: DEPRESSIVE SYMPTOMS AND COPING AMONG PATIENTS WITH 
CONGESTIVE HEART FAILURE. 
142. Harm-Gerd Karl Blaas: THE EMBRYONIC EXAMINATION. Ultrasound studies on the 
development of the human embryo. 
143. Noèmi Becser Andersen:THE CEPHALIC SENSORY NERVES IN UNILATERAL 
HEADACHES. Anatomical background and neurophysiological evaluation. 
144. Eli-Janne Fiskerstrand: LASER TREATMENT OF PORT WINE STAINS. A study of the 
efficacy and limitations of the pulsed dye laser. Clinical and morfological analyses aimed at 
improving the therapeutic outcome. 
145. Bård Kulseng: A STUDY OF ALGINATE CAPSULE PROPERTIES AND CYTOKINES IN 
RELATION TO INSULIN DEPENDENT DIABETES MELLITUS. 
146. Terje Haug: STRUCTURE AND REGULATION OF THE HUMAN UNG GENE ENCODING 
URACIL-DNA GLYCOSYLASE. 
147. Heidi Brurok: MANGANESE AND THE HEART. A Magic Metal with Diagnostic and 
Therapeutic Possibilites. 
148. Agnes Kathrine Lie: DIAGNOSIS AND PREVALENCE OF HUMAN PAPILLOMAVIRUS 
INFECTION IN CERVICAL INTRAEPITELIAL NEOPLASIA. Relationship to Cell Cycle 
Regulatory Proteins and HLA DQBI Genes. 
149. Ronald Mårvik: PHARMACOLOGICAL, PHYSIOLOGICAL AND 
PATHOPHYSIOLOGICAL STUDIES ON ISOLATED STOMACS. 
150. Ketil Jarl Holen: THE ROLE OF ULTRASONOGRAPHY IN THE DIAGNOSIS AND 
TREATMENT OF HIP DYSPLASIA IN NEWBORNS. 
151. Irene Hetlevik:  THE ROLE OF CLINICAL GUIDELINES IN CARDIOVASCULAR RISK 
INTERVENTION IN GENERAL PRACTICE. 
152. Katarina Tunòn: ULTRASOUND AND PREDICTION OF GESTATIONAL AGE. 
153. Johannes Soma: INTERACTION BETWEEN THE LEFT VENTRICLE AND THE SYSTEMIC 
ARTERIES. 
154. Arild Aamodt: DEVELOPMENT AND PRE-CLINICAL EVALUATION OF A CUSTOM-
MADE FEMORAL STEM. 
155. Agnar Tegnander: DIAGNOSIS AND FOLLOW-UP OF CHILDREN WITH SUSPECTED OR 
KNOWN HIP DYSPLASIA. 
156. Bent Indredavik: STROKE UNIT TREATMENT: SHORT AND LONG-TERM EFFECTS 
157. Jolanta Vanagaite Vingen: PHOTOPHOBIA AND PHONOPHOBIA IN PRIMARY 
HEADACHES 
2000 
158. Ola Dalsegg Sæther: PATHOPHYSIOLOGY DURING PROXIMAL AORTIC CROSS-
CLAMPING CLINICAL AND EXPERIMENTAL STUDIES 
159. xxxxxxxxx (blind number) 
160. Christina Vogt Isaksen: PRENATAL ULTRASOUND AND POSTMORTEM FINDINGS – A 
TEN YEAR CORRELATIVE STUDY OF FETUSES AND INFANTS WITH 
DEVELOPMENTAL ANOMALIES. 
161. Holger Seidel: HIGH-DOSE METHOTREXATE THERAPY IN CHILDREN WITH ACUTE 
LYMPHOCYTIC LEUKEMIA: DOSE, CONCENTRATION, AND EFFECT 
CONSIDERATIONS. 
162. Stein Hallan: IMPLEMENTATION OF MODERN MEDICAL DECISION ANALYSIS INTO 
CLINICAL DIAGNOSIS AND TREATMENT. 
163. Malcolm Sue-Chu: INVASIVE AND NON-INVASIVE STUDIES IN CROSS-COUNTRY 
SKIERS WITH ASTHMA-LIKE SYMPTOMS. 
164. Ole-Lars Brekke: EFFECTS OF ANTIOXIDANTS AND FATTY ACIDS ON TUMOR 
NECROSIS FACTOR-INDUCED CYTOTOXICITY. 
165. Jan Lundbom: AORTOCORONARY BYPASS SURGERY: CLINICAL ASPECTS, COST 
CONSIDERATIONS AND WORKING ABILITY. 
166. John-Anker Zwart: LUMBAR NERVE ROOT COMPRESSION, BIOCHEMICAL AND 
NEUROPHYSIOLOGICAL ASPECTS. 
167. Geir Falck: HYPEROSMOLALITY AND THE HEART. 
168. Eirik Skogvoll: CARDIAC ARREST Incidence, Intervention and Outcome. 
169. Dalius Bansevicius: SHOULDER-NECK REGION IN CERTAIN HEADACHES AND 
CHRONIC PAIN SYNDROMES. 
170. Bettina Kinge: REFRACTIVE ERRORS AND BIOMETRIC CHANGES AMONG 
UNIVERSITY STUDENTS IN NORWAY. 
171. Gunnar Qvigstad: CONSEQUENCES OF HYPERGASTRINEMIA IN MAN 
172. Hanne Ellekjær: EPIDEMIOLOGICAL STUDIES OF STROKE IN A NORWEGIAN 
POPULATION. INCIDENCE, RISK FACTORS AND PROGNOSIS 
173. Hilde Grimstad: VIOLENCE AGAINST WOMEN AND PREGNANCY OUTCOME. 
174. Astrid Hjelde: SURFACE TENSION AND COMPLEMENT ACTIVATION: Factors 
influencing bubble formation and bubble effects after decompression. 
175. Kjell A. Kvistad: MR IN BREAST CANCER – A CLINICAL STUDY. 
176. Ivar Rossvoll: ELECTIVE ORTHOPAEDIC SURGERY IN A DEFINED POPULATION. 
Studies on demand, waiting time for treatment and incapacity for work. 
177. Carina Seidel: PROGNOSTIC VALUE AND BIOLOGICAL EFFECTS OF HEPATOCYTE 
GROWTH FACTOR AND SYNDECAN-1 IN MULTIPLE MYELOMA. 
2001 
178. Alexander Wahba: THE INFLUENCE OF CARDIOPULMONARY BYPASS ON PLATELET 
FUNCTION AND BLOOD COAGULATION – DETERMINANTS AND CLINICAL 
CONSEQUENSES 
179. Marcus Schmitt-Egenolf: THE RELEVANCE OF THE MAJOR hISTOCOMPATIBILITY 
COMPLEX FOR THE GENETICS OF PSORIASIS 
180. Odrun Arna Gederaas: BIOLOGICAL MECHANISMS INVOLVED IN 5-AMINOLEVULINIC 
ACID BASED PHOTODYNAMIC THERAPY 
181. Pål Richard Romundstad: CANCER INCIDENCE AMONG NORWEGIAN ALUMINIUM 
WORKERS 
182. Henrik Hjorth-Hansen: NOVEL CYTOKINES IN GROWTH CONTROL AND BONE 
DISEASE OF MULTIPLE MYELOMA 
183. Gunnar Morken: SEASONAL VARIATION OF HUMAN MOOD AND BEHAVIOUR 
184. Bjørn Olav Haugen: MEASUREMENT OF CARDIAC OUTPUT AND STUDIES OF 
VELOCITY PROFILES IN AORTIC AND MITRAL FLOW USING TWO- AND THREE-
DIMENSIONAL COLOUR FLOW IMAGING 
185. Geir Bråthen: THE CLASSIFICATION AND CLINICAL DIAGNOSIS OF ALCOHOL-
RELATED SEIZURES 
186. Knut Ivar Aasarød: RENAL INVOLVEMENT IN INFLAMMATORY RHEUMATIC 
DISEASE. A Study of Renal Disease in Wegener’s Granulomatosis and in Primary Sjögren’s 
Syndrome  
187. Trude Helen Flo: RESEPTORS INVOLVED IN CELL ACTIVATION BY DEFINED URONIC 
ACID POLYMERS AND BACTERIAL COMPONENTS 
188. Bodil Kavli: HUMAN URACIL-DNA GLYCOSYLASES FROM THE UNG GENE: 
STRUCTRUAL BASIS FOR SUBSTRATE SPECIFICITY AND REPAIR 
189. Liv Thommesen: MOLECULAR MECHANISMS INVOLVED IN TNF- AND GASTRIN-
MEDIATED GENE REGULATION 
190. Turid Lingaas Holmen: SMOKING AND HEALTH IN ADOLESCENCE; THE NORD-
TRØNDELAG HEALTH STUDY, 1995-97 
191. Øyvind Hjertner: MULTIPLE MYELOMA: INTERACTIONS BETWEEN MALIGNANT 
PLASMA CELLS AND THE BONE MICROENVIRONMENT 
192. Asbjørn Støylen: STRAIN RATE IMAGING OF THE LEFT VENTRICLE BY 
ULTRASOUND. FEASIBILITY, CLINICAL VALIDATION AND PHYSIOLOGICAL 
ASPECTS 
193. Kristian Midthjell: DIABETES IN ADULTS IN NORD-TRØNDELAG. PUBLIC HEALTH 
ASPECTS OF DIABETES MELLITUS IN A LARGE, NON-SELECTED NORWEGIAN 
POPULATION. 
194. Guanglin Cui: FUNCTIONAL ASPECTS OF THE ECL CELL IN RODENTS 
195. Ulrik Wisløff: CARDIAC EFFECTS OF AEROBIC ENDURANCE TRAINING: 
HYPERTROPHY, CONTRACTILITY AND CALCUIM HANDLING IN NORMAL AND 
FAILING HEART 
196. Øyvind Halaas: MECHANISMS OF IMMUNOMODULATION AND CELL-MEDIATED 
CYTOTOXICITY INDUCED BY BACTERIAL PRODUCTS 
197. Tore Amundsen: PERFUSION MR IMAGING IN THE DIAGNOSIS OF PULMONARY 
EMBOLISM 
198. Nanna Kurtze: THE SIGNIFICANCE OF ANXIETY AND DEPRESSION IN FATIQUE AND 
PATTERNS OF PAIN AMONG INDIVIDUALS DIAGNOSED WITH FIBROMYALGIA: 
RELATIONS WITH QUALITY OF LIFE, FUNCTIONAL DISABILITY, LIFESTYLE, 
EMPLOYMENT STATUS, CO-MORBIDITY AND GENDER 
199. Tom Ivar Lund Nilsen: PROSPECTIVE STUDIES OF CANCER RISK IN NORD-
TRØNDELAG: THE HUNT STUDY. Associations with anthropometric, socioeconomic, and 
lifestyle risk factors 
200. Asta Kristine Håberg: A NEW APPROACH TO THE STUDY OF MIDDLE CEREBRAL 
ARTERY OCCLUSION IN THE RAT USING MAGNETIC RESONANCE TECHNIQUES 
2002 
201. Knut Jørgen Arntzen: PREGNANCY AND CYTOKINES 
202. Henrik Døllner: INFLAMMATORY MEDIATORS IN PERINATAL INFECTIONS 
203. Asta Bye: LOW FAT, LOW LACTOSE DIET USED AS PROPHYLACTIC TREATMENT OF 
ACUTE INTESTINAL REACTIONS DURING PELVIC RADIOTHERAPY. A 
PROSPECTIVE RANDOMISED STUDY. 
204. Sylvester Moyo: STUDIES ON STREPTOCOCCUS AGALACTIAE  (GROUP B 
STREPTOCOCCUS) SURFACE-ANCHORED MARKERS WITH EMPHASIS ON STRAINS 
AND HUMAN SERA FROM ZIMBABWE. 
205. Knut Hagen: HEAD-HUNT: THE EPIDEMIOLOGY OF HEADACHE IN NORD-
TRØNDELAG 
206. Li Lixin: ON THE REGULATION AND ROLE OF UNCOUPLING PROTEIN-2 IN INSULIN 
PRODUCING ß-CELLS 
207. Anne Hildur Henriksen: SYMPTOMS OF ALLERGY AND ASTHMA VERSUS MARKERS 
OF LOWER AIRWAY INFLAMMATION AMONG ADOLESCENTS 
208. Egil Andreas Fors: NON-MALIGNANT PAIN IN RELATION TO PSYCHOLOGICAL AND 
ENVIRONTENTAL FACTORS. EXPERIENTAL AND CLINICAL STUDES OF PAIN WITH 
FOCUS ON FIBROMYALGIA 
209. Pål Klepstad:  MORPHINE FOR CANCER PAIN 
210. Ingunn Bakke: MECHANISMS AND CONSEQUENCES OF PEROXISOME 
PROLIFERATOR-INDUCED HYPERFUNCTION OF THE RAT GASTRIN PRODUCING 
CELL 
211. Ingrid Susann Gribbestad: MAGNETIC RESONANCE IMAGING AND SPECTROSCOPY OF 
BREAST CANCER 
212. Rønnaug Astri Ødegård: PREECLAMPSIA – MATERNAL RISK FACTORS AND FETAL 
GROWTH 
213. Johan Haux: STUDIES ON CYTOTOXICITY INDUCED BY HUMAN NATURAL KILLER 
CELLS AND DIGITOXIN 
214. Turid Suzanne Berg-Nielsen: PARENTING PRACTICES AND MENTALLY DISORDERED 
ADOLESCENTS 
215. Astrid Rydning: BLOOD FLOW AS A PROTECTIVE FACTOR FOR THE STOMACH 
MUCOSA. AN EXPERIMENTAL STUDY ON THE ROLE OF MAST CELLS AND 
SENSORY AFFERENT NEURONS   
 
 
2003 
216. Jan Pål Loennechen: HEART FAILURE AFTER MYOCARDIAL INFARCTION. Regional 
Differences, Myocyte Function, Gene Expression, and Response to Cariporide, Losartan, and 
Exercise Training. 
217. Elisabeth Qvigstad: EFFECTS OF FATTY ACIDS AND OVER-STIMULATION ON 
INSULIN SECRETION IN MAN 
218. Arne Åsberg: EPIDEMIOLOGICAL STUDIES IN HEREDITARY HEMOCHROMATOSIS: 
PREVALENCE, MORBIDITY AND BENEFIT OF SCREENING. 
219. Johan Fredrik Skomsvoll: REPRODUCTIVE OUTCOME IN WOMEN WITH RHEUMATIC 
DISEASE. A population registry based study of the effects of inflammatory rheumatic disease 
and connective tissue disease on reproductive outcome in Norwegian women in 1967-1995. 
220. Siv Mørkved: URINARY INCONTINENCE DURING PREGNANCY AND AFTER  
DELIVERY: EFFECT OF PELVIC FLOOR MUSCLE TRAINING IN PREVENTION AND 
TREATMENT 
221. Marit S. Jordhøy: THE IMPACT OF COMPREHENSIVE PALLIATIVE CARE 
222. Tom Christian Martinsen: HYPERGASTRINEMIA AND HYPOACIDITY IN RODENTS – 
CAUSES AND CONSEQUENCES  
223. Solveig Tingulstad: CENTRALIZATION OF PRIMARY SURGERY FOR OVARAIN 
CANCER. FEASIBILITY AND IMPACT ON SURVIVAL  
224. Haytham Eloqayli: METABOLIC CHANGES IN THE BRAIN CAUSED BY EPILEPTIC 
SEIZURES 
225. Torunn Bruland: STUDIES OF EARLY RETROVIRUS-HOST INTERACTIONS – VIRAL 
DETERMINANTS FOR PATHOGENESIS AND THE INFLUENCE OF SEX ON THE 
SUSCEPTIBILITY TO FRIEND MURINE LEUKAEMIA VIRUS INFECTION 
226. Torstein Hole: DOPPLER ECHOCARDIOGRAPHIC EVALUATION OF LEFT 
VENTRICULAR FUNCTION IN PATIENTS WITH ACUTE MYOCARDIAL INFARCTION 
227. Vibeke Nossum: THE EFFECT OF VASCULAR BUBBLES ON ENDOTHELIAL FUNCTION 
228. Sigurd Fasting: ROUTINE BASED RECORDING OF ADVERSE EVENTS DURING 
ANAESTHESIA – APPLICATION IN QUALITY IMPROVEMENT AND SAFETY 
229. Solfrid Romundstad: EPIDEMIOLOGICAL STUDIES OF MICROALBUMINURIA. THE 
NORD-TRØNDELAG HEALTH STUDY 1995-97 (HUNT 2) 
230. Geir Torheim: PROCESSING OF DYNAMIC DATA SETS IN MAGNETIC RESONANCE 
IMAGING 
231. Catrine Ahlén: SKIN INFECTIONS IN OCCUPATIONAL SATURATION DIVERS IN THE 
NORTH SEA AND THE IMPACT OF THE ENVIRONMENT 
232. Arnulf Langhammer: RESPIRATORY SYMPTOMS, LUNG FUNCTION AND BONE 
MINERAL DENSITY IN A COMPREHENSIVE POPULATION SURVEY. THE NORD-
TRØNDELAG HEALTH STUDY 1995-97. THE BRONCHIAL OBSTRUCTION IN NORD-
TRØNDELAG STUDY 
233. Einar Kjelsås: EATING DISORDERS AND PHYSICAL ACTIVITY IN NON-CLINICAL 
SAMPLES 
234. Arne Wibe: RECTAL CANCER TREATMENT IN NORWAY – STANDARDISATION OF 
SURGERY AND QUALITY ASSURANCE 
2004 
235. Eivind Witsø: BONE GRAFT AS AN ANTIBIOTIC CARRIER 
236. Anne Mari Sund: DEVELOPMENT OF DEPRESSIVE SYMPTOMS IN EARLY 
ADOLESCENCE   
237. Hallvard Lærum: EVALUATION OF ELECTRONIC MEDICAL RECORDS – A CLINICAL 
TASK PERSPECTIVE  
238. Gustav Mikkelsen: ACCESSIBILITY OF INFORMATION IN ELECTRONIC PATIENT 
RECORDS; AN EVALUATION OF THE ROLE OF DATA QUALITY 
239. Steinar Krokstad: SOCIOECONOMIC INEQUALITIES IN HEALTH AND DISABILITY. 
SOCIAL EPIDEMIOLOGY IN THE NORD-TRØNDELAG HEALTH STUDY (HUNT), 
NORWAY 
240. Arne Kristian Myhre: NORMAL VARIATION IN ANOGENITAL ANATOMY AND 
MICROBIOLOGY IN NON-ABUSED PRESCHOOL CHILDREN 
241. Ingunn Dybedal: NEGATIVE REGULATORS OF HEMATOPOIETEC STEM AND 
PROGENITOR CELLS 
242. Beate Sitter: TISSUE CHARACTERIZATION BY HIGH RESOLUTION MAGIC ANGLE 
SPINNING MR SPECTROSCOPY 
243. Per Arne Aas: MACROMOLECULAR MAINTENANCE IN HUMAN CELLS – REPAIR OF 
URACIL IN DNA AND METHYLATIONS IN DNA AND RNA 
244. Anna Bofin:  FINE NEEDLE ASPIRATION CYTOLOGY IN THE PRIMARY 
INVESTIGATION OF BREAST TUMOURS AND IN THE DETERMINATION OF 
TREATMENT STRATEGIES 
245. Jim Aage Nøttestad: DEINSTITUTIONALIZATION AND MENTAL HEALTH CHANGES 
AMONG PEOPLE WITH MENTAL RETARDATION 
246. Reidar Fossmark:  GASTRIC CANCER IN JAPANESE COTTON RATS 
247. Wibeke Nordhøy:  MANGANESE AND THE HEART, INTRACELLULAR MR 
RELAXATION AND WATER EXCHANGE ACROSS THE CARDIAC CELL MEMBRANE 
2005 
248. Sturla Molden:  QUANTITATIVE ANALYSES OF SINGLE UNITS RECORDED FROM THE 
HIPPOCAMPUS AND ENTORHINAL CORTEX OF BEHAVING RATS 
249. Wenche Brenne Drøyvold:  EPIDEMIOLOGICAL STUDIES ON WEIGHT CHANGE AND 
HEALTH IN A LARGE POPULATION.  THE NORD-TRØNDELAG HEALTH STUDY 
(HUNT) 
250. Ragnhild Støen:  ENDOTHELIUM-DEPENDENT VASODILATION IN THE FEMORAL 
ARTERY OF DEVELOPING PIGLETS 
251. Aslak Steinsbekk:  HOMEOPATHY IN THE PREVENTION OF UPPER RESPIRATORY 
TRACT INFECTIONS IN CHILDREN 
252. Hill-Aina Steffenach:  MEMORY IN HIPPOCAMPAL AND CORTICO-HIPPOCAMPAL 
CIRCUITS 
253. Eystein Stordal:  ASPECTS OF THE EPIDEMIOLOGY OF DEPRESSIONS BASED ON 
SELF-RATING IN A LARGE GENERAL HEALTH STUDY (THE HUNT-2 STUDY) 
254. Viggo Pettersen:  FROM MUSCLES TO SINGING:  THE ACTIVITY OF ACCESSORY 
BREATHING MUSCLES AND THORAX  MOVEMENT IN CLASSICAL SINGING 
255. Marianne Fyhn:  SPATIAL MAPS IN THE HIPPOCAMPUS AND ENTORHINAL CORTEX 
256. Robert Valderhaug:  OBSESSIVE-COMPULSIVE DISORDER AMONG CHILDREN AND 
ADOLESCENTS:  CHARACTERISTICS AND PSYCHOLOGICAL MANAGEMENT OF 
PATIENTS IN OUTPATIENT PSYCHIATRIC CLINICS 
257. Erik Skaaheim Haug:  INFRARENAL ABDOMINAL  AORTIC ANEURYSMS – 
COMORBIDITY AND RESULTS FOLLOWING OPEN SURGERY 
258. Daniel Kondziella: GLIAL-NEURONAL INTERACTIONS IN EXPERIMENTAL BRAIN 
DISORDERS 
259. Vegard Heimly Brun:  ROUTES TO SPATIAL MEMORY IN HIPPOCAMPAL PLACE 
CELLS 
260. Kenneth McMillan:  PHYSIOLOGICAL ASSESSMENT AND TRAINING OF ENDURANCE 
AND STRENGTH IN PROFESSIONAL YOUTH SOCCER PLAYERS 
261. Marit Sæbø Indredavik:  MENTAL HEALTH AND CEREBRAL MAGNETIC RESONANCE 
IMAGING IN ADOLESCENTS WITH LOW BIRTH WEIGHT 
262. Ole Johan Kemi:  ON THE CELLULAR BASIS OF AEROBIC FITNESS, INTENSITY-
DEPENDENCE AND TIME-COURSE OF CARDIOMYOCYTE AND ENDOTHELIAL 
ADAPTATIONS TO EXERCISE TRAINING 
263. Eszter Vanky: POLYCYSTIC OVARY SYNDROME – METFORMIN TREATMENT IN 
PREGNANCY 
264. Hild Fjærtoft:  EXTENDED STROKE UNIT SERVICE AND EARLY SUPPORTED 
DISCHARGE.  SHORT AND LONG-TERM EFFECTS   
265. Grete Dyb:  POSTTRAUMATIC STRESS REACTIONS IN CHILDREN AND 
ADOLESCENTS 
266. Vidar Fykse: SOMATOSTATIN AND THE STOMACH 
267. Kirsti Berg: OXIDATIVE STRESS AND THE ISCHEMIC HEART:  A STUDY IN PATIENTS 
UNDERGOING CORONARY REVASCULARIZATION  
268. Björn Inge Gustafsson:  THE SEROTONIN PRODUCING ENTEROCHROMAFFIN CELL, 
AND EFFECTS OF HYPERSEROTONINEMIA ON HEART AND BONE 
2006 
269. Torstein Baade Rø:  EFFECTS OF BONE MORPHOGENETIC PROTEINS, HEPATOCYTE 
GROWTH FACTOR AND INTERLEUKIN-21 IN MULTIPLE MYELOMA 
270. May-Britt Tessem:  METABOLIC EFFECTS OF ULTRAVIOLET RADIATION ON THE 
ANTERIOR PART OF THE EYE 
271. Anne-Sofie Helvik:  COPING AND EVERYDAY LIFE IN A POPULATION OF ADULTS 
WITH HEARING IMPAIRMENT 
272. Therese Standal:  MULTIPLE MYELOMA:  THE INTERPLAY BETWEEN MALIGNANT 
PLASMA CELLS AND THE BONE MARROW MICROENVIRONMENT 
273. Ingvild Saltvedt:  TREATMENT OF ACUTELY SICK, FRAIL ELDERLY PATIENTS IN A 
GERIATRIC EVALUATION AND MANAGEMENT UNIT – RESULTS FROM A 
PROSPECTIVE RANDOMISED TRIAL 
274. Birger Henning Endreseth:  STRATEGIES IN RECTAL CANCER TREATMENT – FOCUS 
ON EARLY RECTAL CANCER AND THE INFLUENCE OF AGE ON PROGNOSIS 
275. Anne Mari Aukan Rokstad:  ALGINATE CAPSULES AS BIOREACTORS FOR CELL 
THERAPY 
276. Mansour Akbari: HUMAN BASE EXCISION REPAIR FOR PRESERVATION OF GENOMIC 
STABILITY 
277. Stein Sundstrøm:  IMPROVING TREATMENT IN PATIENTS WITH LUNG CANCER – 
RESULTS FROM TWO MULITCENTRE RANDOMISED STUDIES 
278. Hilde Pleym: BLEEDING AFTER CORONARY ARTERY BYPASS SURGERY -  STUDIES 
ON HEMOSTATIC MECHANISMS, PROPHYLACTIC DRUG TREATMENT AND 
EFFECTS OF AUTOTRANSFUSION 
279. Line Merethe Oldervoll:  PHYSICAL ACTIVITY AND EXERCISE INTERVENTIONS IN 
CANCER PATIENTS 
280. Boye Welde:  THE SIGNIFICANCE OF ENDURANCE TRAINING, RESISTANCE 
TRAINING AND MOTIVATIONAL STYLES IN ATHLETIC PERFORMANCE AMONG 
ELITE JUNIOR CROSS-COUNTRY SKIERS 
281. Per Olav Vandvik:  IRRITABLE BOWEL SYNDROME IN NORWAY,  STUDIES OF 
PREVALENCE, DIAGNOSIS AND CHARACTERISTICS IN GENERAL PRACTICE AND 
IN THE POPULATION 
282. Idar Kirkeby-Garstad:  CLINICAL PHYSIOLOGY OF EARLY MOBILIZATION AFTER 
CARDIAC SURGERY 
283. Linn Getz: SUSTAINABLE AND RESPONSIBLE PREVENTIVE MEDICINE.  
CONCEPTUALISING ETHICAL DILEMMAS ARISING FROM CLINICAL 
IMPLEMENTATION OF ADVANCING MEDICAL TECHNOLOGY  
284. Eva Tegnander: DETECTION OF CONGENITAL HEART DEFECTS  IN A NON-SELECTED 
POPULATION OF 42,381 FETUSES 
285. Kristin Gabestad Nørsett:  GENE EXPRESSION STUDIES IN GASTROINTESTINAL 
PATHOPHYSIOLOGY AND NEOPLASIA 
286. Per Magnus Haram:  GENETIC VS. AQUIRED FITNESS:  METABOLIC, VASCULAR AND 
CARDIOMYOCYTE  ADAPTATIONS 
287. Agneta Johansson:  GENERAL RISK FACTORS FOR GAMBLING PROBLEMS AND THE 
PREVALENCE OF PATHOLOGICAL GAMBLING IN NORWAY  
288. Svein Artur Jensen:  THE PREVALENCE OF SYMPTOMATIC ARTERIAL DISEASE OF 
THE LOWER LIMB 
289. Charlotte Björk Ingul:  QUANITIFICATION OF REGIONAL MYOCARDIAL FUNCTION 
BY STRAIN RATE AND STRAIN FOR EVALUATION OF CORONARY ARTERY 
DISEASE.  AUTOMATED VERSUS MANUAL ANALYSIS DURING ACUTE 
MYOCARDIAL INFARCTION AND DOBUTAMINE STRESS ECHOCARDIOGRAPHY 
290. Jakob Nakling:  RESULTS AND CONSEQUENCES OF ROUTINE ULTRASOUND 
SCREENING IN PREGNANCY – A GEOGRAPHIC BASED POPULATION STUDY 
291. Anne Engum:  DEPRESSION AND ANXIETY – THEIR RELATIONS TO THYROID 
DYSFUNCTION AND DIABETES IN A LARGE EPIDEMIOLOGICAL STUDY 
292. Ottar Bjerkeset: ANXIETY AND DEPRESSION IN THE GENERAL POPULATION:  RISK 
FACTORS, INTERVENTION AND OUTCOME – THE NORD-TRØNDELAG HEALTH 
STUDY (HUNT) 
293. Jon Olav Drogset:  RESULTS AFTER SURGICAL TREATMENT OF ANTERIOR 
CRUCIATE LIGAMENT INJURIES – A CLINICAL STUDY  
294. Lars Fosse: MECHANICAL BEHAVIOUR OF COMPACTED MORSELLISED BONE – AN 
EXPERIMENTAL IN VITRO STUDY 
295. Gunilla Klensmeden Fosse: MENTAL HEALTH OF PSYCHIATRIC OUTPATIENTS 
BULLIED IN CHILDHOOD 
296. Paul Jarle Mork:  MUSCLE ACTIVITY IN WORK  AND LEISURE AND ITS ASSOCIATION 
TO MUSCULOSKELETAL PAIN 
297. Björn Stenström:  LESSONS FROM RODENTS:  I: MECHANISMS OF OBESITY SURGERY 
– ROLE OF STOMACH.  II: CARCINOGENIC EFFECTS OF HELICOBACTER PYLORI 
AND SNUS IN THE STOMACH 
2007 
298. Haakon R. Skogseth:  INVASIVE PROPERTIES OF CANCER – A TREATMENT TARGET ?  
IN VITRO STUDIES IN HUMAN PROSTATE CANCER CELL LINES 
299. Janniche Hammer:  GLUTAMATE METABOLISM AND CYCLING IN MESIAL 
TEMPORAL LOBE EPILEPSY 
300. May Britt Drugli:  YOUNG CHILDREN TREATED BECAUSE OF ODD/CD:  CONDUCT 
PROBLEMS AND SOCIAL COMPETENCIES IN DAY-CARE AND SCHOOL SETTINGS 
301. Arne Skjold:  MAGNETIC RESONANCE KINETICS OF MANGANESE DIPYRIDOXYL 
DIPHOSPHATE (MnDPDP) IN HUMAN MYOCARDIUM.  STUDIES IN HEALTHY 
VOLUNTEERS AND IN PATIENTS WITH RECENT MYOCARDIAL INFARCTION 
302. Siri Malm:  LEFT VENTRICULAR SYSTOLIC FUNCTION AND MYOCARDIAL 
PERFUSION ASSESSED BY CONTRAST ECHOCARDIOGRAPHY 
303. Valentina Maria do Rosario Cabral Iversen:  MENTAL HEALTH AND PSYCHOLOGICAL 
ADAPTATION OF CLINICAL AND NON-CLINICAL MIGRANT GROUPS 
304. Lasse Løvstakken:  SIGNAL PROCESSING IN DIAGNOSTIC ULTRASOUND:  
ALGORITHMS FOR REAL-TIME ESTIMATION AND VISUALIZATION OF BLOOD 
FLOW VELOCITY 
305. Elisabeth Olstad:  GLUTAMATE AND GABA:  MAJOR PLAYERS IN NEURONAL 
METABOLISM  
306. Lilian Leistad:  THE ROLE OF CYTOKINES AND PHOSPHOLIPASE A2s  IN ARTICULAR 
CARTILAGE CHONDROCYTES IN RHEUMATOID ARTHRITIS AND OSTEOARTHRITIS 
307. Arne Vaaler:  EFFECTS OF PSYCHIATRIC INTENSIVE CARE UNIT IN AN ACUTE 
PSYCIATHRIC WARD 
308. Mathias Toft:  GENETIC STUDIES OF LRRK2 AND PINK1 IN PARKINSON’S DISEASE 
309. Ingrid Løvold Mostad:  IMPACT OF DIETARY FAT QUANTITY AND QUALITY IN TYPE 
2 DIABETES WITH EMPHASIS ON MARINE N-3 FATTY ACIDS 
310. Torill Eidhammer Sjøbakk:  MR DETERMINED BRAIN METABOLIC PATTERN IN 
PATIENTS WITH BRAIN METASTASES AND ADOLESCENTS WITH LOW BIRTH 
WEIGHT 
311. Vidar Beisvåg:  PHYSIOLOGICAL GENOMICS OF HEART FAILURE:  FROM 
TECHNOLOGY TO PHYSIOLOGY 
312. Olav Magnus Søndenå Fredheim:  HEALTH RELATED QUALITY OF LIFE ASSESSMENT 
AND ASPECTS OF THE CLINICAL PHARMACOLOGY OF METHADONE IN PATIENTS 
WITH CHRONIC NON-MALIGNANT PAIN 
313. Anne Brantberg: FETAL AND PERINATAL IMPLICATIONS OF ANOMALIES IN THE 
GASTROINTESTINAL TRACT AND THE ABDOMINAL WALL 
314. Erik Solligård: GUT LUMINAL MICRODIALYSIS 
315. Elin Tollefsen: RESPIRATORY SYMPTOMS IN A COMPREHENSIVE POPULATION 
BASED STUDY AMONG ADOLESCENTS 13-19 YEARS. YOUNG-HUNT 1995-97 AND 
2000-01; THE NORD-TRØNDELAG HEALTH STUDIES (HUNT) 
316. Anne-Tove Brenne:  GROWTH REGULATION OF MYELOMA CELLS 
317. Heidi Knobel:  FATIGUE IN CANCER TREATMENT – ASSESSMENT, COURSE AND 
ETIOLOGY 
318. Torbjørn Dahl:  CAROTID ARTERY STENOSIS.  DIAGNOSTIC AND THERAPEUTIC 
ASPECTS 
319. Inge-Andre Rasmussen jr.:  FUNCTIONAL AND DIFFUSION TENSOR MAGNETIC 
RESONANCE IMAGING IN NEUROSURGICAL PATIENTS 
320. Grete Helen Bratberg:  PUBERTAL TIMING – ANTECEDENT TO RISK OR RESILIENCE ?  
EPIDEMIOLOGICAL STUDIES ON GROWTH, MATURATION AND HEALTH RISK 
BEHAVIOURS; THE YOUNG HUNT STUDY, NORD-TRØNDELAG, NORWAY 
321. Sveinung Sørhaug:  THE PULMONARY NEUROENDOCRINE SYSTEM.  
PHYSIOLOGICAL, PATHOLOGICAL AND TUMOURIGENIC ASPECTS 
322. Olav Sande Eftedal:  ULTRASONIC DETECTION OF DECOMPRESSION INDUCED 
VASCULAR MICROBUBBLES 
323. Rune Bang Leistad:  PAIN, AUTONOMIC ACTIVATION AND MUSCULAR ACTIVITY 
RELATED TO EXPERIMENTALLY-INDUCED COGNITIVE STRESS IN HEADACHE 
PATIENTS 
324. Svein Brekke:  TECHNIQUES FOR ENHANCEMENT OF TEMPORAL RESOLUTION IN 
THREE-DIMENSIONAL ECHOCARDIOGRAPHY 
325. Kristian Bernhard Nilsen:  AUTONOMIC ACTIVATION AND MUSCLE ACTIVITY IN 
RELATION TO MUSCULOSKELETAL PAIN 
326. Anne Irene Hagen:  HEREDITARY BREAST CANCER IN NORWAY.  DETECTION AND 
PROGNOSIS OF BREAST CANCER IN FAMILIES WITH BRCA1GENE MUTATION 
327. Ingebjørg S. Juel :  INTESTINAL INJURY AND RECOVERY AFTER ISCHEMIA.  AN 
EXPERIMENTAL STUDY ON RESTITUTION OF THE SURFACE EPITHELIUM, 
INTESTINAL PERMEABILITY, AND RELEASE OF BIOMARKERS FROM THE MUCOSA 
328. Runa Heimstad:  POST-TERM PREGNANCY 
329. Jan Egil Afset:  ROLE OF ENTEROPATHOGENIC ESCHERICHIA COLI  IN CHILDHOOD 
DIARRHOEA IN NORWAY 
330. Bent Håvard Hellum:  IN VITRO INTERACTIONS BETWEEN MEDICINAL DRUGS AND 
HERBS ON CYTOCHROME P-450 METABOLISM AND P-GLYCOPROTEIN TRANSPORT 
331. Morten André Høydal:  CARDIAC DYSFUNCTION AND MAXIMAL OXYGEN UPTAKE 
MYOCARDIAL ADAPTATION TO ENDURANCE TRAINING 
2008 
332. Andreas Møllerløkken:  REDUCTION OF VASCULAR BUBBLES:  METHODS TO 
PREVENT THE ADVERSE EFFECTS OF DECOMPRESSION 
333. Anne Hege Aamodt:  COMORBIDITY OF HEADACHE AND MIGRAINE IN THE NORD-
TRØNDELAG HEALTH STUDY 1995-97 
334. Brage Høyem Amundsen:  MYOCARDIAL FUNCTION QUANTIFIED BY SPECKLE 
TRACKING AND TISSUE DOPPLER ECHOCARDIOGRAPHY – VALIDATION AND 
APPLICATION IN EXERCISE TESTING AND TRAINING 
335. Inger Anne Næss:  INCIDENCE, MORTALITY AND RISK FACTORS OF FIRST VENOUS 
THROMBOSIS IN A GENERAL POPULATION.  RESULTS FROM THE SECOND NORD-
TRØNDELAG HEALTH STUDY (HUNT2) 
336. Vegard Bugten:  EFFECTS OF POSTOPERATIVE MEASURES AFTER FUNCTIONAL 
ENDOSCOPIC SINUS  SURGERY 
337. Morten Bruvold:  MANGANESE AND WATER IN CARDIAC MAGNETIC RESONANCE 
IMAGING  
338. Miroslav Fris:  THE EFFECT OF SINGLE AND REPEATED ULTRAVIOLET RADIATION 
ON THE ANTERIOR SEGMENT OF THE RABBIT EYE 
339. Svein Arne Aase:  METHODS FOR IMPROVING QUALITY AND EFFICIENCY IN 
QUANTITATIVE ECHOCARDIOGRAPHY – ASPECTS OF USING HIGH FRAME RATE 
340. Roger Almvik:  ASSESSING THE RISK OF VIOLENCE:  DEVELOPMENT AND 
VALIDATION OF THE BRØSET VIOLENCE CHECKLIST 
341. Ottar Sundheim:  STRUCTURE-FUNCTION ANALYSIS OF HUMAN ENZYMES 
INITIATING NUCLEOBASE REPAIR IN DNA AND RNA 
342. Anne Mari Undheim:  SHORT AND LONG-TERM OUTCOME OF EMOTIONAL AND 
BEHAVIOURAL PROBLEMS IN YOUNG ADOLESCENTS WITH AND WITHOUT 
READING DIFFICULTIES 
343. Helge Garåsen:  THE TRONDHEIM MODEL.  IMPROVING THE PROFESSIONAL 
COMMUNICATION BETWEEN THE VARIOUS LEVELS OF HEALTH CARE SERVICES 
AND IMPLEMENTATION OF INTERMEDIATE CARE AT A COMMUNITY HOSPITAL 
COULD PROVIDE BETTER CARE FOR OLDER PATIENTS.  SHORT AND LONG TERM 
EFFECTS  
344. Olav A. Foss:  “THE ROTATION RATIOS METHOD”.  A METHOD TO DESCRIBE 
ALTERED SPATIAL ORIENTATION IN SEQUENTIAL RADIOGRAPHS FROM ONE 
PELVIS 
345. Bjørn Olav Åsvold:  THYROID FUNCTION AND CARDIOVASCULAR HEALTH 
346. Torun Margareta Melø: NEURONAL GLIAL INTERACTIONS IN EPILEPSY 
347. Irina Poliakova Eide:  FETAL GROWTH RESTRICTION AND PRE-ECLAMPSIA:   SOME 
CHARACTERISTICS OF FETO-MATERNAL INTERACTIONS IN DECIDUA BASALIS 
348. Torunn Askim:  RECOVERY AFTER STROKE.  ASSESSMENT AND TREATMENT;  WITH 
FOCUS ON MOTOR FUNCTION 
349. Ann Elisabeth Åsberg:  NEUTROPHIL ACTIVATION IN A ROLLER PUMP MODEL OF 
CARDIOPULMONARY BYPASS.  INFLUENCE ON BIOMATERIAL, PLATELETS AND 
COMPLEMENT 
350. Lars Hagen:  REGULATION OF DNA BASE EXCISION REPAIR BY PROTEIN 
INTERACTIONS AND POST TRANSLATIONAL MODIFICATIONS 
351. Sigrun Beate Kjøtrød:  POLYCYSTIC OVARY SYNDROME – METFORMIN TREATMENT 
IN ASSISTED REPRODUCTION 
352. Steven Keita Nishiyama:  PERSPECTIVES ON LIMB-VASCULAR HETEROGENEITY:  
IMPLICATIONS FOR HUMAN AGING, SEX, AND EXERCISE 
353. Sven Peter Näsholm:  ULTRASOUND BEAMS FOR ENHANCED IMAGE QUALITY 
354. Jon Ståle Ritland:  PRIMARY OPEN-ANGLE GLAUCOMA & EXFOLIATIVE GLAUCOMA. 
SURVIVAL, COMORBIDITY AND GENETICS 
355. Sigrid Botne Sando:  ALZHEIMER’S DISEASE IN CENTRAL NORWAY.  GENETIC AND 
EDUCATIONAL ASPECTS 
356. Parvinder Kaur: CELLULAR AND MOLECULAR MECHANISMS BEHIND 
METHYLMERCURY-INDUCED NEUROTOXICITY 
357. Ismail Cüneyt Güzey:  DOPAMINE AND SEROTONIN RECEPTOR AND TRANSPORTER 
GENE POLYMORPHISMS AND EXTRAPYRAMIDAL SYMPTOMS. STUDIES IN 
PARKINSON’S DISEASE AND IN PATIENTS TREATED WITH ANTIPSYCHOTIC OR 
ANTIDEPRESSANT DRUGS 
358. Brit Dybdahl:  EXTRA-CELLULAR INDUCIBLE HEAT-SHOCK PROTEIN 70 (Hsp70) – A 
ROLE IN THE INFLAMMATORY RESPONSE ? 
359. Kristoffer Haugarvoll:  IDENTIFYING GENETIC CAUSES OF PARKINSON’S DISEASE IN 
NORWAY 
360. Nadra Nilsen: TOLL-LIKE RECEPTOR 2 –EXPRESSION, REGULATION AND SIGNALING 
361. Johan Håkon Bjørngaard: PATIENT SATISFACTION WITH OUTPATIENT MENTAL 
HEALTH SERVICES – THE INFLUENCE OF ORGANIZATIONAL FACTORS. 
362. Kjetil Høydal : EFFECTS OF HIGH INTENSITY AEROBIC TRAINING IN HEALTHY 
SUBJECTS AND CORONARY ARTERY DISEASE PATIENTS; THE IMPORTANCE OF 
INTENSITY,, DURATION AND FREQUENCY OF TRAINING. 
363. Trine Karlsen: TRAINING IS MEDICINE: ENDURANCE AND STRENGTH TRAINING IN 
CORONARY ARTERY DISEASE AND HEALTH. 
364. Marte Thuen: MANGANASE-ENHANCED AND DIFFUSION TENSOR MR IMAGING OF 
THE NORMAL, INJURED AND REGENERATING RAT VISUAL PATHWAY 
365. Cathrine Broberg Vågbø:  DIRECT REPAIR OF ALKYLATION DAMAGE IN DNA AND 
RNA BY 2-OXOGLUTARATE- AND IRON-DEPENDENT DIOXYGENASES 
366. Arnt Erik Tjønna:  AEROBIC EXERCISE AND CARDIOVASCULAR RISK FACTORS IN 
OVERWEIGHT AND OBESE ADOLESCENTS AND ADULTS 
367. Marianne W. Furnes:  FEEDING BEHAVIOR AND BODY WEIGHT DEVELOPMENT:  
LESSONS FROM RATS  
368. Lene N. Johannessen:  FUNGAL PRODUCTS AND INFLAMMATORY RESPONSES IN 
HUMAN MONOCYTES AND EPITHELIAL CELLS  
369. Anja Bye:  GENE EXPRESSION PROFILING OF INHERITED AND ACQUIRED MAXIMAL 
OXYGEN UPTAKE – RELATIONS TO THE METABOLIC SYNDROME. 
370. Oluf Dimitri Røe:  MALIGNANT MESOTHELIOMA:  VIRUS, BIOMARKERS AND GENES.  
A TRANSLATIONAL APPROACH 
371. Ane Cecilie Dale:  DIABETES MELLITUS AND FATAL ISCHEMIC HEART DISEASE. 
ANALYSES FROM THE HUNT1 AND 2 STUDIES 
372. Jacob Christian Hølen:  PAIN ASSESSMENT IN PALLIATIVE CARE:  VALIDATION OF 
METHODS FOR SELF-REPORT AND BEHAVIOURAL ASSESSMENT 
373. Erming Tian:  THE GENETIC IMPACTS IN THE ONCOGENESIS OF MULTIPLE 
MYELOMA 
374. Ole Bosnes:  KLINISK UTPRØVING AV NORSKE VERSJONER AV NOEN SENTRALE 
TESTER PÅ KOGNITIV FUNKSJON 
375. Ola M. Rygh:  3D ULTRASOUND BASED NEURONAVIGATION IN NEUROSURGERY.  A 
CLINICAL EVALUATION 
376. Astrid Kamilla Stunes:  ADIPOKINES, PEROXISOME PROFILERATOR ACTIVATED 
RECEPTOR (PPAR) AGONISTS AND SEROTONIN.  COMMON REGULATORS OF BONE 
AND FAT METABOLISM 
377. Silje Engdal:  HERBAL REMEDIES USED BY NORWEGIAN CANCER PATIENTS AND 
THEIR ROLE IN HERB-DRUG INTERACTIONS 
378. Kristin Offerdal:  IMPROVED ULTRASOUND IMAGING OF THE FETUS AND ITS 
CONSEQUENCES FOR SEVERE AND LESS SEVERE ANOMALIES 
379. Øivind Rognmo:  HIGH-INTENSITY AEROBIC EXERCISE AND CARDIOVASCULAR 
HEALTH 
380. Jo-Åsmund Lund:  RADIOTHERAPY IN ANAL CARCINOMA AND PROSTATE CANCER 
 
2009 
381. Tore Grüner Bjåstad:  HIGH FRAME RATE ULTRASOUND IMAGING USING PARALLEL 
BEAMFORMING 
382. Erik Søndenaa:  INTELLECTUAL DISABILITIES IN THE CRIMINAL JUSTICE SYSTEM 
383. Berit Rostad:  SOCIAL INEQUALITIES IN WOMEN’S HEALTH, HUNT 1984-86 AND 
1995-97, THE NORD-TRØNDELAG HEALTH STUDY (HUNT) 
384. Jonas Crosby:  ULTRASOUND-BASED QUANTIFICATION OF MYOCARDIAL 
DEFORMATION AND ROTATION 
385. Erling Tronvik:  MIGRAINE, BLOOD PRESSURE AND THE RENIN-ANGIOTENSIN 
SYSTEM 
386. Tom Christensen:  BRINGING THE GP TO THE FOREFRONT OF EPR DEVELOPMENT 
387. Håkon Bergseng:  ASPECTS OF GROUP B STREPTOCOCCUS (GBS) DISEASE IN THE 
NEWBORN.  EPIDEMIOLOGY, CHARACTERISATION OF INVASIVE STRAINS AND 
EVALUATION OF INTRAPARTUM SCREENING  
388. Ronny Myhre: GENETIC STUDIES OF CANDIDATE TENE3S IN PARKINSON’S  
DISEASE 
389. Torbjørn Moe Eggebø:  ULTRASOUND AND LABOUR 
390. Eivind Wang:  TRAINING IS MEDICINE FOR PATIENTS WITH PERIPHERAL ARTERIAL 
DISEASE 
391. Thea Kristin Våtsveen: GENETIC ABERRATIONS IN MYELOMA CELLS 
392. Thomas Jozefiak:  QUALITY OF LIFE AND MENTAL HEALTH IN CHILDREN AND 
ADOLESCENTS:  CHILD AND PARENT PERSPECTIVES 
393. Jens Erik Slagsvold:  N-3 POLYUNSATURATED FATTY ACIDS IN HEALTH AND 
DISEASE – CLINICAL AND MOLECULAR ASPECTS 
394. Kristine Misund:  A STUDY OF THE TRANSCRIPTIONAL REPRESSOR ICER.  
REGULATORY NETWORKS IN GASTRIN-INDUCED GENE EXPRESSION 
395. Franco M. Impellizzeri:  HIGH-INTENSITY TRAINING IN FOOTBALL PLAYERS.  
EFFECTS ON PHYSICAL AND TECHNICAL PERFORMANCE 
396. Kari Hanne Gjeilo:  HEALTH-RELATED QUALITY OF LIFE AND CHRONIC PAIN IN 
PATIENTS UNDERGOING CARDIAC SURGERY 
397. Øyvind Hauso:  NEUROENDOCRINE ASPECTS OF PHYSIOLOGY AND DISEASE 
398. Ingvild Bjellmo Johnsen:  INTRACELLULAR SIGNALING MECHANISMS IN THE INNATE 
IMMUNE RESPONSE TO VIRAL INFECTIONS 
399. Linda Tømmerdal Roten:  GENETIC PREDISPOSITION FOR DEVELOPMENT OF 
PREEMCLAMPSIA – CANDIDATE GENE STUDIES IN THE HUNT (NORD-TRØNDELAG 
HEALTH STUDY) POPULATION 
400. Trude Teoline Nausthaug Rakvåg:  PHARMACOGENETICS OF MORPHINE IN CANCER 
PAIN 
401. Hanne Lehn:  MEMORY FUNCTIONS OF THE HUMAN MEDIAL TEMPORAL LOBE 
STUDIED WITH fMRI 
402. Randi Utne Holt:  ADHESION AND MIGRATION OF MYELOMA CELLS – IN VITRO 
STUDIES – 
403. Trygve Solstad: NEURAL REPRESENTATIONS OF EUCLIDEAN SPACE 
404. Unn-Merete Fagerli:  MULTIPLE MYELOMA CELLS AND CYTOKINES FROM THE 
BONE MARROW ENVIRONMENT; ASPECTS OF GROWTH REGULATION AND 
MIGRATION 
405. Sigrid Bjørnelv:  EATING– AND WEIGHT PROBLEMS IN ADOLESCENTS, THE YOUNG 
HUNT-STUDY 
406. Mari Hoff:  CORTICAL HAND BONE LOSS IN RHEUMATOID ARTHRITIS.  
EVALUATING DIGITAL X-RAY RADIOGRAMMETRY AS OUTCOME MEASURE OF 
DISEASE ACTIVITY, RESPONSE VARIABLE TO TREATMENT AND PREDICTOR OF 
BONE DAMAGE  
407. Siri Bjørgen:  AEROBIC HIGH INTENSITY INTERVAL TRAINING IS AN EFFECTIVE 
TREATMENT FOR PATIENTS WITH CHRONIC OBSTRUCTIVE PULMONARY DISEASE 
408. Susanne Lindqvist:  VISION AND BRAIN IN ADOLESCENTS WITH LOW BIRTH WEIGHT 
409. Torbjørn Hergum:  3D ULTRASOUND FOR QUANTITATIVE ECHOCARDIOGRAPHY 
410. Jørgen Urnes:  PATIENT EDUCATION IN GASTRO-OESOPHAGEAL REFLUX DISEASE. 
VALIDATION OF A DIGESTIVE SYMPTOMS AND IMPACT QUESTIONNAIRE AND A 
RANDOMISED CONTROLLED TRIAL OF PATIENT EDUCATION 
411. Elvar Eyjolfsson:  13C NMRS OF ANIMAL MODELS OF SCHIZOPHRENIA 
412. Marius Steiro Fimland: CHRONIC AND ACUTE NEURAL ADAPTATIONS TO STRENGTH 
TRAINING 
413. Øyvind Støren: RUNNING AND CYCLING ECONOMY IN ATHLETES; DETERMINING 
FACTORS, TRAINING INTERVENTIONS AND TESTING 
414. Håkon Hov:  HEPATOCYTE GROWTH FACTOR AND ITS RECEPTOR C-MET.  
AUTOCRINE GROWTH AND SIGNALING IN MULTIPLE MYELOMA CELLS 
415. Maria Radtke: ROLE OF AUTOIMMUNITY AND OVERSTIMULATION FOR BETA-CELL 
DEFICIENCY. EPIDEMIOLOGICAL AND THERAPEUTIC PERSPECTIVES 
416. Liv Bente Romundstad:  ASSISTED FERTILIZATION IN NORWAY:  SAFETY OF THE 
REPRODUCTIVE TECHNOLOGY 
417. Erik Magnus Berntsen: PREOPERATIV PLANNING AND FUNCTIONAL 
NEURONAVIGATION – WITH FUNCTIONAL MRI AND DIFFUSION TENSOR 
TRACTOGRAPHY IN PATIENTS WITH BRAIN LESIONS 
418. Tonje Strømmen Steigedal:  MOLECULAR MECHANISMS OF THE PROLIFERATIVE 
RESPONSE TO THE HORMONE GASTRIN 
419. Vidar Rao:  EXTRACORPOREAL PHOTOCHEMOTHERAPY IN PATIENTS WITH 
CUTANEOUS T CELL LYMPHOMA OR GRAFT-vs-HOST DISEASE 
420. Torkild Visnes:  DNA EXCISION REPAIR OF URACIL AND 5-FLUOROURACIL IN 
HUMAN CANCER CELL LINES 
 
2010 
421. John Munkhaugen:  BLOOD PRESSURE, BODY WEIGHT, AND KIDNEY FUNCTION IN 
THE NEAR-NORMAL RANGE: NORMALITY, RISK FACTOR OR MORBIDITY ? 
422. Ingrid Castberg:  PHARMACOKINETICS, DRUG INTERACTIONS AND ADHERENCE TO 
TREATMENT WITH ANTIPSYCHOTICS: STUDIES IN A NATURALISTIC SETTING 
423. Jian Xu: BLOOD-OXYGEN-LEVEL-DEPENDENT-FUNCTIONAL MAGNETIC 
RESONANCE IMAGING AND DIFFUSION TENSOR IMAGING IN TRAUMATIC BRAIN 
INJURY RESEARCH 
424. Sigmund Simonsen: ACCEPTABLE RISK AND THE REQUIREMENT OF 
PROPORTIONALITY IN EUROPEAN BIOMEDICAL RESEARCH LAW. WHAT DOES 
THE REQUIREMENT THAT BIOMEDICAL RESEARCH SHALL NOT INVOLVE RISKS 
AND BURDENS DISPROPORTIONATE TO ITS POTENTIAL BENEFITS MEAN?  
425. Astrid Woodhouse:  MOTOR CONTROL IN WHIPLASH AND CHRONIC NON-
TRAUMATIC NECK PAIN 
426. Line Rørstad Jensen:  EVALUATION OF TREATMENT EFFECTS IN CANCER BY MR 
IMAGING AND SPECTROSCOPY 
427. Trine Moholdt:  AEROBIC EXERCISE IN CORONARY HEART DISEASE 
428. Øystein Olsen:  ANALYSIS OF MANGANESE ENHANCED MRI OF THE NORMAL AND 
INJURED RAT CENTRAL NERVOUS SYSTEM 
429. Bjørn H. Grønberg:   PEMETREXED IN THE TREATMENT OF ADVANCED LUNG 
CANCER 
430. Vigdis Schnell Husby:  REHABILITATION OF PATIENTS UNDERGOING TOTAL HIP 
ARTHROPLASTY  WITH FOCUS ON MUSCLE STRENGTH, WALKING AND AEROBIC 
ENDURANCE PERFORMANCE 
431. Torbjørn Øien:  CHALLENGES IN PRIMARY PREVENTION OF ALLERGY.  THE 
PREVENTION OF ALLERGY AMONG CHILDREN IN TRONDHEIM (PACT) STUDY. 
432. Kari Anne Indredavik Evensen:  BORN TOO SOON OR TOO SMALL:  MOTOR PROBLEMS 
IN ADOLESCENCE 
433. Lars Adde:  PREDICTION OF CEREBRAL PALSY IN YOUNG INFANTS.  COMPUTER 
BASED ASSESSMENT OF GENERAL MOVEMENTS 
434. Magnus Fasting:  PRE- AND POSTNATAL RISK FACTORS FOR CHILDHOOD 
ADIPOSITY 
435. Vivi Talstad Monsen:  MECHANISMS OF ALKYLATION DAMAGE REPAIR BY HUMAN 
AlkB HOMOLOGUES 
436. Toril Skandsen:  MODERATE AND SEVERE TRAUMATIC BRAIN INJURY.  MAGNETIC 
RESONANCE IMAGING FINDINGS, COGNITION AND RISK FACTORS FOR 
DISABILITY 
437. Ingeborg Smidesang:  ALLERGY RELATED DISORDERS AMONG 2-YEAR OLDS AND 
ADOLESCENTS IN MID-NORWAY – PREVALENCE, SEVERITY AND IMPACT.  THE 
PACT STUDY 2005, THE YOUNG HUNT STUDY 1995-97 
438. Vidar Halsteinli:  MEASURING EFFICIENCY IN MENTAL HEALTH  SERVICE 
DELIVERY:  A STUDY OF OUTPATIENT UNITS IN NORWAY 
439. Karen Lehrmann Ægidius: THE PREVALENCE OF HEADACHE AND MIGRAINE IN 
RELATION TO SEX HORMONE STATUS IN WOMEN. THE HUNT 2 STUDY 
440. Madelene Ericsson:  EXERCISE TRAINING IN GENETIC MODELS OF HEART FAILURE 
441. Marianne Klokk:  THE ASSOCIATION BETWEEN SELF-REPORTED ECZEMA AND 
COMMON MENTAL DISORDERS IN THE GENERAL POPULATION.  THE 
HORDALAND HEALTH STUDY (HUSK) 
442. Tomas Ottemo Stølen: IMPAIRED CALCIUM HANDLING IN ANIMAL AND HUMAN 
CARDIOMYOCYTES REDUCE CONTRACTILITY AND INCREASE ARRHYTHMIA 
POTENTIAL – EFFECTS OF AEROBIC EXERCISE TRAINING  
443. Bjarne Hansen:  ENHANCING TREATMENT OUTCOME IN COGNITIVE BEHAVIOURAL 
THERAPY FOR OBSESSIVE COMPULSIVE DISORDER: THE IMPORTANCE OF 
COGNITIVE FACTORS 
444. Mona Løvlien: WHEN EVERY MINUTE COUNTS. FROM SYMPTOMS TO ADMISSION 
FOR ACUTE MYOCARDIAL INFARCTION WITH SPECIAL EMPHASIS ON GENDER 
DIFFERECES 
445. Karin Margaretha Gilljam:  DNA REPAIR PROTEIN COMPLEXES, FUNCTIONALITY AND 
SIGNIFICANCE FOR REPAIR EFFICIENCY AND CELL SURVIVAL 
446. Anne Byriel Walls:  NEURONAL GLIAL INTERACTIONS IN CEREBRAL ENERGY – AND 
AMINO ACID HOMEOSTASIS – IMPLICATIONS OF GLUTAMATE AND GABA 
447. Cathrine Fallang Knetter:  MECHANISMS OF TOLL-LIKE RECEPTOR 9 ACTIVATION 
448. Marit Følsvik Svindseth:  A STUDY OF HUMILIATION, NARCISSISM AND TREATMENT 
OUTCOME IN PATIENTS ADMITTED TO PSYCHIATRIC EMERGENCY UNITS 
449. Karin Elvenes Bakkelund:  GASTRIC NEUROENDOCRINE CELLS – ROLE IN GASTRIC 
NEOPLASIA IN MAN AND RODENTS 
450. Kirsten Brun Kjelstrup:  DORSOVENTRAL DIFFERENCES IN THE SPATIAL 
REPRESENTATION AREAS OF THE RAT BRAIN 
451. Roar Johansen:  MR EVALUATION OF BREAST CANCER PATIENTS WITH POOR 
PROGNOSIS 
452. Rigmor Myran:  POST TRAUMATIC NECK PAIN.  EPIDEMIOLOGICAL, 
NEURORADIOLOGICAL AND CLINICAL ASPECTS 
453. Krisztina Kunszt Johansen:  GENEALOGICAL, CLINICAL AND BIOCHEMICAL STUDIES 
IN LRRK2 – ASSOCIATED PARKINSON’S DISEASE 
454. Pål Gjerden:  THE USE OF ANTICHOLINERGIC ANTIPARKINSON AGENTS IN 
NORWAY.  EPIDEMIOLOGY, TOXICOLOGY AND CLINICAL IMPLICATIONS 
455. Else Marie Huuse:  ASSESSMENT OF TUMOR MICROENVIRONMENT AND 
TREATMENT EFFECTS IN HUMAN BREAST CANCER XENOGRAFTS USING MR 
IMAGING AND SPECTROSCOPY 
456. Khalid S. Ibrahim:  INTRAOPERATIVE ULTRASOUND ASSESSMENT IN CORONARY 
ARTERY BYPASS SURGERY – WITH SPECIAL REFERENCE TO CORONARY 
ANASTOMOSES AND THE ASCENDING AORTA  
457. Bjørn Øglænd:  ANTHROPOMETRY, BLOOD PRESSURE AND REPRODUCTIVE 
DEVELOPMENT IN ADOLESCENCE OF OFFSPRING OF MOTHERS WHO HAD 
PREECLAMPSIA IN PREGNANCY 
458. John Olav Roaldset:  RISK ASSESSMENT OF VIOLENT, SUICIDAL AND SELF-
INJURIOUS BEHAVIOUR IN ACUTE PSYCHIATRY – A BIO-PSYCHO-SOCIAL 
APPROACH 
459. Håvard Dalen: ECHOCARDIOGRAPHIC INDICES OF CARDIAC FUNCTION – NORMAL 
VALUES AND ASSOCIATIONS WITH CARDIAC RISK FACTORS IN A POPULATION 
FREE FROM CARDIOVASCULAR DISEASE, HYPERTENSION AND DIABETES: THE 
HUNT 3 STUDY 
460. Beate André:  CHANGE CAN BE CHALLENGING.  INTRODUCTION TO CHANGES AND 
IMPLEMENTATION OF COMPUTERIZED TECHNOLOGY IN HEALTH CARE 
461. Latha Nrugham:  ASSOCIATES AND PREDICTORS OF ATTEMPTED SUICIDE AMONG 
DEPRESSED ADOLESCENTS – A 6-YEAR PROSPECTIVE STUDY 
462. Håvard Bersås Nordgaard: TRANSIT-TIME FLOWMETRY AND WALL SHEAR STRESS 
ANALYSIS OF CORONARY ARTERY BYPASS GRAFTS – A CLINICAL AND 
EXPERIMENTAL STUDY 
Cotutelle with University of Ghent: Abigail Emily Swillens: A MULTIPHYSICS MODEL FOR  
IMPROVING THE ULTRASONIC ASSESSMENT OF LARGE ARTERIES 
2011 
463. Marte Helene Bjørk: DO BRAIN RHYTHMS CHANGE BEFORE THE MIGRAINE 
ATTACK?  A LONGITUDINAL CONTROLLED EEG STUDY 
464. Carl-Jørgen Arum:  A STUDY OF UROTHELIAL CARCINOMA:  GENE EXPRESSION 
PROFILING, TUMORIGENESIS AND THERAPIES IN ORTHOTOPIC ANIMAL MODELS 
465. Ingunn Harstad:  TUBERCULOSIS INFECTION AND DISEASE AMONG ASYLUM 
SEEKERS IN NORWAY.  SCREENING AND FOLLOW-UP IN PUBLIC HEALTH CARE 
466. Leif Åge Strand:  EPIDEMIOLOGICAL STUDIES AMONG ROYAL NORWEGIAN NAVY 
SERVICEMEN.  COHORT ESTABLISHMENT, CANCER INCIDENCE AND CAUSE-
SPECIFIC MORTALITY 
467. Katrine Høyer Holgersen:  SURVIVORS IN THEIR THIRD DECADE AFTER THE NORTH 
SEA OIL RIG DISASTER OF 1980.  LONG-TERM PERSPECTIVES ON MENTAL HEALTH 
468. MarianneWallenius:  PREGNANCY RELATED ASPECTS OF CHRONIC 
INFLAMMATORY ARTHRITIDES:  DISEASE ONSET POSTPARTUM, PREGNANCY 
OUTCOMES AND FERTILITY.  DATA FROM A NORWEGIAN PATIENT REGISTRY 
LINKED TO THE MEDICAL BIRTH  REGISTRY OF NORWAY 
469. Ole Vegard Solberg: 3D ULTRASOUND AND NAVIGATION – APPLICATIONS IN 
LAPAROSCOPIC SURGERY 
470. Inga Ekeberg Schjerve: EXERCISE-INDUCED IMPROVEMENT OF MAXIMAL OXYGEN 
UPTAKE AND ENDOTHELIAL FUNCTION IN OBESE AND OVERWEIGHT 
INDIVIDUALS ARE DEPENDENT ON EXERCISE-INTENSITY 
471. Eva Veslemøy Tyldum: CARDIOVASCULAR FUNCTION IN PREECLAMPSIA – WITH 
REFERENCE TO ENDOTHELIAL FUNCTION, LEFT VENTRICULAR FUNCTION AND 
PRE-PREGNANCY PHYSICAL ACTIVITY 
472. Benjamin Garzón Jiménez de Cisneros: CLINICAL APPLICATIONS OF MULTIMODAL 
MAGNETIC RESONANCE IMAGING 
473. Halvard Knut Nilsen: ASSESSING CODEINE TREATMENT TO PATIENTS WITH 
CHRONIC NON-MALIGNANT PAIN: NEUROPSYCHOLOGICAL FUNCTIONING, 
DRIVING ABILITY AND WEANING 
474. Eiliv Brenner: GLUTAMATE RELATED METABOLISM IN ANIMAL MODELS OF 
SCHIZOPHRENIA  
475. Egil Jonsbu: CHEST PAIN AND PALPITATIONS IN A CARDIAC SETTING; 
PSYCHOLOGICAL FACTORS, OUTCOME AND TREATMENT 
476. Mona Høysæter Fenstad: GENETIC SUSCEPTIBILITY TO PREECLAMPSIA : STUDIES ON 
THE NORD-TRØNDELAG HEALTH STUDY (HUNT) COHORT, AN AUSTRALIAN/NEW 
ZEALAND FAMILY COHORT AND DECIDUA BASALIS TISSUE 
477. Svein Erik Gaustad: CARDIOVASCULAR CHANGES IN DIVING: FROM HUMAN 
RESPONSE TO CELL FUNCTION 
478. Karin Torvik: PAIN AND QUALITY OF LIFE IN PATIENTS LIVING IN NURSING 
HOMES 
479. Arne Solberg: OUTCOME ASSESSMENTS IN NON-METASTATIC PROSTATE CANCER 
480. Henrik Sahlin Pettersen: CYTOTOXICITY AND REPAIR OF URACIL AND 5-
FLUOROURACIL IN DNA 
481. Pui-Lam Wong: PHYSICAL AND PHYSIOLOGICAL CAPACITY OF SOCCER PLAYERS: 
EFFECTS OF STRENGTH AND CONDITIONING 
482. Ole Solheim: ULTRASOUND GUIDED SURGERY IN PATIENTS WITH INTRACRANIAL 
TUMOURS 
483. Sten Roar Snare: QUANTITATIVE CARDIAC ANALYSIS ALGORITHMS FOR POCKET-
SIZED ULTRASOUND DEVICES 
484. Marit Skyrud Bratlie: LARGE-SCALE ANALYSIS OF ORTHOLOGS AND PARALOGS IN 
VIRUSES AND PROKARYOTES 
 
485. Anne Elisabeth F. Isern: BREAST RECONSTRUCTION AFTER MASTECTOMY – RISK OF 
RECURRENCE AFTER DELAYED LARGE FLAP RECONSTRUCTION – AESTHETIC 
OUTCOME, PATIENT SATISFACTION, QUALITY OF LIFE AND SURGICAL RESULTS; 
HISTOPATHOLOGICAL FINDINGS AND FOLLOW-UP AFTER PROPHYLACTIC 
MASTECTOMY IN HEREDITARY BREAST CANCER 
486. Guro L. Andersen:  CEREBRAL PALSY IN NORWAY – SUBTYPES, SEVERITY AND 
RISK FACTORS 
487. Frode Kolstad:  CERVICAL DISC DISEASE – BIOMECHANICAL ASPECTS 
488. Bente Nordtug: CARING BURDEN OF COHABITANTS LIVING WITH PARTNERS 
SUFFERING FROM CHRONIC OBSTRUCTIVE PULMONARY DISEASE OR DEMENTIA 
489. Mariann Gjervik Heldahl: EVALUATION OF NEOADJUVANT CHEMOTHERAPY IN 
LOCALLY ADVANCED BREAST CANCER BASED ON MR METHODOLOGY 
490. Lise Tevik Løvseth:  THE SUBJECTIVE BURDEN OF CONFIDENTIALITY  
491. Marie Hjelmseth Aune: INFLAMMATORY RESPONSES AGAINST GRAM NEGATIVE 
BACTERIA INDUCED BY TLR4 AND NLRP12 
492. Tina Strømdal Wik: EXPERIMENTAL EVALUATION OF NEW CONCEPTS IN HIP 
ARTHROPLASTY 
493. Solveig Sigurdardottir:  CLINICAL ASPECTS OF CEREBRAL PALSY IN ICELAND. A 
POPULATION-BASED STUDY OF PRESCHOOL CHILDREN  
494. Arne Reimers: CLINICAL PHARMACOKINETICS OF LAMOTRIGINE 
495. Monica Wegling:  KULTURMENNESKETS BYRDE OG SYKDOMMENS VELSIGNELSE. 
KAN MEDISINSK UTREDNING OG INTERVENSJON HA EN SELVSTENDIG FUNKSJON 
UAVHENGIG AV DET KURATIVE? 
496. Silje Alvestad: ASTROCYTE-NEURON INTERACTIONS IN EXPERIMENTAL MESIAL 
TEMPORAL LOBE EPILEPSY – A STUDY OF UNDERLYING MECHANISMS AND 
POSSIBLE BIOMARKERS OF EPILEPTOGENESIS 
497. Javaid Nauman: RESTING HEART RATE: A MATTER OF LIFE OR DEATH – 
PROSPECTIVE STUDIES OF RESTING HEART RATE AND CARDIOVASCULAR RISK 
(THE HUNT STUDY, NORWAY) 
498. Thuy Nguyen: THE ROLE OF C-SRC TYROSINE KINASE IN ANTIVIRAL IMMUNE 
RESPONSES 
499. Trine Naalsund Andreassen: PHARMACOKINETIC, PHARMACODYNAMIC AND 
PHARMACOGENETIC ASPECTS OF OXYCODONE TREATMENT IN CANCER PAIN 
500. Eivor Alette Laugsand: SYMPTOMS IN PATIENTS RECEIVING OPIOIDS FOR CANCER 
PAIN – CLINICAL AND PHARMACOGENETIC ASPECTS 
501. Dorthe Stensvold: PHYSICAL ACTIVITY, CARDIOVASCULAR HEALTH AND 
LONGEVITY IN PATIENTS WITH METABOLIC SYNDROME 
502. Stian Thoresen Aspenes: PEAK OXYGEN UPTAKE AMONG HEALTHY ADULTS – 
CROSS-SECTIONAL DESCRIPTIONS AND PROSPECTIVE ANALYSES OF PEAK 
OXYGEN UPTAKE, PHYSICAL ACTIVITY AND CARDIOVASCULAR RISK FACTORS 
IN HEALTHY ADULTS (20-90 YEARS) 
503. Reidar Alexander Vigen:  PATHOBIOLOGY OF GASTRIC CARCINOIDS AND 
ADENOCARCINOMAS IN RODENT MODELS AND PATIENTS.  STUDIES OF 
GASTROCYSTOPLASTY, GENDER-RELATED FACTORS, AND AUTOPHAGY 
504. Halvard Høilund-Kaupang:  MODELS AND METHODS FOR INVESTIGATION OF 
REVERBERATIONS IN NONLINEAR ULTRASOUND IMAGING     
505. Audhild Løhre: WELLBEING AMONG SCHOOL CHILDREN IN GRADES 1-10:  
PROMOTING AND ADVERSE FACTORS 
506. Torgrim Tandstad:  VOX POPULI.  POPULATION-BASED OUTCOME STUDIES IN 
TESTICULAR CANCER 
507. Anna Brenne Grønskag:  THE EPIDEMIOLOGY OF HIP FRACTURES AMONG ELDERLY 
WOMEN IN NORD-TRØNDELAG.  HUNT 1995-97, THE NORD-TRØNDELAG HEALTH 
STUDY 
508. Kari Ravndal Risnes: BIRTH SIZE AND ADULT MORTALITY: A SYSTEMATIC REVIEW 
AND A LONG-TERM FOLLOW-UP OF NEARLY 40 000 INDIVIDUALS BORN AT         
ST. OLAV UNIVERSITY HOSPITAL IN TRONDHEIM 1920-1960 
509. Hans Jakob Bøe: LONG-TERM POSTTRAUMATIC STRESS AFTER DISASTER – A 
CONTROLLED STUDY OF SURVIVORS’ HEALTH 27 YEARS AFTER THE CAPSIZED 
NORTH SEA OIL RIG 
510. Cathrin Barbara Canto,  Cotutelle with University of Amsterdam: LAYER SPECIFIC 
INTEGRATIVE PROPERTIES OF ENTORHINAL PRINCIPAL NEURONS 
511. Ioanna Sandvig: THE ROLE OF OLFACTORY ENSHEATHING CELLS, MRI, AND 
BIOMATERIALS IN TRANSPLANT-MEDIATED CNS REPAIR 
512. Karin Fahl Wader:  HEPATOCYTE GROWTH FACTOR, C-MET AND SYNDECAN-1 IN 
MULTIPLE MYELOMA  
 
 
 
